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INTRODUCTION
Summary
M any epileptologists believe that the new antiepileptic drugs as a group constitute a major advance in the treatment of epilepsy. Even their fiercest proponent, however, could not 
convincingly argue that they are the ideal treatment for all patients with 
epilepsy. It is widely accepted that if the ‘magic bullet’ for epilepsy exists, then 
we have still to find it. Given that the development of new antiepileptic 
compounds is an expensive, time-consuming gamble, then it may be more 
beneficial to expend our energies on a quest for better ways of using those 
compounds already available. Combination therapy is commonplace in other 
conditions such as hypertension, Parkinsons disease, cardiac failure, or 
infections such as tuberculosis, and there should be no reason why specific 
treatments should not be combined with particular efficacy in the treatment of 
epilepsy.
Polypharmacy with antiepileptic drugs (AEDs) has fallen out of favour in 
recent times. For some years, the prevailing opinion has been that AED 
combinations merely maximise the incidence of drug-related adverse events 
while conferring little benefit in terms of seizure control. While this may have 
been true of the established drugs, phenytoin, carbamazepine, and valproate 
we should be open to the possibility that the newer AEDs are more suited to 
use as polypharmacy.
We know that the newer AEDs have different mechanisms of action, have 
fewer pharmacokinetic interactions, and cause less sedation than their older 
counterparts, while pre-clinical trials would also suggest that they are more
specific in their actions. These qualities may suggest that there will be a 
reduction in the frequency and / or severity of pharmacodynamic interactions 
when they are used simultaneously.
Aside from chance observation, how else can we begin to plan our treatment 
combinations? The results of basic in-vitro research may suggest certain 
possibilities, but these will only be relevant in our clinics if we are aware of the 
key issues involving each new AED. Most importantly:
• What is/are the relevant mode(s) of action of each drug?
To anticipate pharmacodynamic interactions and therapeutic synergy, we 
need to have a comprehensive view of the actions of each individual drug. For 
example, vigabatrin is known to inhibit GABA-transaminase, but what changes 
does it exert on the metabolism of glutamate? Does it have other important 
effects on GABA? Remacemide, another AED in development was known to 
be a non-competitive n-methyl-d-aspartate (NMDA) receptor antagonist, but 
recent evidence has proven its effect on sodium channel conductance. What 
effect will it have on the GABAergic system?
Even once we have a fuller picture of each drug’s neurochemical effects (and 
we cannot even do this convincingly for those drugs that are licensed in the 
UK!) then how do we proceed in planning the treatment of refractory epilepsy? 
Should we combine drugs which target the same system (e.g. two GABAergic 
drugs)? Or should we aim to manipulate two different systems (e.g. one drug 
acting on the GABAergic system, and one on the excitatory system)?
• Are there any pharmacodynamic or pharmacokinetic interactions between
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the two drugs? Are these effects beneficial or deleterious?
The answer to this can only be gleaned from proper testing during preliminary 
clinical trials. Each new AED firstly has to undergo clinical trials as add-on 
therapy; pharmacokinetic interactions are usually picked up at this relatively 
early stage of investigation. During each trial, it may also be rational to carry 
out meta-analyses to investigate which co-therapies are particularly well or 
poorly tolerated. Despite the relative ease with which this might be 
accomplished in this age of computerisation, no such analyses have been 
carried out (or at least not been published!) for any of the emergent 
treatments, and possible reasons for this will be discussed later.
Once both questions are satisfactorily answered, and we suspect that a 
particular combination of drugs may have some particular merit, then further 
testing against appropriate controls will be required. The difficulties involved 
in this will be addressed.
The experiments described in this thesis investigate different aspects of some 
of the newer AEDs. Animal experiments are used to investigate the 
neurochemical actions of remacemide, gabapentin, tiagabine, and vigabatrin 
at varying doses with particular emphasis on the GABA shunt. Following the 
clinical observation of good additive effect with combined tiagabine and 
vigabatrin, the same parameters were used to look at this particular 
combination. Culture of rat astrocytes and neurones are used to delineate the 
dose-related effects of vigabatrin on GABA uptake, a phenomenon previously 
described in our laboratory. The specific combination of vigabatrin and
3
tiagabine is also used to search for additive or synergistic effects on this 
system.
One set of double-blind clinical studies attempts to investigate interactions 
between remacemide and the established AEDs, while another investigates 
the cognitive effects of add-on gabapentin.
The issues faced by clinicians in the formation of a rational plan for AED 
polypharmacy are discussed, and the scope for further investigation is 
explored.
4
New antiepileptic drugs - the Search For Synergy
introduction
Epilepsy is a common neurological condition, with a lifetime prevalence of 
between two (Goodridge and Shorvon 1983a, Goodridge and Shorvon 
1983b), and five (Shorvon 1990) percent of the general population, and a 
point prevalence of between 4 and 80 per 1000 (Brodie and Dichter 1996). 
There are an estimated fifty million cases world-wide, and even today the 
disease remains both disabling and stigmatising (Shorvon 1990). Even in the 
best centres, full seizure control is not guaranteed; most recent studies still 
suggest that around 30% of all patients will be inadequately controlled when 
using maximum tolerated doses of currently available AEDs (Beghi et al 1986, 
Schmidt 1984, Brodie and Dichter 1996).
Epilepsy has been recognised as a clinical entity for thousands of years, the 
name deriving from the ancient Greek word epilambanein meaning ‘to seize’ 
or ‘to attack’, and should correctly be regarded not so much as a disease, but 
as a symptom with myriad causes. The dysfunction which leads to clinical 
seizure activity may arise as a result of some primary, local event such as 
traumatic damage, inflammatory change or ischaemic events, or there may be 
an innate predisposition to seizure activity by virtue of a genetically-driven 
change in neuronal membrane activity. The relative contributions of nature 
and nurture to the ictal tendency will vary from patient to patient. The 
excessive discharge which is the root cause of the ictal phenomenon may 
remain localised, producing partial seizures, or may spread, producing 
generalised seizures.
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The earliest writings on epilepsy date back to the Babylonians and the 
Chinese in 700 BC (Kinnier Wilson and Reynolds 1990, Lai and Lai 1991). 
Although early civilisations such as the Babylonians correctly associated 
epilepsy with physical illness such as head trauma (Gross 1992), the disorder 
was more usually ascribed to forces as irrelevant as evil spirits or lunar 
phases. Cautery, skull trephination, dietary manipulation, phlebotomy and 
good old-fashioned exorcism were therefore regarded as reasonable
remedies until well past the middle ages.
Despite the ready availability of scientific explanations for it’s basis, western 
societies continue to harbour a widespread ignorance and superstition about 
epilepsy which is all too familiar to sufferers and their families. At least this is 
an improvement. In ancient times, stigmatisation was endorsed by physicians: 
Pliny’s advice included spitting on afflicted patients to “throw off the 
contagion” (Tempkin 1971), a practice that would hopefully not be condoned 
today!
The first physician to attempt a rational as opposed to supernatural
explanation for epilepsy was Hippocrates in around 400 BC: he considered 
that there was an "excess of phlegm (that) overspilled into the bloodstream" 
(Tempkin 1971a). By the end of the second century, seizures were being 
classified according to their clinical manifestation, and around that time, 
Galen recorded the symptoms associated with the onset of seizure activity, 
calling them ‘auras’ a name by which they still go today. He had tried to fuse
his observations on the nature of auras with the prevailing theories of
interactions between body humours in an attempt to provide answers to the
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clinical questions that confronted him (Tempkin 1971b).
Probably fuelled by it’s association with divine intervention in the New 
Testament (Gospels of Mark and Luke), the direction of epilepsy management 
in the ‘civilised’ world remained with the clerics rather than the medics right up 
until the Enlightenment. The Middle Ages did not constitute one of medicine’s 
golden eras, and little progress was made in the development of rational 
thinking in terms of epilepsy.
By 1780 Home had recognised the failings of modern medicine to counteract 
the superstitions of the day, and he was part of a general attempt to look 
closer to earth for an explanation of epilepsy aetiology, and a rational basis 
for it's cure. Leuret and Moreau (Gross 1992) disproved the idea that lunar 
phases were a significant factor in epilepsy aetiology, and useful observations 
were made by physicians such as Bright and Todd in linking focal seizures 
with focal central nervous system pathology (Gross 1992). Hughlings Jackson 
was able to relate these observations with the contemporary experiments that 
showed that electrical stimulation of discrete areas of cortex was related to 
specific motor effects. In doing this he was able to state that:
"A convulsion is but a symptom, and implies only that 
there is an excessive and disorderly discharge of nerve 
tissue on muscles” (Jackson 1873)
The cause of seizures was still not well understood, and most authorities 
believed that hysteria and onanism were important factors in the development
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of an ictal tendency. Work by Fritsch and Hitzig (De Villiers 1993) was pivotal 
in establishing the link between epilepsy and localised cerebral pathology. 
The discovery of weak electrical currents from the brains of rabbits and 
monkeys preceded the development of electroencephalography in 1929, and 
with the association of electrical activity and neuronal dysfunction confirmed, 
not only was the organic nature of epilepsy asserted, but the development of 
animal models would allow for more efficient preclinical testing of potential 
AEDs.
Despite the proven organic causes of this common disorder, the social stigma 
which still surrounds epilepsy is among the many factors which leads to the 
perception of disablement of some epilepsy patients. Surveys have shown 
that even among contemporary physicians, there is an erroneous belief that 
(Beran et al 1981) people with epilepsy lose more time off work than non- 
sufferers, and that they would rather their children did not play alongside 
children with epilepsy (admittedly, this latter answer may reflect a desire not 
to see their children’s friends afflicted by epilepsy).
The continued stigma is as much as anything testament to the relative lack of 
efficacy and imperfections of the established agents. As will be discussed in 
later chapters, the treatment of seizures has advanced enormously in recent 
years, and in the space of around eighty years we have progressed from 
using glorified sedatives to using specifically designed complex antiepileptic 
molecules. We have entered a new era in the treatment of epilepsy.
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A brief history of antiepileptic drug treatment
Even while Hippocrates was trying to rationalise the condition, a regime of 
drugs and dietary manipulation was formulated to treat the disease. The 
(then) rational treatments were placed alongside (still) superstitious remedies: 
the former suited for those rich enough to afford the considerable costs, the 
latter to give the impoverished masses a quick, inexpensive attempt at cure. 
In many different cultures, skull trephination was carried out in an attempt to 
let ‘evil spirits’ escape from the skull (Gross 1992).
The passage of time from ancient times to the mid eighteenth century saw no 
real advance in the treatment of epilepsy. Many animals were sacrificed at 
one time or another in an attempt to provide body parts which would abate 
seizure activity. An unhealthy (and rather unappetising!) interest in other 
species’ genitals was demonstrated for their suggested pharmacological 
properties. Fortunately for the seals, hippopotami, hares, boars and rams 
(among others), the antiepileptic effect of their pudenda has not been proven, 
and their use is thankfully not routine in today’s epilepsy clinics.
Even well into the nineteenth century, the development of rational treatments 
for epilepsy lagged some way behind the knowledge of epilepsy 
pathophysiology. Silver nitrate was commonly used in hospices around 
England, but it was not until the late 19th century that the first steps towards 
effective anticonvulsant pharmacology were made. Working on the 
assumption that epilepsy was a manifestation of either hysteria or sexual 
frustration, bromide salts were prescribed. These were a mixture of 
potassium, sodium and ammonium bromide, and they did, admittedly, possess
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previously unprecedented anticonvulsant properties according to Sir Charles 
Locock’s presentation to the Royal Medical Chirurgical Society in 1857 
(Sieveking 1857), and by the last quarter of the 19th century, 2.5 tonnes of 
bromide salts were being used annually at the National Hospital for Nervous 
Diseases (Holmes 1954). Clouston in the introduction to his open trial of 
bromide salts in 1868, included an elegant plea for evidence-based medicine.
"What asylum physician ... has any approach to a feeling of 
certainty that drugs will have the effect he anticipates? ...
We have statements of individual authors in regard to the 
right mode of giving some drugs, but after all these are 
merely opinions founded on most limited observations, and 
lack the exactitude of research, and the numerical basis on 
which alone scientific truth is based"
This early study of what has transpired to be the first largely GABAergic drug 
showed not only a reduction in seizure frequency, but also changes in seizure 
morphology on treatment with up to 50 grains of bromide salts daily. In 
asylums round the country, bromide-induced stupor and skin abcesses were 
thought to be preferable to poorly controlled epilepsy, but were enough to 
render the bromides obsolete once a we 11-tolerated alternative had been 
discovered.
1912 saw the first use of the sedative barbiturates in epilepsy thanks to a 
chance observation by Hauptmann (Cereghino and Penry, 1995). Although
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less sedative than bromide salts, the barbiturates are far from ideal as AEDs, 
but they remained the only man-made compounds in use as first-line 
anticonvulsants, unrivalled for almost 30 years. With the work of Putnam and 
Merrit on animal seizure models, the modern age of epilepsy treatment had 
begun.
Phenytoin is an effective anticonvulsant drug which was introduced in 1938. 
Phenytoin possessed previously unrivalled antiepileptic properties without 
being overtly sedative, and this advance in the therapy of epilepsy helped to 
fuel a wave of optimism. The emphasis for epilepsy care was to move from 
colonisation to integration. Patients progressed from being ‘epileptics’ to 
being 'people with epilepsy’ and education programmes were set up to 
remove the stigma which accompanied the diagnosis of seizure disorder. It is 
testimony to its efficacy that despite its well recognised adverse event profile, 
phenytoin remains one of the most commonly used AEDs in many parts of the 
developed world, particularly the USA.
After almost 30 years of relative quiescence, following the introduction of 
phenytoin, the 1960's saw the introduction of carbamazepine and sodium 
valproate which, for the moment at least, are the two first-line antiepileptic 
drugs in the UK in terms of both tolerability and efficacy.
Some benzodiazepines, particularly clobazam and clonazepam, did gain in 
popularity in the mid-seventies, although their use was limited by the 
tolerance which develops even with short-term use. Detailed discussion of the 
benefits and drawbacks of each antiepileptic drug will be covered in the next 
chapter, putting the search for new anticonvulsant compounds in context.
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By the late seventies, it was still apparent that more effective, more tolerable 
antiepileptic drugs were still needed. The increasing knowledge of the role 
played by amino acids in neurotransmission allowed us to search for drugs 
with discrete, well defined neurochemical actions. The majority of the newer 
AEDs are a product of this search, and we may at last be moving away from a 
reliance on glorified sedatives which constitute the established 
anticonvulsants. We can only hope that any increased specificity of the new 
generation of AEDs will maintain or improve anticonvulsant efficacy while 
avoiding the array of non-specific side effects associated with the older 
agents. Four new AEDs have been granted a licence for use as add-on 
therapy in the UK in the last 5 years, and there is an unprecedented range of 
compounds which are awaiting further clinical and pre-clinical trials to support 
their claims as effective anticonvulsants. This relatively rapid progress 
contrasts with the slower advances of bygone years (Figure 1), and there may 
be as many as eleven new AEDs on the market by the end of the century 
(Brodie and Dichter 1996) - giving us a potentially bewildering array of 
therapeutic options for patients with epilepsy.
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Figure 1:- Timeline showing the progress in development of AEDs
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Seizure classification
It is pertinent to discuss seizure classification at this point, prior to the 
discussion of each anticonvulsant agent. Understanding the indications for, 
and the failings of, each AED depends in part on the definitions of seizure 
type. In 1981, the International League Against Epilepsy (ILEA) devised in a 
classification which relied on the symptomatology and third party witness 
history of seizures. Eight years later an updated classification was adopted 
by the ILAE (Commission on Classification and Terminology of the ILAE 1989) 
providing a more complex and unyielding classification of seizures which has 
largely superseded the 1981 version.
The 1989 version takes account of syndromic classifications and possible 
aetiologies, and creates a rigorous distinction between epilepsies that are 
idiopathic (“no predisposing cause other than an hereditary disposition”), 
symptomatic (“the consequence of a known or suspected disorder of the 
CNS”), and cryptogenic (“presumed to be symptomatic, but often lack well 
defined electroclinical characteristics”). Within the localisation-related 
epilepsies, the classification also described variants dependent on their 
proposed anatomical localisation. This classification was not intended to be 
exhaustive, and with constant updating of the technologies available for 
structural, electrical and metabolic imaging, our understanding of seizure 
morphology it will undoubtedly require constant updating.
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1 Localisation-related epilepsies and syndromes
1.1 Idiopathic (with age-related onset)
•  Benign Childhood epilepsy with centrotemporal spikes
• Childhood epilepsy with occipital paroxysms
• Primary reading epilepsy
1.2 Symptomatic
• Temporal lobe epilepsies
• Frontal lobe epilepsies
•  Parietal lobe epilepsies
•  Occipital lobe epilepsies
• Chronic progressive epilepsia partialis continua of childhood
(Kojewnikow’s syndrome)
•  Syndromes characterised by seizures with specific modes of precipitation 
(eg reflex epilepsies)
1.3 Cryptogenic
•  As in 1.2, but lack of aetiological evidence.
2 Generalised epilepsies and syndromes
2 .1 Idiopathic (with age-related onset - listed in order of age of onset)
• Benign neonatal familial convulsions
• Benign neonatal convulsions
• Benign myoclonic epilepsy in infancy
• Childhood absence epilepsy
•  Juvenile absence epilepsy
• Juvenile myoclonic epilepsy
•  Epilepsy with grand mal seizure on awakening
• Other generalised epilepsies
• Epilepsies precipitated by specific modes of activation
2.2 Cryptogenic or symptomatic (in order of age of onset)
• West syndrome (infantile spasms)
• Lennox-Gastaut syndrome
• Epilepsy with myoclonic astatic seizures
• Epilepsy with myoclonic absences
2.3 Symptomatic
2.3.1 Non-specific Aetiology
• Early myoclonic encephalopathy
• Early infantile epileptic encephalopathy with suppression burst
• Other symptomatic generalised epilepsies not defined above
2.3.2 Specific syndromes
• Seizures as presentation of other diseases
3 Epilepsies and syndromes undetermined to be focal or
generalised
3 .1 With both focal and generalised seizures 
Neonatal seizures
Severe myoclonic epilepsy in infancy 
Epilepsy with continuous spike-waves during S W  sleep 
Acquired epileptic aphasia 
Other undetermined epilepsies not mentioned above
3.2 Without equivocal features of generalisation or focal seizure
4 Special syndromes
4.1 Situation-related seizures
• Febrile convulsions
• Isolated seizures or isolated status epilepticus
• Seizure only in the presence of an acute metabolic or toxic event
1989 ILAE Classification of seizures and syndromes
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Characteristics of seizures with anatomical localisation
• Temporal lobe epilepsies
Temporal lobe syndromes characteristically cause a range of seizure types 
from simple partial (SP) seizures, complex partial (CP) seizures or secondary 
generalised seizures. Onset is frequently in childhood or young adulthood, 
and there is often a history of febrile convulsions and / or a family history of 
epilepsy.
SP seizures typically involve autonomic or psychic symptoms without 
disturbance of consciousness. These may take the form of auditory or 
olfactory hallucinations. An epigastric ‘rising’ sensation is frequently the first 
symptom to be reported.
CP seizures often begin with motor arrest which is quickly followed by 
primitive automatisms. Other more complex automatisms may follow. Attacks 
usually last longer than 1 minute, and recovery is gradual with post-ictal 
confusion and subsequent amnesia. EEG in temporal lobe epilepsy may be 
normal, or may show slight asymmetry of the background activity. Temporal 
spikes, sharp waves, or slow waves may be bilateral or unilateral, and may be 
better defined by intracranial recordings.
Seizures from specific areas.
Amygdalo-hippocampal seizures (mesiolabial limbic or rhinencephalic) 
Hippocampal seizures are the most common, with features as described 
above except that auditory hallucinations are uncommon. Seizures are 
characterised by rising epigastric discomfort, nausea, autonomic signs and
symptoms such as belching, borborygmi, pallor, facial flushing, pupillary 
dilatation, fear, panic, and olfactory-gustatory hallucinations.
Lateral temporal seizures 
Epileptic foci in this area causes simple seizures characterised by auditory 
hallucinations, illusions, or dreamy states. Visual misperceptions or language 
disorders may occur where the language dominant hemisphere is involved. 
These may progress to complex partial seizures as described above. EEG 
occasionally localises temporal spikes which are most prominent in the lateral 
derivations.
• Frontal Lobe epilepsies.
Epileptic foci in the frontal lobe cause one or more types of SP, CP, or 
secondary generalised (SGTC) seizures. Seizures are frequently nocturnal 
and may be easily mistaken for psychogenic seizures. Status epilepticus is 
more common than with other areas of abnormality.
Frontal lobe foci may be suggested when seizures are short, involve a rapid 
recovery, or may undergo rapid secondary generalisation. Motor 
manifestations are prominent and may be bizarre, with complex gestural 
automatisms frequent at the onset of seizure. If the discharge is bilateral, then 
falls are frequent. Secondary generalisation is more common than with 
temporal lobe foci, and tends to occur more rapidly.
Seizures from specific areas.
0 Supplementary motor seizures
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Patterns of this seizure type involve focal tonic seizures with vocalisation, 
speech arrest, and fencing postures.
0 Cingulate
Cingulate seizures tend to be CP seizures with complex motor gestural 
automatisms at onset. Autonomic signs occur commonly as do changes in 
mood and affect.
0 Anterior frontopolar region
Patterns in this area include forced thinking or initial loss of contact and 
adversive movements of head and eyes. These may evolve into contraversive 
movements and axial clonic jerks, with falls and autonomic signs.
0 Orbitofrontal
The characteristic pattern is of CPS with initial motor and gestural and motor 
automatisms, olfactory hallucinations, illusions and autonomic signs.
0 Dorsolateral
Usually a tonic seizure pattern, less commonly clonic seizures with versive 
head and eye movements and speech arrest.
Opercular
Include mastication, salivation, swallowing, laryngeal, speech arrest, 
autonomic symptoms. Secondary sensory changes may consist of numbness 
particularly in the hands. Gustatory hallucinations are particularly common.
0 Motor cortex
Mainly characterised by simple partial motor epilepsies. The nature of these 
will vary depending on the size and topography of the area involved. In the 
pre-rolandic area, there may be speech arrest, vocalisation, dysphasia, tonic
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clonic movements of the contralateral facial muscles, or swallowing. Foci in 
the rolandic area cause partial motor seizures without march, particularly 
occurring in the contralateral extremities. Todd’s paralysis is frequent.
In frontal lobe epilepsies, the EEG may well be normal, or may show spikes 
sharp waves or slow waves, unilaterally or bilaterally. Intracranial recordings 
may provide more information.
• Parietal lobe epilepsies.
Foci in this region usually cause SP and SGTC seizures. CP seizures may 
evolve from SP seizures with outward spread. Seizures are predominately 
sensory, with positive or negative phenomena which may be confined or may 
spread in a Jacksonian manner. The areas usually affected are those with the 
largest cortical representation (hand, arm, face), and there may be lingual 
crawling, stiffness or coldness affecting the face bilaterally. Occasionally 
abdominal sinking, choking or nausea may be reported, and rarely there may 
be sensation of pain. Parietal visual symptoms may consist of formed 
hallucinations and visual distortions. Inferior parietal lobe involvement may 
cause negative phenomena such as severe vertigo or disorientation in space. 
Paracentral involvement may cause genital sensations, and foci in this area 
have a greater tendency to secondarily generalise.
Occipital seizures
Seizures from this area are usually characterised by SP and SGTC seizures, 
although CP seizures may occur with outward spread. Clinically the seizures
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usually involve visual manifestations which may be negative (scotoma, 
hemianopia, amaurosis) or more commonly positive (sparks, flashes, 
phosphenes). Perceptive illusions may involve a distortion of perceived 
distance, shape, or size of objects. Illusional and hallucinatory visual seizures 
involve discharges at the temporoparieto-occipital junction. Versive 
movements may occur. Frontal lobe seizures may be mimicked if forward 
spread occurs to the suprasylvian convexity or the mesial surface.
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The physiological and biochemical basis of seizures
The last forty years have seen enormous advances in our understanding of neurotransmission, but despite this the basic mechanisms underlying epileptic seizures are still to be fully 
defined. Elucidation of the biochemical defects and effects 
surrounding epileptogenesis has helped to point the way towards newer more 
effective AEDs, and in the future will be essential in highlighting the most 
promising directions for development of future therapies.
Normal neurotransmitter actions
Amino acid neurotransmitters have long been recognised as being of import in 
the propagation and cessation of epileptic activity (Horton 1989). In terms of 
their role in neurotransmission, amino acids can be subdivided into those that 
are excitatory (glutamate, aspartate) and those that have inhibitory actions 
(GABA).
Normal ionic fluxes in neurones.
When an excitatory input arrives at a section of neuronal membrane, the 
membrane potential initially shifts from it’s resting value of -70mV. If the sum 
of all co-incident excitatory post-synaptic potentials (EPSP) is sufficient to 
diminish the membrane potential to around -60mV (the ‘threshold potential’), 
there is a resultant large increase in both Na+ influx and K+ efflux, which is a 
requirement for the generation of a propagated action potential.
Inhibitory factors can diminish the effect of an EPSP, via an increase in Cl"
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conductance which causes the membrane potential to become more negative 
(hyperpolarise). This hyperpolarisation is a result of what is (unsurprisingly) 
termed an inhibitory post synaptic potential (IPSP).
In addition to these ‘fast’ responses in ionic conductance, there are slower, 
neurotransmitter-dependent responses which occur as a result of electrical 
stimulation.
Gamma aminobutvric acid (GABA)
GABA concentration has been shown to be highest in the hypothalamus, 
globus pallidus and substantia nigra (Fahn 1976, Enna 1981). Although 
activation of GABAa receptors inhibits individual neurones, it has been shown 
that the relationship between GABA and the prevention of convulsions is far 
from uniform (Gale 1989, Gale 1992), and while in some brain regions 
localised enhancement of GABA levels may be proconvulsant (eg. pontine 
reticular formation), depletion of GABA in others may not affect seizure 
activity (eg. substantia nigra) (Gale 1992).
GABA formation and metabolism
GABA is formed by the decarboxylation of glutamate (Figure 2), a process 
catalysed by 2 isoforms of the enzyme glutamic acid decarboxylase (GAD) 
(Martin and Rimvall 1993).
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Other routes of synthesis are thought to be of little import in neurological 
tissues under normal conditions, and the immunocytochemical staining for 
GAD is used as a marker for GABAergic neurones (Snead 1983).
As with other decarboxylase enzymes, GAD requires the presence of a 
cofactor, pyridoxal phosphate, for maximal activity. Physiological changes in 
glutamate and adenosine nucleotides may alter enzyme activity in vivo, 
although in mammals, there is no feedback inhibition of GAD activity by GABA 
concentrations (Horton 1989).
It has been shown that GAD undergoes calcium-dependent binding to cell 
membranes, which is itself inhibited by Cl', Zn2+, and sulphydril agents 
(Horton 1989), although the clinical significance of this is unclear. GABA 
release occurs in response to electrical and K+ stimulation of GABAergic 
neurones (Horton 1989). This release is calcium-dependent and blocked by 
tetanus toxoid. An increase in extracellular GABA concentrations, or the 
presence of GABA agonists, inhibits further release of GABA (Horton 1989), 
suggesting that autoreceptors play a part in regulating the extent of 
GABAergic inhibition.
There are two main types of GABA receptors, GABAa and GABAb (Enna and 
Gallagher 1983). Activation of the GABAa receptor leads to Cl' influx into the 
cell with associated hyperpolarisation and resultant diminishment of epileptic 
activity (Enna and Gallagher 1983).
Each GABAa receptor requires five subunits to combine, forming a chloride- 
selective ion channel (Olsen 1982, Levitan et al 1988, Olsen and Tobin 1990), 
with additional binding sites for BDZs (Ehlert 1986), barbiturates (Willow and
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Johnston 1983), picrotoxin (Olsen 1981), penicillin (Twyman et al 1992), and 
neurosteroids (Majewska 1986). At least thirteen different GABAa receptor 
subunit isoforms have been described, although fewer than ten are likely to 
be of importance (McKernan and Whiting 1996). Many GABAa receptor 
subtypes are found only in selected regions of the brain (MacDonald and 
Kelly 1993), which may account for each drug’s specificity of action.
Less is known about the GABAb receptor. It was initially thought to be purely a 
presynaptic autoreceptor, mediating negative feedback of GABA release from 
the presynaptic neurone. It is now clear that GABAb agonism has other effects 
and it’s physiological role is less clear (Enna and Gallagher 1983).
GABA uptake is undertaken by a structurally-specific high affinity active 
transport mechanism which is present in both astrocytes and neurones 
(Iversen and Kelly 1975) presumably to limit the inhibition mediated by 
synaptic GABA. There are four GABA transport structures described (Borden 
et al 1994), one of which (GAT-1) would appear to be the main site of action 
of known uptake inhibitors such as nipecotic acid. The derivatives also 
demonstrate a lesser inhibition of uptake of GABA by the GAT-3 transporter 
mechanism (Clark and Amara 1994). The transport mechanism is 
temperature-dependent, and requires the presence of extracellular Na+ 
(Borden et al 1994). There is a recognised high correlation between GAD 
activity and the rate of GABA uptake, suggesting that, for neurones at least, 
the extent of GABA uptake is related to the GABAergic activity of the cell 
(Horton 1989).
Once inside the cell, GABA is broken down (Meldrum 1975) by GABA-
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transaminase (GABA-T) to succinic semialdehyde (SSA). Subsequent 
breakdown of SSA occurs via the dehydrogenase enzyme (SSADH), a 
reaction that is preferentially inhibited by sodium valproate (Harvey et al 
1975).
Glycine
Glycine is probably of most importance in inhibiting neuronal firing at the level 
of the spinal cord and brainstem. It’s concentration in grey matter is uniformly 
low, although glycine-mediated inhibition has been reported in some higher 
brain centres, such as the substantia nigra, cerebellum and cortex.
Like GABA, it is known to cause hyperpolarisation via an increase in Cl" 
conductance (Horton 1989), although this effect is mediated by different 
receptors. Glycine is metabolised to serine by serine 
hydroxymethyltransferase (SHMT), and also to glycoxylate by glycine 
aminotransferase. Glycine receptors are selectively antagonised by 
strychnine and other related alkaloids (Horton 1989).
Excitatory Amino Acids
Glutamate and Aspartate
These two dicarboxylic acids have similar kinetics, undergo mutual inhibition, 
and are inhibited by the same structural analogues, indicating that they are 
probably taken up by the same carrier (Figure 3). The metabolism of both is 
tied up with the intermediaries of the tricarboxylic acid cycle: aspartate can be 
formed by transamination of oxaloacetate or from C02 fixation with pyruvate.
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Most of the glutamate available as neurotransmitter is derived from neuronal 
de-amination of glutamine, but it can, however, also be formed by the 
transamination of a-oxoglutarate, or direct amination of oxoglutarate by 
ammonia (Peng et al 1991). Like GABA, glutamate is released by electrical or 
potassium-induced depolarisation. This release is Ca2+-dependent, and is 
inhibited by Mg2+ (Horton 1989, Nicholls and Attwell 1990).
Glutamate receptors may be divided into those that are ionotrophic and those 
that are metabotropic (Watson and Girdlestone 1995). The ionotrophic 
glutamate receptors are further divided by their selective agonists, NMDA, 
kainate and AMPA (Monaghan et al 1989). Activation of these receptors is 
thought to make the channels permeable to Na+, K+ and (in the case of the 
NMDA subtype), Ca2+ (Mayer and Miller 1990). The resultant Na+ influx, Ca2+ 
influx, or K+ efflux is thought to be the basic mechanism by which glutamate 
effects cell death (Watkins and Evans 1981). The metabotropic glutamate 
receptors are G-protein linked (Schoepp et al 1990), and there are currently 
thought to be at least 7 subtypes of this (mGIUi-mGluy) (Watson and 
Gridlestone 1995).
Both glutamate and aspartate are removed from the synapse into glial cells 
and neuronal dendrite endings via a high affinity, sodium dependent uptake 
system (Drejer et al 1982). In glial cells, glutamate is converted to glutamine, 
via glutamine synthase (GS) which is then transported out of the astrocyte 
and taken up by neurones, and again de-aminated to form glutamate: the so- 
called glutamine cycle (Watkins and Evans 1981).
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Abnormalities demonstrable in epileptic brain tissue
The exact delineation of the cause and effects of epileptic activity on 
neurones’ structure and function has still to be carried out. The picture is still 
confused, with no real cohesion between proponents of various theories 
involving disturbance of neuronal networks, altered amino acid metabolism, or 
genetic membrane abnormalities.
It is sensible to assume that different seizure types have, at their root, 
different biochemical and pathological changes, and for this reason, these 
seizure types will be considered separately. Gloor and Fariello (1988) in their 
work on feline generalised epilepsy were supportive of the notion that the 
underlying abnormalities in primary generalised epilepsies were different from 
those in focal seizures.
The Focal Epilepsies
Focal seizures are currently better understood than generalised seizures, and 
in localisation-related seizures there are thought to be two different primary 
cellular events, which result in the abnormal activity that produces either ictal 
or interictal discharges (Dingledine et al 1990, Meldrum 1988). The distinction 
between the two types of discharges is made, by definition, on whether it is 
sustained enough or severe enough to produce any clinical sequelae.
Burst firing in single neurones is the basic electrical event underlying the 
appearance of interictal discharges on EEG, having been observed in acute in 
vitro models, as well as in chronic seizure foci in animals and man (Meyer et 
al 1986). The cellular mechanisms responsible for these episodes are
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discussed below. During interictal discharges, intracellular recording has 
shown there to be a paroxysmal depolarising shift (PDS) in the resting 
membrane potential, consisting of a short but sustained period of 
depolarisation, which facilitates a burst of action potentials (Ayala et al 1970). 
Inhibitory interneurone input (Meldrum 1988), then brings about a phase of 
hyperpolarisation which helps to prevent the rapid re-occurrence of a further 
PDS. The PDS in each individual neurone contributes to the extracellular field 
potential which manifests as the interictal spike on surface EEG tracings 
(Matsumoto and Ajmone-Marsan 1964).
Horizontal spread of these interictal events within the same class of neurones 
can result in the progression from involvement of a single cell to multiple burst 
firing within the same neuronal aggregate (Meyer et al 1986). Inhibitory 
mechanisms are responsible for limiting the space and time over which this 
recruitment can continue (Meldrum 1988). These inhibitory mechanisms will 
certainly be synapse mediated (Traub et al 1987), and may also involve gap 
junctions between neurones, extraneuronal ionic changes, and ephaptic 
spread (Dichter and Ayala 1987).
Interictal firing spreads to a variable degree, but the rate of spread increases 
as the abnormal events become more intense and rhythmically recurrent 
(Meldrum 1988). The strength of local inhibitory control mechanisms is an 
important controlling factor determining the rate and extent of any spread.
In projection areas, during this initial activity, there is enhanced inhibitory tone 
which inevitably fades with repetition. Where seizure activity occurs, 
excitatory neurotransmission is predominant, resulting in synchronised burst
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firing in subsequent synaptically-linked neuronal aggregates (Meldrum 1990). 
Collingridge and Singer (1990) asserted that this spread relies on the 
phenomenon of frequency-dependent inhibitory fade.
Where discharges fail to progress to a stage where clinical seizure activity 
occurs, then the event is an interictal discharge. The termination phase of this 
episode involves the onset of sustained hyperpolarisation (Meldrum 1990), 
mediated by inhibitory processes. Why only a proportion of interictal 
discharges progress to frank seizure activity is, like many aspects of basic 
epileptogenesis, a mystery, but it may be the result of frequency-dependent 
depression of local inhibition (Prince 1985).
Disinhibition has two results. Not only will the interictal discharge be 
propagated to the neuronal aggregate, but there is a marked reduction in the 
duration of the hyperpolarisation phase. Increased excitation and decreased 
inhibition combine to give perfect conditions for an increase in frequency of 
interictal discharges and an increase in their propagation. This situation has 
been likened to a fusion of successive PDSs with resultant lack in any 
intervening repolarisation (Meldrum 1988). Ayala et al (1970) characterised 
the prolonged depolarisations with accompanying bursts of action potentials. 
With accompanying disinhibition, this abnormal electrical activity will be 
sufficiently sustained to propagate to the descending motor tracts, resulting in 
clinical seizure activity.
Burst firing, as defined above, could occur in several ways. It may either be 
the result of activity in an abnormal ‘epileptic’ neurone, or may occur in a 
normal neurone either as a response to abnormal input at the nerve terminal-
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dendrite interface, or secondary to an alteration in the local ionic micro­
environment (Meldrum 1989).
Other theories on the basic mechanisms of epileptogenesis include, as a 
prerequisite, some event causing damage to the affected brain tissue. This 
event may be ‘subclinical’ such as minor head injury, or neonatal hypoxia, and 
may excite no clinical interest at the time of occurrence. Pathological 
examination of epileptic foci in human brain has shown some underlying 
neurodegeneration (Schwartzkroin 1994), and this may be a feature of all 
secondary epilepsies. Meldrum (1989) described the appearance of 
histological changes arising from cellular microdysgenesis, congenital 
vascular malformations, neoplasms, ischaemia / infarction, traumatic brain 
lesions, infarcts, abscesses, and cysts. Also implicated was the diffuse 
degeneration associated with diverse neurological disorders, such as 
Huntington’s chorea and Alzheimer’s disease
Whether localised injury preferentially affects GABAergic neurones is a point 
of some debate. There is evidence in animals to suggest that, in infancy, 
hypoxia can selectively damage cortical GABA neurones (Sloper et al 1980). 
Ribak et al (1979) showed that local application of alumina gel to cerebral 
cortex in monkeys prompted the appearance of an epileptic focus which 
demonstrated a selective loss of GABAergic nerve terminals. Babb and 
colleagues (1989) on the other hand, showed that neurones staining for 
glutamic acid decarboxylase (GAD) were not selectively affected in human 
epileptic hippocampus.
Ischaemic lesions of the spinal cord have been related to the selective loss of
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inhibitory glycinergic interneurones (Meldrum 1989), a decrease in inhibition 
and resultant spasticity. Potential mediators of this specific cell loss have 
been associated with cellular microdysgenesis, ischaemia / infarction, 
traumatic injury, and focal neoplasia. Meldrum (1989), however, felt there was 
an equal reduction in both excitatory and inhibitory neurones from epileptic 
foci.
Whatever the cause of loss of GABAergic neurones, when their number or 
function is impaired, the balance tips towards excitation, and other neurones 
are predisposed to burst firing (Miles and Wong 1987). When GABAergic 
interneurones can induce adequate hyperpolarisation, the soma is well 
protected against invasion by burst firing and PDSs from the nerve terminal 
dendritic interface (Meldrum 1989). Where GABAergic neurones have 
incomplete input, the reduced hyperpolarisation is not enough to resist 
electrical changes, and somal recordings will show evidence of PDSs and 
burst firing (Schwartzkroin and Wyler 1980). The loss of excitatory neurones 
may be a direct result of seizure activity, as has been shown in electrically 
kindled seizures in animals (Sutula 1990).
Is it possible that a seizure-induced alteration in neuronal glutamate 
sensitivity may also predispose to epileptic activity? Meldrum (1989) 
described secondary phenomena occurring with cell loss induced by local 
neuronal degeneration which may increase the predisposition to spontaneous 
neuronal discharge. Neurones which are postsynaptic to the degenerating 
cells ‘upgrade’ their receptors and show supersensitivity to the 
neurotransmitter which is lacking. The hippocampus of kindled rats will
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demonstrate this under experimental conditions. Kindling-induced loss of 
excitatory pyramidal neurones is followed by supersensitivity of CA1 dendritic 
zones and the dentate molecular layer to excitatory amino acid (EAA) 
neurotransmitters such as aspartate and glutamate (Mody and Heineman 
1987). Interestingly, Louvel et al (1992) found an alteration in responsivity to 
NMDA in slices of neocortices from patients with epilepsy, a finding that would 
be consistent with this hypothesis. This may predispose to an exaggerated 
response to normal extracellular concentrations of EAA, perhaps sufficient to 
precipitate burst firing. There is further evidence to support this theory, where 
neocortex which has been deafferented by undercutting shows an enhanced 
tendency to display epileptiform “afterdischarges” following electrical 
stimulation (Meldrum 1989). Some animal models suggested that the 
development of this supersensitivity develops over a similar length of time as 
can be taken to develop focal epilepsy. In patients developing epilepsy 
secondary to focal pathology, however, the time course is variable and often 
much longer than the time required to upgrade receptors (Meldrum 1989). 
Where synaptic degeneration occurs, adjacent dendrites can ‘sprout’ and 
grow to form new synapses in the vacant spaces. These synapses can 
provide inappropriate input (Meldrum 1989), as discussed below. Neuronal 
degeneration will inevitably lead to some degree of sprouting and 
supersensitivity, and the combination may provide the basis for all 
symptomatic epilepsies (Meldrum 1989).
The use of silver staining techniques shows neuronal changes which are 
universally seen in histologically examined epileptogenic tissue. The
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architecture of the hippocampus and neocortex becomes simplified. There is a 
progressive loss of the complex dendritic trees, with a loss of spinous 
processes. The reasons for this degeneration are unclear, although it may be 
at least in part due to supersensitivity to n-methyl-d-aspartate (NMDA), as is 
observed in electrophysiological studies (Meldrum 1989). Such simplification 
has been observed experimentally, in the region of an alumina-induced 
epileptic focus in the monkey cortex (Ribak et al 1979). How this can occur 
alongside the occurrence of sprouting is not fully understood, and it should be 
said that sprouting is a process which is not specific to epilepsy, having been 
reported in a wide range of other neurodegenerative disorders (Meldrum 
1989).
Simplification of epileptic tissue may correlate with an enhanced tendency to 
develop PDSs, either via an increased instability of the degenerating neurone, 
or an increased susceptibility of the soma to invasion due to electrotonic 
shortening (Meldrum 1989).
The role of glial cells in the development of epilepsy
Glial cells are the predominant cell type in the CNS, outnumbering neurones 
by a factor of ten in mammalian brain (Kimelberg 1983). Around half of all glial 
cells are astrocytes, and these are now subdivided into type I and type II 
astrocytes. Traditionally, as the name suggested, it was believed that glial 
cells were the glue in the CNS, being a sophisticated scaffolding around 
which neurones are draped. At their most sophisticated, astrocytes were 
thought to act out a ‘housekeeping’ role (Montgomery 1994). The evolution of
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astrocyte culture techniques has allowed selective culture of type I and type II 
astrocytes, and thereby permit differentiation of their physiological function. 
Type I astrocytes are the more common, and among other functions, are 
involved in potassium homeostasis. They are known to accumulate amino 
acid transmitters, express receptors for a multitude of neurotransmitters, and 
play a role in calcium signalling (Juurlink and Hertz 1992).
Type II astrocytes, by contrast, demonstrate many properties that are 
traditionally ‘neuronal’ in nature. They have been shown to synthesise and 
take up GABA, and there is evidence that they may release GABA in 
response to glutamatergic stimulation. They possess intense basal glutamine 
synthase activity which may signal that they play a major role in nitrogen 
homeostasis and / or neurotransmitter inactivation (Juurlink and Hertz 1992).
In some brain areas, astrocytes comprise up to half of the total tissue volume 
(Kimelberg 1983), and given the complexity of their role (Montgomery 1994), 
and the frequency with which they appear in the CNS, it would seem 
reasonable to assume that astrocytes play some part in the development of 
epilepsy.
One long-observed characteristic of epileptic pathology is a localised increase 
in the number of fibrous or reactive astrocytes, or gliosis (Meldrum 1990). 
Gliosis is seen in epileptogenic foci and in diffuse degenerative disorders, and 
is known to develop secondary to seizure activity. It has been suggested that 
these reactive astrocytes may be functionally inept, and that they may fail to 
carry out the normal protective ‘housekeeping’ duties of the functional 
astrocyte. Walz (1989) discussed the capacity of the astrocyte to act as a
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“potassium sink”, postulating that any impairment of this capacity could 
theoretically contribute to spontaneous neuronal discharge. Studies of 
astrocyte function in epileptic foci, however, have actually demonstrated an 
enhanced ability to regulate extracellular potassium concentrations (Meldrum 
1989), so the role of gliosis in basic epileptogenesis remains to be evaluated. 
The role of the astrocyte in maintaining and perhaps initiating neuronal output 
is becoming clearer (Juurlink and Hertz 1992). As further work is carried out 
on astrocyte subpopulations, they may be found to have an increasingly 
important part to play in initiation and limitation of seizure activity.
Changing neuronal networks and seizure propagation 
One further approach to the rationalisation of localisation-related seizures 
involves development of theories in changes to neuronal networks. Since the 
days of Gowers, it has been known that seizures beget seizures. Clinical 
experience would suggest that the more epileptic activity that a patient 
experiences, the more chance there is that further seizure activity will occur in 
the future.
Why this should happen is not entirely clear, but two recent histologically- 
based theories have been formed (Shin and McNamara 1994) which may 
explain this tendency.
The normal function of neuronal networks is shown in diagrammatic form 
below. ‘G’ represents the cerebellar granule cell which receives excitatory 
input from the dendrites above. When ‘G’ depolarises, this exerts positive 
effects on the basket cell (‘B’) both directly and indirectly via the mossy cell
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(M ). The basket cell produces inhibitory effects on ‘G’ which causes a 
hyperpolarisation, inhibiting further depolarisation as part of a negative 
feedback loop. In animals with epilepsy, it is known that continued excitotoxic 
stimulation causes degeneration of memory cells, and it is thought that this 
feedback is disrupted in one of two ways (see Figure 5).
1) The dormant basket cell theory
Seizure induced death of ‘M’ leads to a dormancy of basket cells. Any 
excitatory activity by ‘G’ therefore fails to provoke inhibitory input from ‘B’, and 
leaving ‘G’ more susceptible to continued depolarisation following excitatory 
input from synapses.
2) The Mossy Fibre Sprouting Theory
As a response to the loss of M  by exposure to exitotoxins, the mossy fibres 
from ‘G’ sprout and synapse to replace ‘M’s input to ‘G’s dendrites. This 
positive feedback loop, also lacking the excitation of inhibitory basket cells, 
leads to a predisposition towards excessive epileptic activity. Masakuwa et al 
(1992) suggested that the degree of excitability of human hippocampal slices 
is directly correlated with the extent of mossy fibre sprouting seen 
histologically.
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The idiopathic generalised epilepsies
Despite some earlier expectations, we have not yet found a single molecular 
defect which can on its own account for the development of the primary 
generalised epilepsies (PGEs). This section will deal with the evidence of 
specifically disordered neuronal structure and function related to PGE in 
animal models and in their human counterparts.
Given the pattern of distribution of animal seizure models such as the 
audiogenic seizures or the GAERS, and allowing for the strong family 
histories which occur in many cases of PGE, it would be fair to assume that 
any defects which lead to PGE are genetic in origin. The progress in 
elucidation of specific genetic abnormalities which correlate with clinically 
well-defined epilepsy syndromes adds further weight to this assumption.
The pathological processes have been best demonstrated in the absence 
epilepsies, where the ‘spikes’ of the characteristic rhythmic synchronised 
activity on surface EEG represent excitatory postsynaptic potentials 
superimposed on action potentials, and the ‘waves’ represent prolonged 
inhibitory postsynaptic potentials (Gloor and Fariello 1988). In this form of 
primary generalised seizure at least, therefore, inhibitory processes must by 
definition be intact, so the simplistic notions of epilepsy arising from excesses 
of excitation or paucity of inhibition which serve us well in explaining 
localisation-related epilepsies, must (unfortunately!) be laid to rest.
Evidence for qualitative changes in neuronal tissue in the primary
generalised epilepsies.
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Samples of brain tissue prone to epileptic activity have been shown to 
manifest defects in adenosine triphosphate (ATP) hydrolysis mechanisms 
which drive the cell membrane ionic pumps (Grisar et al 1992). In DBA/2 
mice, a species prone to audiogenically induced seizures, both Na+-Kf 
dependent and Ca2+-activated ATPase systems were reduced in neuronal 
membranes (Palayoor et al 1986). Rosenblatt et al (1977) confirmed the 
presence of abnormalities in membrane ATPases in strains of other species 
such as chicks and gerbils prone to induced seizures. Meldrum (1989) and 
Grisar and Delgado-Escueta (1986) described abnormalities in Na+-hC and 
Ca2+-dependent ATPases in human epileptogenic tissue. Significantly, 
however, reductions in Na+-K*-dependent ATPase have been shown even 
where the seizure focus has been induced by experimental work, raising the 
possibility that changes in ATP-ase activity may be a secondary phenomenon. 
Other alterations have been described in genetic models of epilepsy. Age- 
dependent changes in density of GABAa subunit labelling have been found in 
the GAERS strain of rats by autoradiography (Spreafico et al 1993), with no 
demonstrable changes in GABAb receptor density. Significantly, this decrease 
in the distribution of B2-B3 GABAa-R subunits is demonstrable only at the age 
where absence epilepsy becomes apparent, again raising the possibility that 
GABAa-R expression is altered by seizure activity.
GAERS also have alterations in glutamatergic transmission, demonstrating 
less sensitivity to glutamate receptor blockade by CNQX than a control 
population (Pumain et al 1992). Staining of glutamate receptor subunits, again 
in GAERS, showed a decrease in proportion of GLU-R2 and GLU-R3 subunits
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compared to control rats (Avanzini et al 1996) underlying these qualitative 
changes.
To understand how changes in calcium channels may predispose to the 
seizure generations, the role of calcium currents in normal thalamic neurones 
has to be defined. Different types of thalamic neurones play different roles in 
thalamic function. Curtis and Avanzini (1994) summarised the roles played by 
thalamocortical relay (TCR) neurones, local circuit interneurones (LCI), and 
neurones that form the reticularis thalami (RT neurones).
Chief among the differences between TCR, RT and LCI neurones is a 
variation in voltage-dependent ion channels (Curtis and Avanzini 1994) which, 
at least in part, control neuronal firing. Curtis and Avanzini (1994) described 
five key voltage-dependent currents: the inward T-type calcium channel (lT), 
the outward calcium-activated cationic channels (lC) U p, and ICan), and the 
hyperpolarisation-activated cationic current (lh). When the thalamic neuronal 
membrane potential is depolarised by neuromodulatory activity, lT is 
inactivated, and the single spiking, relay mode of activity is promoted. 
Hyperpolarisation, however, de-inactivates lT channels, producing a burst of 
action potentials superimposed on a low-threshold calcium spike. This 
depolarisation inactivates lh channels, while the associated calcium entry 
promotes the activation of Ca+-K+ currents. These events lead to a GABAb- 
mediated hyperpolarising overshoot which is suitable for reactivation of the lT 
current, i.e. conditions suitable for a repeating pattern. This cycle can be 
broken by, for example, acetylcholine or monoamines which shift the 
membrane potential away from that required for reciprocal interactions, and
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into a range which leads to the tonic firing mode.
On comparison with control populations, qualitative changes have been 
described in thalamic calcium channel activation of GAERS. Thalamic T-type 
Calcium currents (lT) are specifically increased in GAERS (Curtis and 
Avanzini 1994), which may predispose to the rhythmic oscillatory activity 
described above. The dysfunction of calcium channels leading to oscillatory 
thalamic activity is a reasonably attainable target for putatively anticonvulsant 
drugs, assuming that the actions are specific enough. Certainly the 
anticonvulsant actions of at least one drug, ethosuximide, are probably due to 
a blockade of T-type calcium channels (Dichter and Brodie 1996).
Evidence for changes in neuronal interaction in generalised epilepsies
While basic properties of neuronal cell membranes are known to be altered in
some seizure types, the site of the neuronal changes is also important for the 
development of a primary generalised epilepsies. Because of its functional 
connections, the thalamus is known to be important in primary generalised 
epilepsies. Why should a disorder of thalamic function cause such 
generalised regularised pathological behaviour?
As defined above, TCR and RT neurones are driven by inputs from excitatory 
synapses. In addition, TCR neurones are inhibited by RT and LCI neurones. 
LCI neurones are responsible for local feedback and feed-forward circuits 
within the thalamus, while RT neurones exert a more diffuse generalised 
inhibition, whose extent varies with the functional state of activation of the 
thalamus. Activation of RT neurones, therefore will lead to an inhibition of,
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among others, TCR neurones.
Given the connections described, bursting behaviour in TCR neurones will 
therefore lead to excitation of, and subsequent inhibition from the RT system 
in a cyclical pattern which could account for the characteristic synchronous 
EEG changes.
The role of LCI neurones in synchronisation of thalamic activity is less well 
understood, and they are known not to be essential in the maintenance of 
spindle rhythm generation. The function of LCI neurones may be to control 
TCR neurone excitability during the relay mode (Curtis and Avanzini 1994). 
The state of activation of the thalamus both influences and is dependent on 
the activity of the RT neurones. The sleeping, oscillatory mode of activation is 
associated with rhythmic burst firing, while the relay mode (where the 
thalamus is processing sensory information) is associated with tonic firing, or 
a desynchronised state. Any switch from relay to oscillatory function, and vice 
versa, depends on alterations in membrane and synaptic properties of the 
thalamic neurone. These changes come about as a result of intrathalamic and 
cortico-thalamic interactions and by the influence of brainstem 
catecholamines and cortical afferents (Curtis and Avanzini 1994). That the 
physiology of normal sleep associated changes should be so closely linked 
with the pathophysiology of generalised seizures would come as no surprise 
to the doctors of the nineteenth century who were quick to spot an association 
between fatigue or sleep deprivation and seizures. Recently Niedermyer 
(1996) among others has stressed the importance of arousal and sleep 
deprivation on all forms of PGE and their electrophysiological counterparts.
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Summary
The development of PGE is not a simple process which can be ascribed to the 
deviant action of one simple molecular or membranous defect, or even a 
defect at one specific site. Each clinical manifestation of PGE will probably 
prove to be due to a number of factors, including multiple gene defects which 
lead to the gross changes of increased neuronal excitability.
A multifactorial basis for seizures may play an important role in determining 
our therapeutic approach to the generalised epilepsies. Given the degree of 
complexity, simply decreasing the effects of excitatory neurotransmission will 
not in itself prove sufficient. Likewise, this multifactorial aetiology will go some 
way to explaining why an increase in GABAergic tone may merely aggravate 
primary generalised epilepsies in both human (Michelucci and Tassinari 
1989) and animal models (Coenen et al 1995). The occasional AED-related 
increase in seizures (observed at some point with almost every known AED) 
may prove to be a result of the multiplicity of actions of each of these 
complicated compounds.
This wide range of pathological processes involved in epileptogenesis should 
at least reinforce the concept of carefully examining the effects of all new 
AEDs on every potential convulsant and anticonvulsant mechanism. An 
anticonvulsant effect at one site is no guarantee against convulsant actions at 
another. Only through further work to elucidate the genesis of partial and 
generalised epilepsies, and to fully assess the effects of each AED will we be 
able to accurately predict the reaction of individuals to specific AEDs.
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Is disturbed amino acid neurotransmission the root cause of epilepsy?
Evidence for the role of decreased inhibition as a cause of epilepsy
• Epileptogenic foci in primates show a selective loss of GABAergic inhibitory 
terminals (Ribak et al 1979), implying some local deficit in inhibitory 
activity.
• In tissue resected from humans there is a demonstrable decrease in GAD 
activity alongside increased GABA-T activity (Lloyd et al 1985), and a 
decrease in binding to the GABAVbenzodiazepine receptor complex (Savic 
et al 1988).
• CSF GABA levels are reduced in patients with chronic epilepsy (Maynham 
et al 1980).
• GABAergic impairment is the basis for many chemically-induced animal 
seizure models (Fisher 1989).
• Increase in GABA concentrations or GABAergic actions is likely to be an 
important action of some anticonvulsant compounds (vigabatrin, tiagabine, 
valproate) (Schachter 1995).
Evidence for the role of increased excitation as a cause of epilepsy
• Glutamate is known to be epileptogenic when applied directly to 
mammalian brain (Stone and Javid 1983), or when given systemically 
(Bradford and Dodd 1975).
• Kindling (an animal model of epilepsy) is dependent on the presence of 
glutamate (Sutula 1990)
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• An increase in glutamate receptor density has been demonstrated In 
children with generalised seizures, (Represa et al 1989), and similar 
changes have been shown in adults with temporal lobe epilepsy (Geddes 
et al 1990).
• In patients with generalised epilepsy, and in their first degree relatives, 
plasma glutamate has been shown to be increased (Janjua et al 1992).
• In animals (Koyama 1972) and in man (van Gelder et al 1972), there is 
decreased glutamate concentration within epileptic foci, which may explain 
glutamate receptor upregulation.
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Antiepileptic Drug Treatment
The Established Anticonvulsants
As this thesis nears completion, lamotrigine, and to a lesser extent vigabatrin, are in some centres considered to have attained the status of ‘established’ anticonvulsant drugs. For the purposes of this 
thesis, the word ‘established’ will be used to describe those drugs which were 
licensed for use prior to the late 1980’s. Before we dwell on the qualities of 
the newer agents, it is appropriate to summarise the qualities of the older 
agents at this point.
Phenobarbitone
Phenobarbitone was first widely used as a 
sedative drug, its anticonvulsant efficacy 
being discovered serendipitously. First 
proven to be effective in 1912 by Loewe 
et al (Gallagher and Freer 1985), it is one 
of the family of barbiturate compounds 
that have been synthesised as part of the search for the ideal anticonvulsant 
(Pritchard and Ransom 1995). With the advent of better AEDs, the present 
day use of barbiturates in this country is more usually as a remnant of 
longstanding AED regimes.
Barbiturates have been shown to have a wide range of effects on many 
neurobiological systems (Prichard and Ransom 1995). They have a specific 
binding site on the GABAa receptor, the binding of which increases the 
frequency of chloride channel opening for a given exposure to GABA
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Phenobarbitone
(MacDonald and Olsen 1994). Phenobarbitone has been shown to be 
effective against partial and generalised tonic-clonic seizures, as well as in 
prevention of febrile seizures and treatment of some cases of status 
epilepticus (Painter and Gauss 1995).
The continued use of this landmark in AED development has suffered 
because of its sedative effects (Schmidt 1985), although paradoxically 
hyperactivity and irritability are more important adverse effects in paediatric 
practice (Consensus Statement 1980). The long term irreversible effects of 
these symptoms are not clear (Guest et al 1970).
Another drawback of phenobarbitone is that, unusual among anticonvulsant 
drugs, withdrawal can induce further seizures (Butchal et al 1968), while 
development of tolerance can also prove to be a problem (Gallagher and 
Freer 1985). Patients who remain well controlled on phenobarbitone should 
not have their treatment altered unless there is good reason, because of the 
danger of withdrawal seizures.
Phenobarbitone is a very cheap anticonvulsant, and will remain popular in 
developing countries for that reason. In the developed world, where cost is 
less of a determining factor, it will remain less attractive than its better 
tolerated descendants.
Primidone
Although it has anticonvulsant activity, primidone has now ceased to be used 
as a first line anticonvulsant agent, following the large controlled trial (Mattson 
et al 1985) which showed it to be less effective and less well tolerated than
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carbamazepine, phenytoin or phenobarbitone.
The main side effects leading to 
withdrawal were drowsiness, gastro­
intestinal intolerance and psychosis. 
Physical dependence (Anonymous 1992) 
and, in common with phenobarbitone, 
withdrawal seizures (Norton 1970) are also barriers to long term use. Aside 
from those patients who are already well controlled on primidone, it is widely 
recognised that this drug has no role to play in the formulation of modern 
anticonvulsant regimes (Brodie 1990).
Phenytoin
Phenytoin entered the clinical arena in 
1938 (Merrit and Putnam, 1938), and is still 
considered to be a first line anticonvulsant, 
especially in the USA (Brodie and Dichter 
1996). Its activity against partial seizures, 
until then very resistant to treatment, was one of it’s main advantages over 
phenobarbitone (Jones and Wimbish 1985). Phenytoin was rightly considered 
a breakthrough in AED development because, unlike its predecessors, the 
antiepileptic properties it displayed outstripped its sedative qualities. More 
sophisticated psychomotor testing however, has confirmed that in both 
patients and volunteers, phenytoin causes a deleterious effect on
Phenytoin
Primidone
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psychomotor and cognitive processing (Thomson and Trimble 1981, 
Andrewes et al 1986, Gilham et al 1990). In some patients with a degree of 
learning disability, there is an increase in intellectual function (Goldberg and 
Kurland 1970), although this may be secondary to improved seizure control. 
Phenytoin is one of the most extensively studied AEDs, and laboratory studies 
have demonstrated it’s effect on many facets of neuronal physiology and 
biochemistry. It modifies Na7K* ATPase in-vitro and in-vivo (Delguado- 
Escueta and Horan 1980), inactivates sodium channels (MacDonald and Kelly 
1993), inhibits neurotransmission (DeLorenzo 1986), blocks L-type calcium 
channels (Rivet et al 1990), and affects numerous other neuronal biochemical 
parameters such as chloride permeability, cyclic nucleotide metabolism, and 
metabolism of GABA, glutamine and glutamate (DeLorenzo 1995). It is 
unlikely that any one single action is the source of it’s anticonvulsant activity, 
and more probable that this depends on a combination of it’s many effects. 
Phenytoin has marked activity against partial seizures with or without 
secondary generalisation. In some developed countries, particularly the USA, 
it is also drug of choice for primary generalised epilepsies. Adjunctive 
phenytoin has been found to be of use in patients with multiple seizure types 
if other drugs fail to control the tonic-clonic component. Intravenous phenytoin 
is still considered the treatment of choice for status epilepticus (Wilder 1995). 
The saturable kinetics and multiple drug interactions exhibited by phenytoin 
combine to make it a drug that demands careful monitoring during dose 
titration (Brodie 1990) particularly when it is one of the constituents of 
polypharmacy. In clinical practice this need for monitoring is a distinct
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disadvantage (McKee and Brodie 1994).
Chronic phenytoin use, even at therapeutic concentrations can cause 
hirsutism, gum hyperplasia and facial coarsening. Although not life 
threatening, these cosmetic effects can make the drug unpleasant to use in 
young women. Vitamin D metabolism can be affected, to the extent of causing 
hypocalcaemia or osteomalacia in non-ambulant patients (Ashworth and Horn
1977), and interference with folate metabolism can result in a mild macrocytic 
anaemia of folate deficiency (Jones and Wimbish 1985). There is a 
recognised risk of fetal abnormality with phenytoin treatment (Hanson and 
Smith 1975), although on balance, the risks to the fetus of uncontrolled 
epilepsy would justify phenytoin use in pregnancy in some patients (Brodie 
and Dichter 1996).
In the UK at least, the rise in popularity of valproate has displaced phenytoin 
as the treatment of choice for generalised seizures. In other developed 
countries such as the USA however, phenytoin remains a first-line 
anticonvulsant drug.
Carbamazeoine
Carbamazepine is chemically related to the tricyclic antidepressants, and was 
first used in trials of antiepileptic activity in 1963 by Theobold and Kunz. It has 
become one of the first line anticonvulsants in the UK, with particular benefit 
in localisation-related seizures whether or not there is any secondary
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generalisation (Cereghino et al 1974, Troupin et al 1977).
Like phenytoin, carbamazepine has been 
shown to have a wide range of 
neurochemical and neurophysiological 
actions (MacDonald 1995a). Although the 
blockage of sodium channels, which limits 
sustained repetitive firing, is probably the 
most important effect, other synaptic effects have been described (MacDonald 
1995a). Synaptic effects of carbamazepine include non-competitive NMDA 
receptor blockage (Lancaster and Davies 1992), adenosine-A1 receptor 
antagonism (Skerrit et al 1983), enhancement of effect at the GABAa receptor 
(MacDonald 1992), and inhibition of uptake of norepinephrine by brain 
synaptosomes (Purdy et al 1977), although the clinical importance of these is 
dubious.
In the UK, carbamazepine is considered the drug of choice for any patient 
with partial seizures, whether or not there is any secondary generalisation. It 
has documented efficacy against primary generalised seizures, but not 
against generalised absences, or myoclonic seizures, which may be 
exacerbated by the introduction of carbamazepine (Sheilds and Saslow 
1983).
Although it is generally well tolerated, carbamazepine’s autoinduction and 
multiple pharmacokinetic interactions are disadvantageous in terms of general 
use of the drug (Perucca and Richens 1984, McKee et al 1992), leading to 
marked inter- and intraindividual variation in response. Rashes of variable
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severity occur in up to 15% of patients on carbamazepine, and hyponatraemia 
can occur in some patients (Gram and Jensen 1989). Haematological 
monitoring has been shown to be unnecessary, as the risk of agranulocytosis 
or aplastic anaemia is sufficiently slight (Holmes 1995). Neurological side 
effects can occur, mainly nausea, headache, dizziness, and diplopia. The 
incidence and severity of these correlate with the levels of both 
carbamazepine and it’s active metabolite carbamazepine, 10-11-epoxide 
(CBZ-E) (Patsalos 1985, Gilham et al 1988). The incidence of drowsiness is 
probably less than with some other first line anticonvulsants (Thompson and 
Trimble 1982, Andrewes 1986, Gillham et al 1990), although psychomotor 
testing has shown there to be a discernible negative effect on psychomotor 
function when carbamazepine is administered to both healthy volunteers 
(Macphee et al 1986a) and patients with epilepsy (Macphee et al 1986b). 
Carbamazepine reportedly has positive effects on mood (Loiseau and Duche 
1995), although this is not surprising given it’s chemical similarity to currently 
used antidepressant medicines.
Carbamazepine is a highly successful antiepileptic drug, although it does 
have some limitations. This success has been augmented by the development 
of the slow release preparation, which leads to an increased tolerability via a 
decrease in plasma level variability, while not significantly reducing bio­
availability (McKee et al 1991).
Sodium valproate
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The discovery of the anticonvulsant properties of sodium valproate were 
rather serendipitous. In 1963, valproic acid was being used as a solvent for 
new anticonvulsants undergoing testing (Meunier et al 1963), when it was first 
noted as having antiepileptic effects. Valproate was formally licensed for use 
in 1974, having been tested in most animal models of epilepsy, unlike it’s 
predecessors (Fariello et al 1995).
The exact mechanism by which sodium 
valproate exerts its anticonvulsant effect is 
unknown. It has several effects on neuronal 
GABA metabolism, including inhibition of 
succinic semiadehyde dehydrogenase 
(SSADH) (Harvey et al 1975), and GAD induction (Loscher et al 1991) which 
combine to increase whole brain GABA content (Godin et al 1969). The 
inhibitory effect on depolarisation-induced gamma-hydroxybutyrate release 
(Vayer et al 1988) may be of some importance, as may blockage of voltage- 
sensitive sodium channels (MacDonald and Kelly 1993), an increase in Ca2+- 
dependent K* influx (Francesschetti et al 1986), and a decrease in 
concentration of excitatory amino acids such as aspartate (Schechter et al
1978).
Valproate’s efficacy against generalised tonic clonic seizures (Gram and 
Bentsen 1984, Shakir et al 1981) and partial seizures (Shakir et al 1981) have 
been confirmed. Other seizure types, such as myoclonic epilepsy and 
absence attacks (Sato et al 1982, Gram and Bentsen 1985, Chadwick 1990) 
are ameliorated by valproate, and the drug is considered treatment of choice
Valproic acid
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in both conditions (Brodie and Dichter 1996).
Adverse effects of valproate include tremor, hair loss and weight gain (Gram 
and Bentsen 1985) the latter two causing problems particularly among young 
female patients. Dose reduction may partially solve these, but withdrawal of 
the drug may be necessary in some patients. Rarer, though more serious, are 
the episodes of hepatitis, hepatic failure, pancreatitis, thrombocytopenia, and 
coma (Dreifuss 1989) which have been associated with sodium valproate use. 
The adverse effects, particularly the hepatic ones, are more common in 
children, but their rarity has ensured that valproate is still considered to be 
safe. Use of the compound in countries such as the USA is still limited as a 
result of concerns regarding these adverse effects.
Valproate does have some advantages over other first line agents, including a 
lack of sedation (Thompson and Trimble 1981, 1982, Gillham et al 1991). 
Cognitive effects are less severe than with other AEDs, and valproate use has 
been recommended where psychomotor performance is an important
r
consideration (Gilham et al 1991).
Valproate is not an enzyme inducer, and unlike the other first line AEDs, it 
does not display autoinduction or saturable pharmacokinetics. Neither efficacy 
nor toxicity of valproate can be correlated with plasma levels (Chadwick 1985, 
Brodie and Feely 1988), so serum level monitoring is not necessary in 
patients on valproate monotherapy. Drug interactions are less troublesome 
than with enzyme-inducing AEDs, although valproate has some enzyme 
inhibiting properties (Kapetanovic and Kupferberg 1980, Koch et al 1981). 
This is of clinical significance when the drug is added to existing
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anticonvulsant treatment regimes (Levy and Koch 1982, Leach and Brodie 
1995). In summary, valproate is one of the most important anticonvulsants in 
clinical use, and along with carbamazepine, is one of the most commonly 
used in the UK.
Benzodiazepines
In 1960, Randall and colleagues 
demonstrated the efficacy of the 
benzodiazepine compounds in 
preventing seizure induction by 
maximal electroshock and 
pentylenetetrazol. This family of 
compounds probably exert their anticonvulsant effect on binding with their 
specific binding site on the y-subunit of the GABAa receptor (Ehlert 1986), 
which results in an increased hyperpolarisation of affected neurones (Twyman 
et al 1989).
An additional effect on sodium channels has been described, similar to that 
caused by carbamazepine, phenytoin, and sodium valproate. This blockage 
occurs at concentrations of benzodiazepine attained during treatment of 
status epilepticus, and, as it is not blocked by flumazenil (McLean and 
MacDonald 1988), it would appear to be independent of the effect on GABAa 
receptors. The reported changes in calcium channels (MacDonald 1995b)
occur at concentrations higher than those attained during treatment, and
would appear to have little clinical relevance.
Diazepam Clobazam
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Benzodiazepines still have a place in the immediate, parenteral treatment of 
status epilepticus (Simon 1985). Although diazepam is the benzodiazepine 
most commonly used in this situation, the derivatives clobazam (Shorvon 
1995) and clonazepam (Shakir et al 1979, Mikkelsen et al 1981) have been 
shown to have beneficial effects against a wide range of seizure types when 
given orally as adjunctive long-term treatment. Clobazam is less sedative than 
the older benzodiazepines (Hindmarch and Gudgeon 1980, Trimble and 
Robertson 1986) but as with the barbiturates, tolerance (Trimble and 
Robertson 1986) and withdrawal seizures (Fialip et al 1987, Allen et al 1983) 
can be a problem. Despite this, clobazam can be useful when given as 
intermittent adjunctive treatment, as in the treatment of catamenial epilepsy 
(Feely et al 1982).
Ethosuximide
First introduced in 1958, this drug remains a 
useful compound in paediatric practice in the 
treatment of absence seizures (Brodie and 
Dichter 1996). It acts by blocking voltage- 
dependent calcium conductance in thalamic 
neurones. Side effects of ethosuximide use are either gastro-intestinal 
(nausea, vomiting, abdominal pain) or involving the central nervous system 
(lethargy, dizziness, ataxia).
Ethosuximide does not affect the metabolism of other drugs, but its own
Ethosuximide
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metabolism is affected by enzyme-inducing or inhibiting antiepileptic drugs 
(Pisani et al 1990). The efficacy and safety of valproate has ensured that 
ethosuximide has become a second line treatment for this seizure type (Sato 
et al 1982).
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Monotherapy or Polypharmacy?
For many years monotherapy has been regarded as the ideal management 
strategy for epilepsy. Publication of a series of studies by Shorvon and 
Reynolds (1977, 1979, Reynolds and Shorvon 1981) led to the view that AED 
polypharmacy was largely useful only in producing more adverse events. 
Noone would argue that anticonvulsant treatment should begin with anything 
other than a trial of monotherapy, as this will suffice for around two thirds of all 
newly diagnosed patients. For the remainder, however, polypharmacy is a 
necessary evil, and it falls to us to formulate a rational strategy to deal with 
those patients who are refractory to first-choice monotherapy. That our 
established AEDs have limited efficacy is attested to by an audit at one 
epilepsy clinic which showed that 42% of patients attending were on long-term 
AED polypharmacy (Schmidt and Gram 1995). In the normal clinical setting, 
which is best, monotherapy or polytherapy?
AED Monotherapy
In patients with newly-diagnosed epilepsy, phenobarbitone, phenytoin, 
carbamazepine, and valproate have shown similar efficacy as monotherapy 
(Verity et al 1995). Newer drugs such as lamotrigine and vigabatrin, as will be 
discussed, also have proven efficacy as monotherapy. Since one third of our 
patients will not be well controlled on monotherapy, what can be done to 
maximise the chances of its success?
To state the obvious, as a first principle every clinician must aim to commence 
what is, for each patient, the right drug at the right dose. Proper history-taking
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and investigation should ensure that patients with primary generalised 
epilepsy (Covanis et al 1982), juvenile myoclonic epilepsy, or absence 
seizures (Chadwick 1990) receive initial treatment with valproate 
monotherapy. Localisation-related seizures would appear to be better 
controlled by carbamazepine. Careful expert assessment may reveal the 
presence of a discrete syndrome, such as Lennox Gastaut syndrome, which 
may indicate that monotherapy is less likely to be adequate to achieve optimal 
control (Dulac and N’Guyen 1993). The correct dose of the chosen AED 
should be used: some studies have shown that increasing the dose of current 
therapy to maximally tolerated levels attains seizure control in almost one 
third of those patients who were ‘refractory’ to monotherapy with phenytoin or 
primidone (Schmidt 1983). Adverse events can be minimised by avoiding 
over-rapid dose titration or by using controlled release formulations, 
particularly with carbamazepine (McKee et al 1991, Persson et al 1990), and 
less convincingly with valproate (Imaizumi et al 1992).
When one monotherapy fails, it need not necessarily follow that polypharmacy 
is an inevitable requirement. Hakkareinen (1980) looked at the success rate 
of alternative monotherapy with carbamazepine or phenytoin when the other 
had failed, and found that one third of the treatment failures were successfully 
controlled by the alternative drug. In the Veterans’ Administration Study 
(Mattson et al 1985), 46% of those who were unsuccessfully treated with the 
first monotherapy chosen, responded to an alternative monotherapy. It should 
be remembered, however, that in this study some were originally treated with 
phenobarbitone or primidone, neither of which would today be accepted as
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reasonable first line monotherapy.
In summary, AED monotherapy will be adequate for a majority of patients with 
newly diagnosed epilepsy. It is obviously of paramount importance that the 
correct steps are taken to ensure that the chances of monotherapy 
succeeding are maximised. Even if the first drug fails at maximally tolerated 
doses, a second choice may well prove to be effective as monotherapy in a 
substantial minority of patients.
Polypharmacy
Polypharmacy has long been held to cause an increased incidence of adverse 
events (Schmidt and Gram 1995), pharmacokinetic interactions (Brodie 1992), 
and teratogenesis (Nakane et al 1980) while conferring, at best a limited 
improvement in efficacy (Reynolds and Shorvon 1981). In one study (Beghi et 
al 1986), treatment with phenytoin or carbamazepine alone produced side 
effects in 28 and 38% of patients respectively. Combination of the two, 
however, produced adverse events in around three quarters of all patients. 
Lammers et al (1995) following a retrospective review, however, were of the 
opinion that it was dosage rather than the number of AEDs used which 
determined the frequency and severity of adverse events.
Despite polypharmacy’s poor image, there can be no doubt that for some 
patients, even when the ‘right’ drug is given at the right doses, under carefully 
controlled conditions, that monotherapy may fail and that polypharmacy will 
be required to gain full seizure control. In the Veterans Administration Study 
(Mattson et al, 1985), 39% of ‘non-responders’ were helped by the addition of
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a second drug, with 11% becoming seizure free. One trial of adjuvant 
valproate in cases where carbamazepine had failed as monotherapy (Dean
1988) showed a similar number of patients improved on combination therapy, 
with 17% becoming seizure free.
There are good reasons why combination of the older agents would not be 
universally successful. As described in earlier chapters, each of these drugs 
has a wide range of actions, while their anticonvulsant efficacy will rely, at 
least in part, on a non-specific blockage of sodium channels. Combination of 
these widely active drugs will therefore merely increase the degree of sodium 
channel blockade while producing a host of more complicated biochemical 
and physiological effects.
Despite the negative aspects of the older drugs, it is still surprising that so few 
studies have been carried out to detail which AED combinations will provide 
maximal benefit with minimal adverse events.
With the advent of a new generation of drugs, there are reasons why 
polypharmacy should be better tolerated and, perhaps, as efficacious. There 
have been a number of studies investigating the efficacy and tolerability of 
specific AED combinations.
Specific combinations
These are discussed in the sections dealing with individual drugs. The 
combination of old and new (lamotrigine/ valproate, carbamazepine/ 
vigabatrin), and two new drugs (lamotrigine/ vigabatrin, tiagabine/ vigabatrin) 
have been attempted with some success, although none has been set out in
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the recommended double-dummy design required to discover particular 
benefit (Richens 1995).
The dearth of trials which examine the optimal combinations of AEDs, may 
itself be testimony to how poorly we understand their basic mechanisms of 
actions. The further preclinical investigation of the new AEDs will be vital in 
this respect. It is probable that the more questions we ask of these drugs, the 
more surprises they will spring on us. Vigabatrin is a case in point: described 
for years as a GABA-T inhibitor, we will see in later chapters how it has other 
actions which may explain some of the drug’s antiepileptic effect. 
Remacemide may be a similar case: having been thought to exert its 
anticonvulsant effect via NMDA antagonism, its significant effects on GABA 
metabolism will be demonstrated in one of our models. The preclinical 
investigation of these two compounds proves that the ancillary modes of 
action of AEDs are not always easy to predict, and that a comprehensive 
investigation of each AED’s in a wide range of models needs to be carried 
out.
Any patient studies investigation drug combinations will be complicated by the 
presence of any pharmacokinetic interactions. Although less prone to initiate 
interactions, the newer AEDs’ metabolism and disposition is affected by the 
enzymic effects exerted by their older counterparts. The positive interaction 
between valproate and lamotrigine which has been described for example 
(Ferrie and Panayiotopoulos 1994, Brodie et al - submitted), although perhaps 
partly a pharmacodynamic interaction, is probably magnified by the inhibition 
of lamotrigine’s metabolism by valproate.
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In summary, monotherapy would be the ideal to which everyone would adhere 
if we had anticonvulsants that were universally efficacious. This is obviously 
not the case at present. As a result polypharmacy is, for a significant minority 
of patients, a necessary evil. With a new generation of drugs available with 
novel anticonvulsant actions, our next challenge is to optimise AED 
combinations to allow improved efficacy and tolerability for patients who are 
currently refractory.
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The new anticonvulsant drugs
The following chapter deals with the drugs that have been developed in the last fifteen years. With the exception of lamotrigine, they are either awaiting full approval in the UK, or remain licensed only for 
use as add-on therapy in refractory epilepsy. The development of new AEDs 
is continuing at an unprecedented rate, and more compounds will certainly be 
licensed for use in this country in the next few years.
This chapter deals largely with the drugs that are either licensed for use in the 
UK (vigabatrin, lamotrigine, gabapentin, topiramate), those that may be 
licensed for use in the near future (oxcarbazepine, tiagabine), those that 
came close to being licensed (felbamate) and those that have undergone 
particular study as part of this thesis (remacemide). There are other 
compounds which are at various stages of development, such as 
levetiracetam, zonisamide, losigamone, stiripentol and CGP33 101 (Stables et 
al 1995). They are not dealt with in any great detail in this thesis.
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Vigabatrin
Vigabatrin (gamma-vinyl GABA) was the 
herald of a new era in the therapy of 
epilepsy, being the first ‘designer’ AED 
(Leach and Brodie 1995). Binding of 
vigabatrin to GABA-transaminase leads to 
an irreversible covalent bonding which inactivates the GABA-T, hence 
vigabatrin’s description as a ‘suicide inhibitor’ of GABA-T (Leach and Brodie 
1995). The increase in whole brain GABA which results from decreased 
GABA-T activity is thought to lead to an increase in synaptic GABA levels and 
an augmentation of GABAergic inhibition. Vigabatrin was granted a licence in 
the UK in 1989.
Mechanisms of action
The S-enantiomer of vigabatrin is a very specific enzyme inhibitor, while the 
R-enantiomer is completely inactive (Haegele and Schechter 1986). In vitro 
studies would suggest that the S-form acts only against GABA-T, being 
essentially inactive against GAD, ornithine transaminase, and aspartate 
transaminase even at high concentrations in-vitro (John et al 1979, Jung and 
Palfreyman 1995). In vivo studies have shown that there is a decrease in GAD 
activity following exposure to high dose vigabatrin, although whether this is 
secondary to the raised GABA or to the vigabatrin itself is a moot point (Leach 
et al - submitted, Jung et al 1977, Horton 1989, Jung and Palfreyman 1995). 
Some studies have shown that concentrations of glutamate, aspartate and
Vigabatrin
glutamine may be favourably affected in specific areas of the brain such as 
the hippocampus (Halonen et al 1991), perhaps a sign that vigabatrin may 
exert its effect via other mechanisms.
Other changes in the GABAergic system have been reported. Some inhibition 
of GABA release by vigabatrin has been described (Abdul-Ghani et al 1980), 
although tolerance to this effect has been demonstrated in vitro (Neal and 
Shah 1990). Some work has suggested that some of the anticonvulsant effect 
of vigabatrin may come from a direct effect on the GABAa receptor (Xu et al
1991), although this has not been widely confirmed.
Preclinical testing
Vigabatrin affords good protection against audiogenic seizures in DBA/2 mice 
(Schechter et al 1977), photically induced seizures in baboons (Meldrum and 
Horton 1978), and other reflex-induced seizures in other species (Jung and 
Palfreyman 1995). The duration of absence seizures in Wistar rats is 
increased by vigabatrin, an effect that is antagonised by diazepam 
(Marescaux et al, 1985).
Pharmacokinetics and interactions
Being a small, water soluble molecule, vigabatrin is rapidly absorbed after 
oral administration (Ben Menachem 1995). Peak serum levels occur at around 
2 hours after dosing, and the drug is not significantly protein bound 
(Schechter 1989). Despite the differences in the enantiomers’ 
pharmacodynamic activity, vigabatrin is given as a racemic mixture.
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The majority of each dose is excreted unchanged in the urine, the plasma 
elimination half life being between 5 and 8 hours (Ben Menachem 1995) in 
normal subjects. As a result of the site and mode of action, however, the 
pharmacological effect of vigabatrin is much longer than it’s pharmacokinetics 
would suggest, levels of brain GABA remaining high up to 120 hours post 
dose (Schechter et al 1977). Clinical effects in man last up to 48 hours post­
dose (Ben Menachem 1990). Dose-related increases in CSF GABA levels 
have been observed following vigabatrin administration (BenMenachem et al,
1989), which have been postulated to be related to anticonvulsant efficacy 
(Riekkinen et al 1989).
As would be expected with a drug that is excreted entirely unchanged in the 
urine, no clinically important interactions with other anticonvulsants have been 
described. Vigabatrin has been shown to decrease serum phenytoin via an 
unknown mechanism by a mean of 20% (Rimmer and Richens 1989), but in 
only one (open!) study has this been thought to compromise seizure control 
(Browne et al 1987).
Efficacy
Many studies have confirmed the efficacy of vigabatrin as add-on therapy for 
refractory epilepsy in adults (Browne et al 1987, Gram et al 1985, Remy et al 
1986, Rimmer and Richens 1984, Tassinari et al 1987, Reynolds et al 1991, 
Browne et al 1991, Loiseau et al 1986) and children (Herranz et al 1991, Luna 
et al 1989). On average, 50% of patients had their seizure frequency at least 
halved, and of those who had no change in frequency, the seizure severity
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was often found to be reduced (Sander et al 1990, Tassinari et al 1987). 
When used as add-on therapy, greater efficacy is seen in patients with partial 
seizures (Michelucci et al 1989). The reported effect on generalised seizures 
is variable (Browne et al 1987).
A meta-analysis of the European placebo-controlled studies (Mumford and 
Dam 1989) looked at the 398 patients who had been enrolled in studies in the 
early and mid-1980s. This showed a reduction in seizure frequency 
associated with vigabatrin use, confirming that this was most marked in those 
patients with partial seizures whether or not there was any secondary 
generalisation.
On controlled comparative testing against steroids, vigabatrin has been 
shown to be the superior treatment for infantile spasms (Chiron et al 1991), 
and some authorities have suggested that it has become treatment of choice 
for West syndrome (Appleton 1995)
Withdrawal due to poor tolerability of vigabatrin is much the same as for other 
treatments, i.e. 5 - 15% (Browne et al 1987), and tolerance is not thought to 
be a feature of it's long term use. Long term follow up shows that even up to 6 
years after commencing treatment there is no evidence of tolerance (Tartara 
et al, 1992). The efficacy of vigabatrin may not be improved by dose 
increases beyond 2 grams per day (McKee et al, 1993), possibly as a result of 
the GAD inhibition that occurs.
Specific combinations of drugs are not commonly tested in the field of 
antiepileptic medication. One trial has been published which proves 
vigabatrin’s role as a good add-on drug when combined with carbamazepine
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(Murri and Ludice 1995) in 40 patients with refractory localisation-related 
epilepsy. There was a significant reduction in mean seizure frequency, and 
17.5% of patients became seizure free on the combination. The authors 
conclude that vigabatrin should be an early choice of drug for add-on therapy.
Monotherapy trials
One monotherapy trial has so far been published, comparing vigabatrin 
monotherapy with carbamazepine monotherapy (Kailviainen et al 1995). A 
total of 100 patients were followed for up to 12 months. Sixty percent of both 
treatment groups completed one years treatment being rendered either 
seizure-free or having an acceptably low seizure frequency. Vigabatrin was 
better tolerated, no patients requiring withdrawal because of side effects 
(against 24% of the carbamazepine group). Significantly more patients in the 
carbamazepine-treated group were rendered seizure-free (52% on 
carbamazepine against 32% on vigabatrin), with fewer patients on the 
established drug requiring withdrawal due to lack of efficacy (6% on 
carbamazepine against 26% on vigabatrin).
Toxicity
A review of over 2000 patients on vigabatrin (Grant and Heel 1991) gave the 
incidence of drowsiness at around 10%, with some dizziness, headache, 
diplopia, ataxia and vertigo reported in around 2%. Psychiatric side effects 
such as anxiety, depression, and aggression are well recognised: the 
precipitation of psychosis at high doses or following sudden withdrawal of the
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drug should lead to cautious use of vigabatrin in those with a history of 
psychiatric illness (Brodie and McKee 1990, Sander et al 1991) This 
association of vigabatrin with psychosis is likely to be more than an 
association between the drug and so-called forced normalisation. 
Maintenance at low dose may avoid psychiatric problems while still providing 
some benefit (Brodie and McKee 1990).
Neuronal cytoplasmic vacuoulation, though visible in rodents and dogs after 
chronic dosing (Hammond and Wilder, 1985; Butler et al, 1989), has not been 
seen in human or even primate brain despite extensive searching (Cannon et 
al 1991).
The association of high dose vigabatrin and rapid titration of vigabatrin dose 
with psychosis has probably been damaging for this drug’s prospects. The 
improved tolerability that more cautious use of the drug evokes, however, has 
allowed its use to steadily increase over the last few years, and it is likely that 
the drug will be granted a license for use in the USA in the near future. 
Results from other monotherapy trials are awaited to allow a review of the 
drug’s position in treatment of epilepsy in the twenty first century.
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Lamotrigine
Folic acid was shown to have proconvulsant 
properties in the mid-sixties, and 
anticonvulsant drug development at the 
Wellcome Institute concentrated on modifying 
folate antagonists in order to uncover an 
anticonvulsant compound. Lamotrigine (3,5-diamino-6-[2,3-dichlorophenyll]- 
1,2,4-triazine) was noted to be both a mild folate antagonist and an 
anticonvulsant, although it is now known that these properties are not linked 
(Rogawski and Porter 1990).
Mode of Action
Lamotrigine is a phenyltriazine derivative, and is chemically and functionally 
unrelated to other antiepileptic drugs. The development of burst firing is 
inhibited by lamotrigine in a manner similar to that of phenytoin and 
carbamazepine (Macdonald and Kelly, 1993).
At an early stage of investigation (Leach et al 1986), it was found that 
lamotrigine blocked veratridine rather than potassium-evoked release of 
endogenous amino acids implying that the anticonvulsant effect arose at least 
in part from a blockage of voltage-sensitive sodium channels.
Lamotrigine preferentially inhibits release of glutamate, having a lower ED50 
for this than for inhibition of GABA release after electrophysiological 
stimulation (Leach MJ et al 1995). The blockage of sustained repetitive firing 
by lamotrigine is thought to be a result of the frequency and voltage-
NH,
Lamotrigine
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dependency of sodium channel inactivation (Cheung et al 1992, Lees and 
Leach 1993). This blockage occurs when the channel is at the slow 
inactivated state (Xie et al, 1995), and this selectivity may account for the 
drugs tolerability (Brodie and Dichter 1996).
Recent studies have shown that lamotrigine has a mild calcium channel 
blocking effect: the narrow dose range at which this occurs, however, 
suggests that this is probably of little clinical import (Lees and Leach 1993). 
Lamotrigine does not bind to adenosine, GABAb or opioid receptors (Leach 
MJ et al 1995), although there is some weak binding to the 5-HT3 receptor 
which is of dubious functional significance. Lamotrigine has no effect on either 
GABAa or NMDA receptors (Leach MJ et al 1995).
Pharmacokinetics and Interactions
Oral administration leads to rapid and near complete absorption of 
lamotrigine. The elimination half life is around 29 hours (Cohen et al 1987), 
with metabolism largely by hepatic glucuronidation. The most common 
metabolite (70% of the dose) is the N-2 glucuronide conjugate (Magdalou et al
1992). Interestingly, patients with Gilbert's disease demonstrate a longer 
lamotrigine half life due to a decrease in the activity of diphosphate glutamyl 
transferase (Posner et al 1989).
Lamotrigine does not induce or inhibit hepatic enzymes. Consequently, it has 
no influence on the metabolism of other lipid-soluble drugs, such as the oral 
contraceptive pill and warfarin (Leach and Brodie 1995). There have been 
reports of symptoms of neurotoxicity (headache, nausea, dizziness, diplopia,
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ataxia) in patients when lamotrigine is added to a stable carbamazepine 
regime (Warner 1992). This has since been shown to be a pharmacodynamic 
rather than a pharmacokinetic interaction (Stolarek et al 1994, Pisani et al
1994).
The half life of lamotrigine is more than doubled by concomitant valproate to 
around 59 hours (Yuen et al 1992), while enzyme-inducing anticonvulsants 
such as carbamazepine and phenytoin have the opposite effect, reducing it to 
around 12 hours (Binnie et al 1989).
Preclinical testing
Lamotrigine is active against the tonic phase of both PTZ- and MES-induced 
seizures (Yuen 1991), blocks the development and expression of amygdaloid 
kindled seizures (Miller et al 1986), and reduces electrically-evoked 
afterdischarge duration in the rat, dog, and marmoset (Wheatley and Miller, 
1989). It is, however, ineffective against both threshold and clonic seizures 
induced by PTZ (Rogawski and Porter 1990). The reduction in glutamate 
release is likely to account for the long-term neuroprotective actions of 
lamotrigine shown in animal models whether given before or after the onset of 
ischaemia (Smith et al 1995, Shuaib et al 1995).
Efficacy
Eleven double-blind placebo-controlled studies have been published (Jawad 
et al 1989, Sander 1990; Loiseau et al 1990; Binnie et al 1989; Risner et al 
1990, Dren et al 1991, Schapel et al 1993, Smith et al 1993, Matsuo et al
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1993, Messenheimer et al 1994, Schachter et al 1995), showing success as 
add-on treatment of partial seizures with or without secondary generalisation. 
Only the most relevant will be discussed here.
Messenheimer and colleagues (1994) examined 98 patients with localisation- 
related epilepsy, as part of a double blind placebo controlled crossover trial, 
with patients titrated to a maximum tolerated dose not greater than
400mg/day. 44% of the subjects experienced a reduction in seizure frequency 
of at least 25%, with 20% having their seizures frequency at least halved.
A double-blind placebo-controlled study comparing the efficacy of lamotrigine
at 300mg/day with 500mg/day (Matuso et al 1993) in 216 patients with
refractory partial seizures showed the higher dose to cause a significantly 
greater reduction in seizure frequency compared to both the lower dose and 
placebo. 300mg/day was not significantly better than placebo.
Schapel et al (1993) during a relatively short treatment period showed a 
significant reduction in partial seizure numbers and total seizure numbers with 
lamotrigine titrated up to a maximum tolerated dose not greater than
300mg/day. There was a trend towards reduction in secondary generalised 
seizures, although this did not reach statistical significance. One of the largest 
studies (Schachter et al 1995) involved 446 patients in a six-month treatment 
period, showing a beneficial effect of lamotrigine when used as add-on 
therapy for refractory partial seizures. Alongside its anticonvulsant effect, 
lamotrigine has been shown in one study to have a positive effect on some 
measures of happiness and mastery (Smith et al 1993).
Lamotrigine has been said to work particularly in combination with some other
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anticonvulsant drugs, particularly sodium valproate (Ferrie and 
Panayiotopoulos 1994) and vigabatrin (Robinson et al 1993, Stolarek et al
1994). Schapel and colleagues assessed the vigabatrin\ lamotrigine 
combination in a study of 42 patients. In this refractory population 40% had a 
reduction in seizure frequency of at least 80% compared to baseline, and 69% 
had their seizure frequency at least halved while on both new drugs. Addition 
of one of the new agents did not cause a significant reduction in mean seizure 
frequency, and no one drug was more efficacious than the other. Only on 
addition of the second drug was there a significant reduction in seizure 
frequency, which persisted despite withdrawal, or at least reduction in the 
baseline AED therapy. Perhaps significantly, 30 of the patients were also 
receiving valproate in the third phase, which allowed them to tolerate a higher 
plasma lamotrigine concentration.
Brodie et al (paper submitted) as part of a withdrawal to monotherapy study in 
347 patients, showed a better response to add-on lamotrigine in those 
receiving valproate (n=117) compared to those on carbamazepine or 
phenytoin. This improvement occurred irrespective of seizure type and 
patients on valproate had similar plasma lamotrigine levels. On withdrawal of 
valproate, despite an associated rise in lamotrigine dose to raise the 
lamotrigine levels above those in the add-on phase, valproate-treated 
patients, unlike those on other baseline therapies had a loss in seizure 
control, suggesting that the benefits of combined treatment were greater. 
Experience in some units suggests that lamotrigine also has great success in 
primary generalised epilepsy (Stewart et al 1992, Richens 1994). It has been
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suggested that lamotrigine may have efficacy in the Lennox-Gastaut 
syndrome (Timmings and Richens 1992), juvenile myoclonic epilepsy 
(Timmings and Richens 1993), and Rett Syndrome (Uldall et al 1993). Any 
suggested benefit in neuroprotection during cerebral infarction or Parkinson’s 
disease (Zipp et al 1993), has not yet been substantiated by controlled trials.
Monotherapy trials
Brodie et al (1995) as part of a large double-blind trial comparing efficacy of 
lamotrigine monotherapy with that of carbamazepine monotherapy, followed 
260 patients with newly diagnosed localisation related epilepsy over a 48- 
week treatment period. Doses of both treatments were controlled by an 
unblinded observer on the basis of serum levels, in order to maintain serum 
levels within an arbitrary (for lamotrigine) target range. During the treatment 
period, once doses were stabilised, lamotrigine showed similar efficacy to that 
of carbamazepine when measured by time to first seizure. During the last six 
months, almost identical numbers (38% on carbamazepine, 39% on 
lamotrigine) remained seizure free.
On comparison of tolerability, however, lamotrigine was clearly preferable. 
Fewer patients on lamotrigine withdrew from the study because of adverse 
events (27% of those on carbamazepine, 15% of those on lamotrigine). It was 
mainly as a result of this and other trials that lamotrigine was given a licence 
for use as monotherapy in the UK and elsewhere in 1995. A similar 
comparative trial with phenytoin has been carried out which shows similar 
benefits of lamotrigine treatment compared to phenytoin monotherapy in a
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similar patient group (Steiner and Yuen 1994).
Toxicity
By November 1992, more than 5800 patient years experience had been 
gained with lamotrigine, mostly as add-on therapy (Richens 1994). Skin rash 
occurs in around 5% of those involved in clinical trials with lamotrigine 
(Richens 1994), but requires withdrawal from trial in only 2% of patients 
(Messenheimer et al 1994) a figure substantially lower than the incidence 
during carbamazepine treatment. Rechallenge of patients at lower starting 
dose and slower titration of lamotrigine dose can be successful in avoiding 
reemergence of the rash (Tavenor et al 1995).
As described above, there is a well-defined pharmacokinetic effect of sodium 
valproate on the kinetics of lamotrigine which increases the risk of onset of 
adverse events. This interaction necessitates a reduced starting dose and 
reduced lamotrigine titration rate in patients on regimes containing valproate 
(Leach and Brodie 1995).
Mild central nervous system events, such as dizziness, ataxia, drowsiness, 
headache, and diplopia, occur with lamotrigine use in a dose-dependent 
manner, although the side effect profile compares favourably with that of the 
established anticonvulsants (Richens 1994).
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GABAPENTIN
Gabapentin [l-(aminomethyl)
cyclohenanacetic acid] is an anticonvulsant 
drug which was given a licence for use in the 
UK as add-on therapy in 1993. It was 
developed in an attempt to exploit a 
presumed direct GABAmimetic effect (Ojemann et al 1988). GABA itself does 
not cross the blood brain barrier when given systemically, and work was 
carried out in order to manipulate the structure of GABA to allow a direct 
GABA agonist to do this with ease. Further work has demonstrated 
gabapentin’s lack of binding to GABA receptors (Bartoszyk et al 1986).
Mode of Action
The full effects of gabapentin on specific receptors has not yet been clearly 
defined, although it has been shown that there is no direct action on GABAa 
or GABAb receptors, and no effect on benzodiazepine receptors (Schmidt
1989). There may be a specific, previously undescribed receptor for 
gabapentin, similar to one binding 3-isobutyl GABA (Taylor et al 1993, Hill et 
al 1993).
Enhancement of GABA release may be important in the actions of gabapentin 
(Honmou et al 1995). At therapeutic concentrations, gabapentin increases 
GABA release from neostriatal slices in-vitro, an effect that is blocked by 
GABAa receptor antagonists (Gotz et al 1993). Gabapentin does not alter 
GABA uptake into neurones or astrocytes (Schmidt 1989).
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Gabapentin
The activity of GAD is said to be increased by gabapentin (Loscher et al 1991, 
Taylor et al 1992), and other enzymes of importance in the GABA shunt have 
been shown to be affected in the presence of gabapentin, including a minor 
inhibition of GABA-T, and more significant inhibition of glutamate 
dehydrogenase, and branched chain amino acid transferase (Goldlust et al
1995). It was felt that the reduction in glutamate synthesis may be more 
important mechanism of action than an increase in GABA. The effects of 
gabapentin treatment on glutamate levels has yet to be assessed by this 
method.
CSF GABA levels have previously been shown to be unchanged by 
gabapentin after single dose (Ben Menachem et al 1992), or three months 
treatment (Ben Menachem et al 1995). NMR spectroscopy in man, however, 
has suggested that an elevation of GABA occurs on treatment with 
gabapentin which is more marked at higher doses (>3gm/day) than with 
'standard’ doses (1.2-2.4gm/day) (Petroff et al 1996).
The peak anticonvulsant effect of gabapentin lags some two hours behind 
peak serum levels (Welty et al 1993), supporting the theory that enzyme 
inhibition may be the principle mode of action.
Thurlow et al (1993) have shown binding to a site proposed to be a cellular L- 
amino acid transporter, suggesting that gabapentin could affect transport of 
other neurotransmitter amino acids in vivo.
Pharmacokinetics and Interactions
Oral dosing of gabapentin gives rapid absorption, and the drug has a
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bioavailability of 60%. Maximum levels occur 2-3 hours after administration 
and the half life is 5-7 hours (Vollmer et al 1986). There is no significant 
protein binding, and the drug is excreted unchanged in the urine (Vollmer et al 
1986, Stewart et al 1993) with clearance rates equivalent to creatinine 
clearance. This rapid clearance currently would suggest that three times daily 
dosing is required with gabapentin, although some clinicians suspect that 
twice daily dosing may be equally effective.
Unsurprisingly, gabapentin’s pharmacokinetic characteristics are not changed 
with chronic dosing, and the lack of drug interactions with other AEDs (Tyndel 
1994, Radulovic et al 1994, Hooper et al 1991) and the oral contraceptive pill 
(Eldon 1993) has been widely reported. Stewart and colleagues (1993) have 
demonstrated a disproportionately small rise in serum levels on increasing 
gabapentin dosage, possibly because of a saturable intestinal L-amino acid 
transport mechanism.
Preclinical testing
Work in rodents (Bartosyk et al 1986) has shown gabapentin to be effective 
against a wide variety of electrical, physical and chemical stimuli. 
Anticonvulsant effects were apparent against NMDA induced seizures, but not 
those produced by kainate or quisqualate (Bartosyk et al 1986). Gabapentin 
has been shown to have an experimental anticonvulsant profile similar to that 
of sodium valproate (Rogawski and Porter, 1990): the drug is effective against 
tonic seizures induced by a variety of chemoconvulsants including PTZ, 
bicuculline, picrotoxin, and strychnine (Foot and Wallace 1991), and is also
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active in the MES test in rats (Rogawski and Porter, 1990) and against reflex 
seizures in DBA/2 mice, Mongolian gerbils (Foot and Wallace 1991), and 
genetically epilepsy-prone rats (Foot and Wallace 1991). It has weak activity 
in the photosensitive Papio papio baboon and was without effect in the 
kindling model (Foot and Wallace, 1991).
Efficacy
A small double-blind cross-over study (Crawford et al 1987) was the first 
published work to prove the efficacy of gabapentin, comparing an eight week 
period on three different doses (300, 600, or 900mg/day) to a similar length of 
time on baseline observation. At 900mg/day, seizure frequency was 
significantly reduced, most striking was the reduction in secondary 
generalised seizures. No changes in psychometric testing were apparent at 
these doses (Crawford et al 1987).
A later placebo-controlled double-blind study randomised 43 patients to 
receive placebo or one of two doses of gabapentin (Sivenius et al 1991). After 
three months, 900mg/day gabapentin was found to be ineffective, while those 
patients on gabapentin 1200mg/day experienced a significant reduction (57%) 
in frequency of both tonic-clonic and partial seizures. A 4-year follow-up at the 
same centre (Sivenius et al 1994) showed that 25% of those remaining on the 
drug after 4 years had a consistent reduction in seizure frequency.
A later, larger double-blind parallel-group study (UK Gabapentin Study Group
1990) randomised 127 patients to either 1200mg daily of gabapentin or 
placebo. Compared to placebo, more gabapentin-treated patients (25.0%
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against 9.8%) experienced a reduction of >50% in seizure frequency, the 
mean reduction in seizure frequency after the 12-week treatment phase being 
29.2% on gabapentin and 12.5% on placebo.
Anhut et al (1994) used similar doses in their double-blind placebo-controlled 
study of 272 refractory patients. Response rate and percentage change in 
seizure frequency were significantly better with gabapentin treatment of either 
900 or 1200mg/day. The incidence of adverse events, at first sight seems 
high in those on gabapentin, 69% and 64% of patients in the low and high- 
dose groups respectively reporting adverse events. 52% of patients in the 
placebo-treated group also experienced significant events however.
A large study using higher doses has been carried out. The US Gabapentin 
Study Group (1993) had 306 patients in four parallel groups on placebo or 
gabapentin at 600, 1200, or 1800mg/day. A significantly higher number of 
responders were seen in the 1200 and 1800mg/day groups. Mild to moderate 
adverse events were reported in 88% of patients on active treatment, 
compared to 72% of those on placebo.
A pooling of data from double-blind trials (McLean 1995) confirmed 
gabapentin’s efficacy: the ‘response rate’ (>50% reduction seizure frequency) 
was 26% of patients suffering from partial seizures, and 54% of those with 
generalised seizures. The effect on myoclonic and absence seizures does not 
appear promising (Stables et al 1995) and in our clinical experience, the drug 
may even exacerbate or precipitate these seizure types, especially at high 
dose, and in combination with carbamazepine.
Handforth and Treiman (1994) were not alone in suggesting that the drug
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could be used at much higher doses to boost efficacy even further, given how 
well the drug was tolerated at doses used in clinical trials.
Monotherapy Trials
Ojemann et al (1992), as part of an open label trial of gabapentin, 
successfully converted 5 patients from 9 potential candidates on to 
gabapentin monotherapy. A prospective short-term double-blinded in-patient 
study of around 80 patients (Bergey et al 1995) showed that 3600mg/day was 
better tolerated than 300mg/day when used as monotherapy.
Further, more definitive evidence of the efficacy of gabapentin as 
monotherapy is awaited. Several trials are underway, and the results should 
be available shortly.
Safety and toxicity
Gabapentin is a very well tolerated drug, and any drug-related problems are 
usually of early onset, easing after around two weeks. These adverse events 
are relatively rare, but usually manifest themselves as mild CNS toxicity 
(Browne 1993), although few studies have been done to assess the 
psychomotor and cognitive effects of the drug. Gabapentin is not yet licensed 
for use during pregnancy, and any experience of this has been gained on an 
ad-hoc basis.
In the report by the UK study group (1990), 62% of those receiving 
gabapentin reported side effects, the most common being somnolence 
(14.8%), fatigue (13.1%), dizziness (6.6%) and weight gain (4.9%). In the
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placebo group, however, 41% reported side effects including headache 
(9.1 %) followed by dizziness and somnolence (both 4.5%). Of the 11 patients 
who withdrew due to side effects, seven were on gabapentin
86
Felbamate
Felbamate is chemically unrelated to the 
established anticonvulsants, and was 
approved for use in the USA as add-on and 
monotherapy in adults with partial seizures 
alone or with secondary generalisation. The 
drug was first marketed there in December 1992 (Brodie and Pellock 1995), 
and subsequently approval was given for use in children with partial or 
generalised seizures associated with Lennox-Gastaut syndrome. The UK 
licensing authorities, with a wisdom commendable in hindsight, refused to 
approve the use of this drug around that time, requesting more proof of 
efficacy and safety. Later developments would prove their reservations to be 
well founded.
Mechanisms of action
The mechanisms of action of felbamate are not completely understood, but at 
therapeutically relevant concentrations it has been shown to reduce voltage 
dependent sodium currents in a use-dependent manner (analogous to 
phenytoin and carbamazepine) (White et al 1992), enhance GABAergic 
inhibition, block the NMDA receptor site (Rho et al 1994), probably with 
significant glycine antagonism (McCabe et al 1993). Each of these 
mechanisms could be wholly or partly responsible for felbamate’s antiepileptic 
effect. Felbamate is effective against animal seizure models, including MES- 
and PTZ-induced seizures. There was a wide separation between therapeutic
Felbamate
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and toxic doses.
Pharmacokinetics and interactions
Felbamate is well absorbed orally and is about 22-25% bound to plasma 
proteins (Perhach and Shumaker 1995). Its plasma half-life is approximately 
20 hours, indicating it could be given twice daily, although three to four 
divided doses are recommended by the manufacturer (Dichter and Brodie
1996). Felbamate undergoes hydroxylation by the liver, although around half 
of each dose is excreted unchanged in the urine (Shumaker 1990).
There are significant mutual drug interactions between felbamate and the 
other established AEDs. Felbamate increases phenytoin levels and can 
precipitate phenytoin toxicity when added to a previously stable regimen 
(Graves et al 1989). Concomitant felbamate decreases serum carbamazepine 
levels while increasing levels of carbamazepine-10,11-epoxide (Wagner et al
1993) theoretically producing toxicity at a lower serum carbamazepine levels 
than would otherwise be expected. Felbamate also increases valproate levels, 
although inconsistently (Wagner et al 1991). Thus, if felbamate is started in a 
patient taking any of the established AEDs, concomitant reduction in their 
dose (by 20-33%) is indicated to prevent toxicity (Dichter and Brodie 1996). 
Phenytoin and carbamazepine (but not valproate) increase felbamate 
clearance (Dichter and Brodie 1996).
Efficacy
Three double-blind, placebo-controlled, add-on studies demonstrated
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felbamate’s efficacy in reducing intractable focal seizures in adults compared 
to placebo (Theodore et al 1991, Leppik et al 1991, Bourgeois et al 1993). In 
two innovative trial designs, utilising monotherapy in patients in whom 
conventional therapy was withdrawn (Sachdeo et al 1992), and in patients 
being evaluated for epilepsy surgery whose concomitant AEDs were being 
discontinued (Faught et al 1993), felbamate was shown to be better than 
placebo or low-dose valproate in preventing the recurrence of seizures. In 
children with the Lennox-Gastaut syndrome (Felbamate Study Group 1993), 
felbamate was demonstrated to be superior to placebo for reducing total 
seizure frequency and reducing atonic seizures.
Within controlled clinical studies, felbamate was considered to be a well 
tolerated compound, many of the documented side-effects being attributed to 
the interaction of felbamate with concomitant AEDs. Felbamate use was 
associated with nausea, decreased appetite, insomnia, agitation and 
headache (Liporace et al 1994, Bebin et al 1995). Post-marketing, however, 
these side-effects appeared to be more prominent and resulted in a significant 
number of patients discontinuing the medication (Wolff et al 1994). Within a 
year, after around 100,000 patients had been exposed to felbamate, two very 
serious problems arose. By 1995, aplastic anaemia had developed in 32 
patients, and hepatic failure in 19 patients (Brodie and Pellock 1995). It has 
been reported that five of those with hepatotoxicity, and ten of those with bone 
marrow suppression have died (Brodie and Pellock 1995).
Felbamate use in the UK is rare, and on a named patient basis only. In the 
USA, however, the FDA have restricted use to those patients refractory to all
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other medications and in whom the risk-benefit relationship is favourable. 
Weekly or bi-weekly blood counts and liver function tests must be performed, 
although it is not known whether early detection of either of these 
idiosyncratic reactions will prevent the most serious outcomes.
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Topiramate
Topiramate [2,3:4,5-bis-0-(1-
methylethylidene)B-D-fructo-pyranose 
sulfamate] is chemically unrelated to other
AEDs, deriving as it does from D-fructose, and
containing a sulfamate functionality (Shank et al 1994). In November 1995,
topiramate received its UK license for use as add-on therapy for refractory
epilepsy.
Mode of Action
The precise mechanisms by which topiramate exerts its anticonvulsant effect 
are as yet unknown. It is likely that, like the established anticonvulsants, 
topiramate has several effects on neuronal physiology and biochemistry, and 
that the anticonvulsant activity depends on a combination of these effects.
Like the established AEDs, topiramate decreases sodium channel 
conductance (Taylor 1993b), an action which occurs at a wide range of doses, 
and which prevents sustained repetitive firing (Coulter et al 1993). As with 
barbiturates and the benzodiazepines, topiramate’s efficacy may depend to a 
degree on the potentiation of GABA’s action on chloride channel conductance 
(Brown et al 1993): topiramate increases the frequency rather than the 
duration of chloride channel opening in response to GABA (Twyman et al - In 
Press), an action which is not blocked by flumazenil (White et al 1995).
A modest block of AMPA and kainate receptors has been described (Coulter 
et al 1993a, Stables et al 1995), although the relative importance of this
91
Topiramate
blockade is as yet unknown. The drug is known to have some carbonic 
anhydrase inhibitory activity (Shanks et al 1994), although this is mild across 
several species, and is felt to have little bearing on its anticonvulsant action.
Pharmacokinetics and interactions
In man, topiramate has 80% bioavailability, which is unchanged with 
concomitant food ingestion. It is weakly (15%) protein bound, and is largely 
eliminated unchanged by the kidney. In non-enzyme induced patients, around 
20% is metabolised, and when used as monotherapy, the drug has a half life 
of around 20-30 hours. Pharmacokinetics are linear, the plasma level 
increasing in proportion to the dose. Of the fraction that is metabolised by the 
liver, there are six different metabolites formed: none have any important 
anticonvulsant actions. In patients with renal or hepatic impairment, and in 
whom elimination or metabolism is decreased, lesser doses of topiramate may 
be required to avoid dose-dependent side effects.
The established enzyme-inducing AEDs increase the clearance of topiramate. 
Phenytoin increases the total clearance by a factor of 2 or 3 (Willensky et al 
1989), while carbamazepine increases only the non-renal clearance (Floren et 
al 1989). Concomitant valproate (Floren et al 1989), like phenobarbitone, 
does not significantly affect topiramate clearance.
Topiramate exerts no effects on the metabolism of the established AEDs other 
than phenytoin. In this case topiramate reduces total clearance of phenytoin 
to a variable degree (Floren et al 1989), occasionally by as much as 15%, 
leading to occasional rises in phenytoin steady state concentrations of as
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much as 25%. Notwithstanding this, it is reported that there is usually no 
change in phenytoin dose required in patients commencing topiramate.
In relation to other drugs, it is known that clearance of both digoxin and 
oestrogen are increased by topiramate. This may have important connotations 
for the drug’s usage in old and younger patient groups respectively.
Preclinical testing
In both rats and mice, topiramate has been shown to be efficacious against 
MES one hour after dosing, with a potency similar to that of phenytoin or 
carbamazepine (Shank et al 1994). In the case of treated rats, the 
anticonvulsant effect was still evident 24 hours after dosing. Potency in rats 
was 2-5 times greater than in mice (Shank et al 1994), the converse of the 
situation with phenytoin. In animal models, the D-isoform is between 2 and 5 
times more potent than the L-isoform.
In mice, topiramate had only a weak effect against those seizures provoked 
by PTZ (Shank et al 1994), but had no effect against those induced by 
picrotoxin or bicuculline even 4 hours after dosing with topiramate at 
800mg/Kg. Like phenytoin, topiramate did not block PTZ, or DMCM-induced 
seizures up to 6 hours after dosing.
Efficacy
Double-blind trials of anticonvulsant efficacy in patients with epilepsy have 
been carried out, although fully published information is scanty and most data 
are only available in abstract form. At 400mg daily in 46 patients (Martinez-
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Lage et al 1995), 22% of the topiramate-treated group had their seizure 
frequency reduced by at least 75%, compared to 4% of those in the placebo- 
treated group. The commonly used ‘responder rate’ (>50% reduction in 
seizure frequency) was 35% and 8% for topiramate and placebo groups 
respectively.
In another placebo-controlled study involving 60 patients (Tassinari et al
1995), topiramate at least halved the seizure frequency in 47% of topiramate 
treated patients at 600mg/day (10% placebo). 23% of those on active 
treatment had their seizures reduced by 75% compared to only 3% of the 
placebo-treated group. There were no serious adverse events reported during 
either of these trials.
In another more complex study involving 56 patients (Ben Menachem et al 
1995b), patients were given either 800mg/day or the maximum tolerated dose, 
whichever was the greater. None of the placebo treated group had their 
seizure frequency reduced by 50% or more. In contrast, 43% of the actively 
treated group had their seizure frequency at least halved, with 36% having 
seizure frequency reduced by at least 75%.
Assessment of higher doses has been attempted (Privitera et al 1995). 
Comparison of placebo treatment with topiramate at higher doses showed that 
the ‘responder rate’ was 44%, 40%, and 35% at 600, 800, and 1000mg daily 
respectively compared to only 9% of the placebo treated group.
So far 70 patients have been reported as having been treated with topiramate 
for over five years with no loss of efficacy (Stables et al 1995).
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Monotherapy Trials
A comparison of low (100mg/day) and high (1000mg/day) topiramate when 
given as monotherapy in newly diagnosed patients (Sachdeo et al 1995) 
showed more patients receiving the higher dose remained seizure-free at the 
conclusion of the 112-day study period. More information is required before 
these results can be easily interpreted.
Tolerability
Many of the side effects experienced during the clinical trials are said to be a 
consequence of the rapid titration schedule. Certainly the generally accepted 
titration rates are less than those used during the trial programme, although 
whether this relaxation will ease the side effect profile is still to become 
apparent.
The most commonly described adverse events (Ben-Menachem et al 1995b) 
involved the central nervous system, including ataxia, dizziness, poor 
concentration, asthenia, paraesthesiae and weight loss. Meta-analysis of all 
clinical trials has confirmed that nephrolithiasis occurs more commonly during 
treatment with topiramate (Wasserstein et al 1995a), probably due to a 
treatment-related decrease in urinary citrate excretion (Wasserstein et al 
1995b). Most renal calculi were passed spontaneously and asymptomatically. 
Teratogenesis has been demonstrated at a wide range of doses in mice 
(BenMenachem et al 1995b), but only at the highest doses used in rats 
(500mg/kg/day). No teratogenic effect was seen in rabbits at any dose tested 
(BenMenachem et al 1995b).Oxcarbazepine
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Oxcarbazepine (oxcarbazepine) is the 10-keto analogue of carbamazepine 
whose modifications ensure that it has a different metabolic profile from its 
ancestor, oxcarbazepine is essentially a pro-drug (Dichter and Brodie 1996), 
which is rapidly and completely reduced in the liver to the active moiety,
Oxcarbazepine Carbamazepine
NH •NHj
Reduction Oxidation
(CBZ-E)HOv
■NH
Conjugation Hydrolysis
Glue - O HO, OH
■NH “NH j
Figure 5: Metabolic pathways for both carbamazepine 
and oxcarbazepine
10,11 -dihydro-10-hydroxycarbamazepine (OHCBZ) (Figure 6). The main 
advantage of oxcarbazepine arises from avoidance of formation of 
carbamazepine 10,11 epoxide (CBZ-E) (Patsalos and Sander 1994) during its
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metabolism. As described earlier (See Established Antiepileptic Drugs - 
Carbamazepine), CBZ-E accounts for many of the adverse events 
experienced during carbamazepine treatment (Patsalos et al 1985, Gillham et 
al 1988).
Mode of action
There is little specific information available on the mechanism of action of 
oxcarbazepine, as it has always been thought to be closely related to that of 
carbamazepine. Certainly the effect of both compounds on animal seizure 
models is similar, although not identical. The assumption, therefore, is that 
oxcarbazepine has its major effect in preventing repetitive firing of neurones 
by blocking voltage-dependent Na+ channels (Rogawski and Porter 1990). 
There may be some differences between oxcarbazepine and carbamazepine, 
in the way that high-voltage-activated (HVA) calcium currents are affected 
(Stefani et al, 1995), and in the modulation of
corticostriatal synaptic transmission (Calabresi et al, 1995). One trial (McKee 
et al 1994) demonstrated that oxcarbazepine could be added into a regime 
containing carbamazepine without necessarily provoking toxicity, and with 
occasional benefit.
Pharmacokinetics and interactions
Oxcarbazepine is rapidly and almost completely absorbed (96%) after oral 
dosing (Dam and Ostergaard 1995). After a rapid presystemic hydroxylation, it 
is excreted in the urine, 85% of each dose being excreted in the first 48 hours.
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oxcarbazepine is immune to oxidative attack and it is the mono-hydroxy 
derivative of oxcarbazepine (OHCBZ) which accounts for the drug’s 
pharmacological actions. Oxcarbazepine itself is only transiently present in 
the circulation (Theisohn and Heimann 1982). OHCBZ is approximately 40% 
bound to circulating plasma proteins; its elimination half-life ranges from 11 to 
17 hours (Kristensen et al 1983).
Treatment with oxcarbazepine does not result in autoinduction of metabolism 
(Larkin et al 1991). In patients changed from carbamazepine to 
oxcarbazepine, steady-state plasma concentrations of concomitant phenytoin 
and valproate rose by 20-30%. oxcarbazepine had little effect on levels of 
established AEDs when used as add-on therapy suggesting an absence of 
important metabolic interference with these agents (McKee and Brodie 1994). 
The converse does not apply, however, as enzyme induction by 
phenobarbitone (Tartara et al 1993), phenytoin or carbamazepine may 
decrease OHCBZ concentrations. That the efficacy of oxcarbazepine relies on 
the production of OHCBZ may explain why twice-daily dosing may be 
adequate for a compound with a relatively short half life (Arnoldussen and 
Husmann 1991).
Efficacy
A number of clinical trials in which oxcarbazepine was substituted for 
carbamazepine have supported similar efficacy for the two compounds. In a 
double-blind randomised comparative trial with carbamazepine in 235 newly 
diagnosed patients (Dam et al 1989) no significant difference was found
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between the two agents in terms of seizure control. Like carbamazepine, 
oxcarbazepine is not effective against absence seizures or myoclonic jerks 
(Friis et al 1993). Controlled trials in children are needed, although open 
studies support similar efficacy to that reported in adults.
Tolerability
Side-effects associated with oxcarbazepine are similar to those produced by 
carbamazepine (Friis et al 1993) with dizziness, drowsiness, headache, 
nausea, vomiting and diplopia being the most prominent symptoms. 
Comparative studies (Dam et al 1989) have reported these to be less frequent 
and less severe than with carbamazepine. In addition, oxcarbazepine 
produces fewer rashes and perhaps fewer idiosyncratic reactions. 
Hyponatraemia, probably secondary to an antidiuretic hormone-like property, 
is more common with oxcarbazepine than with carbamazepine (Amelsvoort et 
al 1994). This can occasionally present clinically but is usually mild and 
asymptomatic. There is no evidence yet of teratogenesis with oxcarbazepine. 
Oxcarbazepine has the potential to become a well established first-line 
antiepileptic drug when the current programme of research has been 
completed. Studies to date suggest that it is as effective as carbamazepine, 
but with lower propensity to induce idiosyncratic reactions and drug 
interactions. There is no evidence of teratogenicity so far, and the drug may 
have a less deleterious influence on cognitive function than carbamazepine. 
Placebo-controlled clinical trials are underway investigating the efficacy and 
safety of oxcarbazepine as adjunctive therapy in refractory epilepsy, as
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monotherapy in newly diagnosed patients, in children and in the elderly. 
Finally, further studies on the basic mechanisms of action may dissect out 
important pharmacological differences between oxcarbazepine and 
carbamazepine.
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Tiagabine
Tiagabine [(R-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid 
hydrochloride] like other nipecotic acid derivatives, inhibits GABA
reuptake into both neurons and glial cells in 
rodents (Nielsen et al 1991). The large 
addition to the nipecotic acid molecule acts 
as a lipophilic anchor, helping the compound 
to cross the blood-brain barrier following oral 
administration.
Mode of Action
Tiagabine is a potent GABA re-uptake blocker (Nielsen et al 1991), and the 
resultant increase in synaptic GABA, as demonstrated by microdialysis (Fink- 
Jensen et al 1992), is thought to account for tiagabine’s anticonvulsant
activity. As previously described, there are four GABA liptake transport
mechanisms characterised, and nipecotic acid derivatives have been shown 
to be fairly specific for one of these (GAT-1), with some lesser effects on 
GAT-3 (Clark and Amara 1994).
Tiagabine only very weakly interacts with the BDZ receptor and the chloride 
ion channel of the GABAa receptor, and it does not appreciably bind to other 
neurotransmitter receptors (Rogawski and Porter 1990).
Predinical testing
Tiagabine has been shown to protect against audiogenic seizures, PTZ-
Tiagabine
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induced seizures, and DMCM-induced seizures in mice. In rats, it has activity 
against PTZ picrotoxin and bicuculline-induced seizures as well as against 
amygdaloid kindling. It has some effect against photically induced seizures in 
baboons (Ostergaard et al 1995). Like vigabatrin, tiagabine increases the 
frequency and duration of spike wave discharges in Wistar rats (Coenen et al 
1995)
In rat synaptosomal preparations, tiagabine inhibits the uptake of GABA into 
both neurons and glial cells (Braestrup et al 1990). At 100uM, tiagabine 
weakly (<20%) inhibits the binding of specific ligands for the dopamine D1 
and D2, muscarinic, 5-HT2, GABAa and Glycine receptors. Radiolabelled 
tiagabine also showed saturable and reversible binding to rat brain 
membranes, which was inhibited by known inhibitors of H3-GABA binding. 
There is no change seen in the transport of dopamine or noradrenaline. 
Radiolabelled tiagabine is not a substrate for the carrier process, and does 
not alter the rate of release of GABA from presynaptic neurones.
Interestingly, Honmou and colleagues (1995) have described an intriguing in- 
vitro example of pharmacological synergism. Gabapentin’s action in 
stimulating non-synaptic GABA release is said to be potentiated on exposure 
to nipecotic acid. The mechanism by which this occurs is unknown, but it may 
be a harbinger of an important clinical finding.
Pharmacokinetics and interactions
Tiagabine is easily and rapidly absorbed following oral administration, with 
maximum concentrations occurring in most subjects less than 1 hour after
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ingestion (Ostergaard et al 1995). In healthy volunteers pharmacokinetics are 
linear (Gustavson and Mengel 1995), with a half life between 5 and 8 hours 
(Brodie 1995). One quarter of each dose is metabolised and excreted in the 
urine, with the majority undergoing faecal excretion as two, as yet 
unidentified, metabolites (Ostergaard et al 1995).
Patients on a regime containing enzyme-inducing drugs would appear to 
metabolise tiagabine faster than untreated volunteers or patients on valproate 
monotherapy (Richens et al 1991, So et al 1995). Co-administration of 
tiagabine does not have an effect on the pharmacokinetics of concomitant 
AEDs (Richens et al 1995).
Clinical Studies
Published clinical studies are scanty, but the first fully published clinical study 
showed a positive effect (at least 25% reduction in seizure frequency) in 46 
out of 94 patients with refractory localisation-related epilepsy (Richens et al 
1995) during the open titration phase. Subsequent treatment during the 
placebo-controlled arm showed complex partial seizures to be at least halved 
in 26% of those undergoing double-blind testing against placebo. Of those 
with secondary generalised seizures, 63% had seizure frequency at least 
halved by tiagabine.
Tolerability
Tolerability seems to compare favourably with the established AEDs (Richens 
et al 1995). Ninety of the 94 recruits to the double-blind study (Richens et al
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1995) reported some adverse events, unsurprisingly given that tiagabine dose 
was titrated to maximum tolerated dosage. Most adverse events were mild or 
moderate, with withdrawal being provoked in 14 patients. Of the ten 
considered retrospectively to be treatment associated, six complained of 
fatigue. During the double blind treatment phase, adverse events were slightly 
more common with placebo than with tiagabine treatment (62% and 50% 
respectively). Only one case of overdose has been reported (Leach et al 
1995) which ended uneventfully despite the tiagabine serum level being thirty 
times greater than the mean serum level during treatment with the drug.
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Remacemide
Remacemide is a novel 
antiepileptic agent which 
emerged from a drug discovery 
programme aimed at creating a 
molecule with a 3-dimensional 
structure similar to that of 
phenytoin (Rogawski and 
Porter, 1990). It is chemically unrelated to any other anticonvulsant, and is 
currently undergoing testing to assess its suitability for use as an add-on 
anticonvulsant drug. As well as being an anticonvulsant (Garske et al 1991), 
remacemide hydrochloride may be effective in preventing cell damage in the 
course of ischaemic injury (Bannan et al 1994) or Parkinson’s disease 
(Greenamyre et al 1994).
Mode of action
At least part of the activity of remacemide arises from the active desglycinate 
metabolite, ARL12495XX. This metabolite has a longer half life than 
remacemide, and is commonly used in in-vitro experiments of anticonvulsant 
activity.
In keeping with the structural similarities with phenytoin, remacemide and 
ARL12495XX have been shown to inhibit sustained repetitive firing in cultured 
neurones (Cheung et al 1992) consistent with a blockage on fast sodium 
channels at concentrations which is suggested by the binding of both
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Remacemide
ARL12495
remacemide and ARL12495 to the batrachotoxin-binding site of the sodium 
channel (Clark et al 1995).
Remacemide demonstrated no affinity for receptors to adenosine-1, GABAa, 
benzodiazepines, glycine (Garske et al 1991), or the AMPA subtype of 
glutamate receptor (Hu and Davies 1994).
In-vitro studies have demonstrated no modification of evoked synaptic 
response or penicillin induced bursting in isolated rat hippocampal slices 
(Palmer et al 1992) by remacemide or ARL12495XX. Subsequent work in 
brain slices has demonstrated a change by ARL12495XX in K*- and 
veratridine-mediated glutamate release (Srinivasan et al 1994).
A non-competitive antagonism at NMDA receptors (Palmer et al 1993) has 
also been demonstrated, which is more potent for ARL12495XX than for the 
parent compound, and an inhibition of NMDA-induced currents in cultured 
neurones was shown on exposure to both compounds (Subramaniam et al 
1993). Other NMDA antagonists have been developed for use in seizures and 
ischaemic\anoxic brain injuries, but so far only remacemide has had sufficient 
tolerability to survive phase 1 testing.
Pharmacokinetics
The compound is a diphenyl-ethyl-acetamide derivative, and is rapidly and 
near-completely absorbed within two hours (Muir and Palmer 1991). In 
healthy volunteers, single doses up to 300mg were well tolerated, above 
which light-headedness and gastrointestinal upset became increasingly 
common. The elimination half life of remacemide in healthy volunteers is
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around four hours, a rate that is independent of dose, with no evidence of any 
autoinduction. About 25% of the drug is excreted in the urine (Muir and 
Palmer 1991), mostly as glucuronide conjugates. The ubiquitous 
aminopeptidases are responsible for producing the main metabolite, 
ARL12495XX. This has a much longer half life (12-15 hours), and is thought 
to be, at least in part, responsible for the efficacy of remacemide. Levels of 
the desglycinate became detectable in volunteers at doses of remacemide 
above 300mg (Palmer et al 1992a). The elimination of ARL12495XX also 
demonstrates first order kinetics.
Preliminary evaluation in a small number of volunteers had suggested that the 
elimination of both remacemide and ARL12495XX was increased in those on 
monotherapy with enzyme-inducing anticonvulsants. There was some 
evidence that oral administration of remacemide hydrochloride had enzyme- 
inhibiting properties, which increased levels of concomitant carbamazepine.
In vitro studies (Riley et al 1995) had confirmed some effect of remacemide, 
albeit at high doses, on CYP3A4 and to a lesser extent CYP2C9. These 
enzymes are responsible for the oxidation of carbamazepine and phenytoin 
respectively.
Preclinical animal testing
In rodents, both the parent compound and ARL12495XX protected against 
MES-induced (Stagnitto et al 1990). After a single dose, this protection was 
sustained for up to 4 hours, longer than any of the established antiepileptic 
agents. After multiple doses, the anticonvulsant effect lasted for 8 hours,
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longer than any of the established agents apart from phenobarbitone. The 
negative enantiomer is more potent at preventing MES induced seizures (Muir 
and Palmer 1991). No anti-seizure effect was found against seizures 
provoked by picrotoxin, strychnine, PTZ, or bicuculline (Muir and Palmer 
1991).
Administration of remacemide to mice prevented NMDA-induced mortality. 
Interestingly, while ARL12495XX offered protection only against NMDA, 
remacemide itself also protected against kainate-induced mortality (Palmer et 
al 1992a).
Efficacy
Seizure frequency was reduced following administration of remacemide 
hydrochloride as add-on therapy in 28 patients with refractory epilepsy 
(Crawford et al 1992). One third of all patients had their seizure frequency cut 
by at least 50%, with a mean seizure reduction of around 33%. The results of 
much larger efficacy studies are awaited, these having ‘unblinded observer’ 
designs to compensate for the effects of pharmacokinetic interactions with 
other AEDs. More information on tolerability is also required.
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Recurrent Materials and Methods
MATERIALS
Radioisotopes: y-[14C]-aminobutyric acid was obtained from DuPont (New 
England Nuclear).
Pharmaceuticals
Tiagabine was donated by Novo Nordisk 
Vigabatrin was donated by Marion Merrell Dow 
Remacemide was donated by Fisons Pharmaceuticals 
Gabapentin was donated by Parke Davis
Chemicals: Ammonium dihydrogen orthophosphate (NH4H2PO4),
ammonium sulphate ((NH4)2S04), calcium chloride (CaCI2), glacial acetic acid, 
D-glucose, hydrochloric acid (HCI), magnesium sulphate (MgS04), perchloric 
acid, phosphoric acid, potassium chloride (KCI), potassium dihydrogen 
orthophosphate (KH2P04), sodium bicarbonate (NaHC03), sodium chloride 
(NaCI), di-sodium hydrogen orthophosphate (Na2HP04), sodium hydroxide 
(NaOH), and sodium dihydrogen orthophosphate (NaH2P04) were all obtained 
from Merck.
Para-aminobenzoic acid (PABA), y-aminobutyric acid (GABA), 2- 
aminoethylisothironium bromide (AET), boric acid, bovine serum albumin 
(BSA), cytosine arabinoside (ARA-C), 3'5'-dibutyryl cyclic adenosine 
monophosphate (cAMP), dithiothreitol, ethylene diamine tetra-acetic acid
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(EDTA), DNase I, gabaculline, L-glutamic acid, HEPES, insulin, a-ketoglutaric 
acid (a-KG), 3-mercaptopropionic acid (3-MPA), D,L,-norvaline, 
o-phthalaldehyde (OPA), poly-D-lysine, pyridoxal-5'-phosphate (PLP), soya 
bean trypsin inhibitor (SBTI), trypsin, and nipecotic acid were all obtained 
from Sigma Chemical Company.
Dulbecco’s modified Eagle’s medium (DMEM), Earle’s balanced salt solution 
(EBSS), foetal calf serum (FCS), L-glutamine, horse serum (HS), minimal 
essential medium (MEM), penicillin, phosphate buffered saline (PBS), sterile 
culture water, and streptomycin were all obtained from Gibco BRL. 
Acetonitrile and methanol were obtained from Rathburn Chemicals Ltd. 
Coomassie Brilliant Blue G-250 protein assay dye reagent and Dowex 
AG50Wx8 ion exchange resin were from BIORAD.
A standard balanced salt solution (BSS) was used throughout the 
investigation of GABA uptake. Its composition was as follows: 136mM NaCI, 
5mM KCI, 0.8mM MgS04, 2.6 mM NaHC03, 0.4mM KH2P04i 0.34mM 
Na2HP04, 1.3mM CaCI2, 5.6 mM D-glucose, and 15mM HEPES. The solution 
was adjusted to pH 7.4 with NaOH and warmed to 37°C before use.
Equipment
Centrifugation: A Wifug haemicrofuge was employed for small volume 
samples and a refrigerated MSE Mistral 2L centrifuge for all other samples. 
Eiectroshock stimulation: A Ugo Basile 7801 electroconvulsive therapy
110
(ECT) unit was used.
High performance liquid chromatography: For determination of amino acid 
concentrations, a Waters model 510 pump, a Waters WISP 71 OB injector, a 
Perkin Elmer LS-5 luminescence spectrophotometer, and a computer-based 
Jones Chromatography JCL-6000 integration package were used. Excitation 
and emission wavelengths were 330 and 440 nm respectively, with 
bandpasses of 15 and 20 nm.
Homogenisation: Where preservation of an enzyme was important a glass 
Potter Elvehjam vessel and motor powered teflon pestle were used. The 
alternative method employed a polytron homogeniser and included sonication 
in the homogenisation process. Small volume samples were homogenised by 
sonication alone in a MSE Soniprep 150.
Scintillation counting: A Canberra Packard 2000CA TRI-CARB liquid 
scintillation counter was used.
Spectrophotometry: Protein concentrations were assayed with a Philips Pye 
Unicam PU-8600 UV/vis spectrophotometer incorporating a PU-8605 cell 
programmer. (ELISA)
Statistical analysis: Statistical analysis was performed using the MINITAB 
statistical package (V8) on a Viglen 486DX microcomputer.
111
GENERAL METHODS 
Animals used
ICR mice were supplied by Harlan Olac. Studies involving rats used the 
out-bred Sprague Dawley (SD) strain, which were supplied by Bantin and 
Kingman and again latterly by Harlan Olac. Neonatal and foetal animals 
required for cell culture techniques were supplied by the Joint Animal Facility 
at the University of Glasgow from a breeding colony of SD rats. Experimental 
animals were housed in the departmental animal unit. Animals were exposed 
to a controlled temperature and humidity environment throughout with a 12 
hour light/dark cycle and had access to food and water ad libitum.
Brain tissue removal
Animals were sacrificed by a blow to the head followed by decapitation. The 
skin and tissues overlying the skull were incised and then removed. The point 
of a pair of bone cutters or scissors was inserted into the foramen magnum 
and the occipital bone incised, in either direction, in the dorsal plane. The 
occipital bone was then prised free of the underlying cerebellum. Next, the 
parietal bones of the skull were incised down either side, again in the dorsal 
plane, roughly at the level of the base of the brain. The parietal bones were 
prised clear of the brain surface taking care not to damage the underlying 
tissues. The meningeal membranes were cleared from the brain surface. 
Finally, the frontal bones were removed by a sharp fracture in the coronal 
plane just anterior to the olfactory lobes of the brain. Following severance of 
the optic nerves, the intact brain was removed with the aid of spatulas.
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weighed where applicable, and stored appropriately at -70°C until required. In 
studies involving analysis of discrete brain regions, the brain was carefully 
dissected in accordance with the method of Glowinski and Iversen (1966) and 
each region weighed prior to storage.
Determination of protein concentrations
Many of the assays reported in this thesis required accurate and reproducible 
analysis of sample protein content to enable quantifiable calculation of 
experimental results. The BIORAD method is a sensitive test of protein 
concentration of use particularly when small volume samples with low protein 
content are under investigation. The method relies on the colour change of a 
dye (Coomassie Brilliant Blue G-250) in response to protein concentration. 
Standards were prepared, in duplicate, over the range 0.5 - 2.0 pg/ml BSA. 
Samples of unknown protein concentration, also analysed in duplicate, were 
diluted into this range. BIORAD protein assay dye reagent was diluted 1:1 
with water and added, in equal volume, to standards and samples alike. 
Following vortex-mixing, tubes were incubated at room temperature for 5 
minutes and then read in the spectrophotometer. The intensity of the colour 
obtained was proportional to the amount of protein present and after 
construction of a standard curve, the protein content of samples could be 
determined. Results were corrected for dilution, averaged, and expressed in 
mg/ml.
Sample storage
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Plasma and brain samples for drug assay were stored at -20°C until analysis. 
Brain samples for the study of enzyme activities and neurotransmitter levels 
were stored at -70°C until required.
DETERMINATION OF GABA-AMINOTRANSFERASE ACTIVITY
This method was devised from modifications of the methods of White and 
Sato (1978) and Larsson and co-workers (1986).
Reagents
All solutions required for enzyme assay were prepared in deionised water. An 
EDTA buffer was prepared weekly for sample preparation and stored at 4°C. 
The buffer consisted of 0.1 mM EDTA, 0.5 mM dithiothreitol, and 0.1 mM 
KH2P04. PLP was added daily as required (final concentration = 0.2 mM) and 
the buffer adjusted to pH 8.0 with 4 M NaOH. A [14C]-GABA incubation 
medium was prepared every 2 -3  months and stored at -20°C. The incubation 
medium consisted of 0.68 mM GABA (specific activity = 1.46 mCi/mmol), 1.8 
mM EDTA, and 200 mM K H2P04 with the pH adjusted to 6.9 with 1 M NaOH.
Sample preparation
Neurological tissue was thawed and homogenised in 4 volumes (v/w) of EDTA 
buffer. All samples were centrifuged at 2000 rpm for 20 minutes at 4°C. The 
resultant supernatant was decanted and its protein content determined, in 
duplicate, by the BIORAD method (see above: General Methods - 
determination of protein concentration). The volume of the remaining
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supernatant was adjusted with EDTA buffer to give a final protein 
concentration of 1 mg/ml.
Assay for enzyme activity
A 50 pi volume of the adjusted supernatant was added to 25 pi of 0.68 mM a- 
Ketoglutarate (a-KG) and 25 pi of the [14C]-GABA incubation medium to give a 
final assay volume of 100 pi. Assays were performed in duplicate with a blank 
assay included for each sample by replacing the a-KG with 25 pi water. All 
samples were vortex-mixed for 10 seconds and then incubated for 60 minutes 
at 37°C. The reaction was terminated by the addition of 10 pi 2M HCI followed 
immediately by vortex-mixing for 10 seconds. The incubation mixtures were 
transferred to the surface of a resin in small disposable ion-exchange columns 
(Dowex AG50Wx8, pre-washed with deionised water, 0.5 x 3.0 cm, in 9 inch 
glass Pasteur pipettes plugged with a glass bead). Radioactive products were 
eluted directly into glass scintillation vials using 3 portions of 0.5 ml water. 
Each portion was placed in the original incubation tube and transferred to the 
column with the same pipette used to transfer the incubation mixture. Twelve 
ml of Picofluor 40 scintillation fluid was added to each vial and the 
disintegrations per minute (dpm) were counted for 10 minutes by liquid 
scintillation counting.
Calculations
The radioactive content of samples was analysed in comparison to the dpm 
obtained from standard solutions containing known amounts of radioligand.
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Results were corrected for background and blank sample counts and 
quantified in relation to protein content and reaction time. Enzyme activities 
were expressed as nmol/min/mg protein.
DETERMINATION OF AMINO ACID CONCENTRATIONS BY HIGH 
PERFORMANCE LIQUID CHROMATOGRAPHY
This method for the measurement of GABA, glutamate and glutamine was 
devised from a modification of the method of Durkin and colleagues (1988).
Reagents
Stock solutions of GABA (1 mg/ml in distilled water) were prepared monthly, 
stored at 4°C, and diluted to working standard solutions daily as required. The 
derivatization reagent mixture (OPA-3-MPA) was prepared weekly by 
dissolving 50 mg OPA in 4.5 ml methanol and 0.5 ml borate buffer then 
adding 50 pi 3-MPA with the mixture being stored at 4°C in the dark. The 
borate buffer was made weekly by adjusting 0.5 M boric acid to pH 9.5 with 1 
M NaOH.
Mobile phase
Glutamate and glutamine concentrations were determined in mobile phase 
consisting of 75:25 (v/v) 0.57 M acetate buffer (pH 3.75, containing 100 mg/l 
EDTA) / acetonitrile. For GABA analysis the mobile phase was 60:40 (v/v) 0.2 
M acetate buffer (pH 3.80, containing 100 mg/l EDTA) / acetonitrile. Acetate 
buffers were prepared by adding 32.8 ml (0.57 M) or 11.5 ml (0.2 M) glacial
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acetic acid to 925 ml of water, adjusting the pH with 3 M NaOH and diluting to 
1 litre with water. Flow rates were 1.0 ml/min throughout.
Calibration
Calibration curves (in water) were constructed for glutamate (0.5 - 5.0 pg/ml), 
glutamine, and GABA (2.0 - 20 pg/ml) and were seen to be linear (r > 0.930) 
in all cases. Limits of detection for both glutamate, glutamine and GABA were 
found to be 5 ng/ml in a 50 pi sample. Intra- and inter-assay variations for 
GABA were calculated at 2.8% and 7.9% respectively, while for glutamate 
they were 3.4% and 8.7%, and for glutamine, 3.8% and 8.2%.
Sample preparation
Whole brains were homogenised in 10 volumes (v/w) of 1% perchloric acid 
and an aliquot taken for determination of protein content by the BIORAD 
method (see above: General Methods - determination of protein
concentration). All samples were centrifuged at 2000 rpm for 5 minutes, the 
supernatant decanted and diluted 1/10 with water prior to derivatization.
Derivatization
A 50 pi aliquot of the diluted supernatant was reacted with 200 pi methanol, 
200 pi borate buffer, and 50 pi OPA-3-MPA solution. D,L-norvaline (50 pi) was 
added as an internal standard to give a total reaction volume of 550 pi. 
Reaction mixtures were vortexed and allowed to stand at room temperature 
for 4 minutes prior to injection of 10 pi onto the column.
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Calculations
Amino acid concentrations were calculated by comparison of peak height 
ratios of analyte to internal standard and quantified in relation to the wet 
weight of tissue for brain samples and the protein concentration for cell 
culture samples. Results were expressed as pg/g protein.
DETERMINATION OF GLUTAMIC ACID DECARBOXYLASE ACTIVITY
This method was devised from modifications of the methods of Kocchar and 
colleagues (1989), Wolf and Klemisch (1991), and Chakraborty and 
co-workers (1991).
Reagents
A sodium phosphate-AET buffer was prepared weekly for sample preparation 
and stored at 4°C. The buffer consisted of 0.1 M Na2HP04 and 1 mM AET. 
The buffer pH was adjusted to 7.0 with 0.1 M NaH2P04. An incubation medium 
was prepared daily as required and consisted of 50 mM L-glutamic acid, 250 
pM PLP, 0.4% 2-mercaptoethanol, and 57 pM gabaculline.
Sample preparation
Whole brains were thawed and homogenised in 10 volumes (v/w) sodium 
phosphate-AET buffer. Samples were then centrifuged at 2000 rpm for 10 
minutes. The supernatant was decanted and an aliquot taken for
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determination of protein content by the BIORAD method (see above: General 
Methods - determination of protein concentration).
Assay for enzyme activity
Incubation medium (100 pi) was added to each of two 100 pi aliquots of 
supernatant per sample. The reaction in one aliquot (Zero-time) was 
terminated immediately while the other (test) was allowed to continue for a 
period of 60 minutes at 37°C. Termination was performed in both cases by the 
addition of 100 pi 1% perchloric acid. Terminated blank and test reaction 
mixtures were diluted 1/10 with water and assayed for GABA content by high 
performance liquid chromatography (See above: HPLC - derivitization).
Calculations
Enzyme activity was calculated by subtraction of the zero-time GABA 
concentration from the test GABA concentration to give a value for GABA 
production during the reaction period. Results were quantified in relation to 
both reaction time and protein concentration and were expressed as 
nmol/min/mg protein.
PRIMARY CULTURE OF CEREBRAL CORTICAL ASTROCYTES
This method was devised from modifications of the methods of Larsson and 
co-workers (1981) and Bender and Hertz (1984).
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Reagents
A culture medium was prepared which consisted of DMEM supplemented with 
20% (v/v) HS, 2.5 mM L-glutamine, 50 I.U./ml penicillin, and 50 pg/ml 
streptomycin. The medium was further supplemented with 0.25 mM cAMP, 
where indicated, to facilitate differentiation of the cells. The medium was 
prepared under sterile conditions and filter sterilised through a 0.2 pm pore 
filter prior to use and/or storage. Media were stored sterile at 4°C for up to 5 
days.
Tissue preparation
Tissue for cell isolation was removed under aseptic conditions. One day old 
rat pups were decapitated and the skin overlying the skull was peeled away. 
The entire skull surface was removed by inserting the point of a pair of 
scissors into the foramen magnum and incising the skull down either side in 
the dorsal plane, taking care not to damage the underlying cortex. The 
cerebral cortices were removed from either hemisphere with a sharp pinch 
between the points of a pair of curved watchmaker’s forceps. The removed 
tissue was placed in a 55 mm2 culture dish containing DMEM and, with the aid 
of a dissecting microscope, the olfactory bulbs, basal ganglia, hippocampal 
formations and meninges were removed. The dissected neopallia were then 
transferred to a sterile universal tube containing 6 ml of DMEM prior to cell 
isolation.
Cell isolation
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The dissected neopallia were cut into small cubes (0.5 mm3) by two passes 
(at 90°) in a Mcllwain tissue chopper. The chopped tissue was transferred to a 
sterile filter (80 pm nylon mesh) and the filtrate collected in a sterile beaker. 
The chopped material was washed through the filter with culture medium to 
give a final volume of 3 ml per brain. A sterile plastic pipette was used to aid 
this process. The filtrate was passed through a sterile needle (BD Microlance 
21G 0.8 x 40) three times to separate the cells. The volume of the resulting 
suspension was adjusted with culture medium to allow a 3 ml aliquot per petri 
dish with a ratio of 1 brain to 3 dishes. A 3 ml volume of the final cell 
suspension was plated onto 55 mm2 Falcon Primaria culture dishes.
Culture maintenance
The cultures were maintained at 37°C in an environment of 95% 0 2 / 5% C02 
with a humidity of > 90%. The culture medium (3 ml) was replaced every 3 -4  
days throughout. The HS concentration was reduced to 10% at the first 
medium change with a final reduction to 5% at the second change. The HS 
concentration remained at 5% thereafter. Once the cells reached confluence 
(usually after 14 days in culture) the medium was supplemented with 0.25 mM 
cAMP. At this stage penicillin and streptomycin were omitted from the culture 
medium due to possible interference with subsequent experimental 
procedures. Cultures were seen to be fully mature and ready for use between 
day 21 and day 24 and were viable for up to 42 days.
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f,4C1-GABA UPTAKE INTO CULTURED ASTROCYTES
This method was devised from modifications of the methods of Larsson and 
co-workers (1981) and Yu and colleagues (1984).
Reagents
A standard balanced salt solution (BSS) was used throughout the 
investigations of [14C]-GABA uptake. Its composition was as follows: 136 mM 
NaCI, 5 mM KCI, 0.8 mM MgS04l 2.6 mM NaHC03, 0.4 mM KH2P04, 0.34 mM 
Na2HP04l 1.3 mM CaCI2l 5.6 mM D-glucose and 15 mM HEPES. The solution 
was adjusted to pH 7.4 with 1 M NaOH and stored, at 4°C, for up to 1 week. 
BSS was warmed to 37°C prior to use.
Culture preparation
Cultures for investigation were removed from the incubator and the existing 
culture medium aspirated. Cultures were washed twice (2x1 ml neurones, 2 x 
2 ml astrocytes) with BSS (37°C) before being returned to the incubator in a 
further volume of BSS (2 ml neurones, 3 ml astrocytes) for an equilibration 
period of 20 minutes.
[14C]-GABA uptake procedure
The pre-washed cultures were removed from the incubator and the existing 
BSS aspirated. This solution was replaced by BSS (1 ml neurones, 2 ml 
astrocytes) containing the drug concentrations appropriate to the individual 
experiment. Control plates received BSS alone. All culture plates were
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returned to the incubator for a further period of 1 hour. After the incubation 
period, a further 1 ml of BSS (with appropriate control/drug treatment) 
containing 150 pM [14C]-GABA (specific activity = 1 mCi/mmol) was added to 
each plate. Incubation was allowed to continue for 5 minutes before the 
cultures were washed with 5 volumes (2 ml) of warmed BSS. Cells were finally 
removed from the plates by scraping in 1.0 ml 1 M NaOH. Aliquots were taken 
for protein determination by the BIORAD method (see above: General 
Methods - determination of protein concentration) and liquid scintillation 
counting in 8 ml of Picofluor 40 scintillation fluid.
Calculations
Liquid scintillation counting was employed to analyse GABA uptake in 
individual cultures in comparison to the dpm of standard solutions containing 
known amounts of radioligand. Results were quantified by the relation of 
GABA uptake to the protein concentration and expressed as pmol/min/mg 
protein in individual cultures. Tiagabine
Tiagabine [(R-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid 
hydrochloride] like other nipecotic acid derivatives, inhibits GABA
reuptake into both neurons and glial cells in 
rodents (Nielsen et al 1991). The large 
addition to the nipecotic acid molecule acts 
as a lipophilic anchor, helping the compound 
to cross the blood-brain barrier following oral 
administration.
Tiagabine
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Clinical investigation into the interactions
between remacemide hydrochloride and 
phenvtoin. carbamazepine. and sodium
valproate
Clinical evaluation of the pharmacokinetic interactions of
remacemide with established AEDs
Standard development and clinical assessment of new AEDs requires that 
they are initially used and assessed as add-on therapy. The first impression 
gained of any new drug will therefore be affected by any pharmacokinetic or 
pharmacodynamic interactions that occur when the drugs are used alongside 
established AEDs. In remacemide’s case, early assessment is doubly 
important because use in man involves production of an active desglycinyl 
metabolite, ARL12495XX.
In the following set of studies three patient populations undertook a trial of 
oral remacemide hydrochloride. Patients studied were on monotherapy with 
either valproate, carbamazepine or phenytoin. The trial protocol, common to 
all three groups will first be described. The demographics and 
pharmacokinetic responses of each group will then be dealt with separately.
Protocol
The study had a double-blind, random order, placebo-controlled, crossover 
design, preceded by an open, single-dose treatment phase. Patients 
continued to take their baseline AED in their usual dose throughout. One 
week following a screening visit, each patient received a single dose of 
300mg remacemide hydrochloride. Plasma levels of baseline AED, CBZ-E 
(where applicable), remacemide, and ARL12495XX, were measured 0, 0.5, 1,
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1.5, 2, 4,6, 8,10, 12, 24, and 48 hours after dosing.
One week later, patients entered the first arm of chronic treatment, receiving 
either remacemide hydrochloride or matched placebo (100mg twice daily on 
day 1, 200mg twice daily on day 2, and 300mg twice daily thereafter). The 
total treatment period was 14 days, after which remacemide hydrochloride 
was stopped to allow measurement of washout concentrations at the same 
times after dosing as before. Seven days later, the second treatment phase 
was commenced and the whole procedure was repeated. Morning pre-dose 
(trough) samples were taken on the 5th, 12th and 15th day after initiation of 
treatment.
Initially, as with those patients on enzyme inducing AEDs, valproate-treated 
patients were given remacemide at a dose of 300mg BD during the multiple 
dosing phase. Recognising the possibility of a pharmacokinetic interaction 
between remacemide and valproate, the protocol allowed for a dose reduction 
to 150mg BD in the event of any perceived adverse event. After four out of the 
first nine patients on concomitant valproate had required reduction in 
remacemide dose, the dose of remacemide hydrochloride was reduced to 
150mg BD throughout the multiple dosing phase. The doses preceding forty- 
eight hour plasma level monitoring remained 300mg.
All blood samples were taken into heparinised tubes from a cannulated 
forearm vein, which was kept patent between aspirations with normal saline. 
On each occasion, the first 1 ml withdrawn was discarded, and the subsequent 
15ml were chilled until centrifugation. All samples were spun at 3,000 rpm for
10 minutes, and the separated plasma frozen at -4°C for batch analysis.
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The study was approved by both the West Ethical Committee in Glasgow and 
the Research Ethics Committee in Cardiff. Written informed consent was 
obtained from each participant
Assays
All assays were carried out by the laboratories at Astra Pharmaceuticals. 
Remacemide and its desglycinyl metabolite were quantified by high 
performance liquid chromatography (HPLC). This was a modification of a 
previously reported method (Flynn and O’Brien 1992), adjusted to allow 
automated sample preparation and improve selectivity. The method involved 
solid phase extraction followed by separation on a reverse phase HPLC 
system utilising a octadecyl (C-18) HPLC column, an acetonitrile based 
eluent, and ultraviolet (uv) detection at 210 nm. Limits of quantification for the 
two analytes were 10 ng/ml. Only samples from the active leg of the double­
blind phase were analysed for remacemide and ARL12495XX. 
Carbamazepine, phenytoin and CBZ-E were measured by liquid-liquid 
extraction of plasma followed by reverse phase HPLC utilising a C8 column, a 
methanol-based mobile phase, and uv detection at 210nm. Sodium valproate 
was extracted from acidified plasma using chloroform and was analysed by 
flame-ionised chromatography on DB-WAX.
Pharmacokinetics
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The following non-compartmental pharmacokinetic parameters were
computed where appropriate for valproate, phenytoin, carbamazepine and
CBZ-E for all three phases of serial blood sampling:
• area under the concentration-time curve over a dosing interval (AUC0-t) 
calculated using the linear trapezoidal method
• peak concentration (Cmax) over the dosing interval
• trough/pre-dose concentration (Cmin) over the dosing interval
• time to maximum concentrations (Tmax)
• Cmin 5, 12, and 15 days after initiation of multiple dosing with remacemide 
hydrochloride or placebo
For remacemide hydrochloride and ARL12495XX, the parameters calculated
following single dose and multiple dosing were:
• Cmax
• Tmax
• AUC after single dose was extrapolated to infinite time (AUC*,), calculated 
from AUC = AUCt + Ct/kel where AUCt = area under the curve up to the 
last point at which the concentration could be quantified, and kel = the 
terminal phase plasma elimination rate constant. After multiple doses AUC 
was calculated over a 12-hour dosing interval (AUC o-i2h)
• Elimination half-life, (tvs) after the single dose and during washout of the 
multiple dose remacemide hydrochloride treatment phase. This was 
calculated from tVt = 0.693/kel.
• Cmin 5, 12, and 15 days into remacemide hydrochloride treatment.
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Statistics
Statistical comparisons of the pharmacokinetic parameters obtained for 
baseline AEDs and CBZ-E at the end of the two multiple dose phases were 
compared using an analysis of variance with treatment, period, order, group 
and patients as factors. Logarithmically transformed data were used for 
analysis of the AUC, Cmax and Cmin comparisons. Analysis of the trough 
concentrations used ANOVA for the three concentrations per patient (5, 12, 
and 15 days after initiation of multiple dosing) with factors of treatment, 
period, sequences, day number and patient. Single and multiple dose phases 
were compared using a non-parametric procedure, the Wilcoxon matched 
pairs signed rank test. A probability less than 5% indicated statistical 
significance.
Results in carbamazepine-treated patients 
Patients
Of the 14 patients recruited (Table 2), 10 completed the study as per protocol. 
One patient (C018) withdrew a few hours following administration of the single 
remacemide hydrochloride dose because he disliked intravenous cannulation. 
Another (C021) pulled out 5 days after single dose administration because of 
an intercurrent viral illness. One patient (C024) was withdrawn from the study 
because of suspected poor compliance, while a fourth (C016) had the dose of 
remacemide hydrochloride halved following the onset of adverse events 
suspected to be due to the study drug. This last patient's data
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Table 2
of carbamazeoine-treated patients.
Patient Sex Age
(years)
Seizure
type
CBZ dose 
(mg/L)
Dosage
interval
(hours)
C001 M 36 CP, CPGTC 600 8
C 002 M 47 SP, SPGTC 800 8
C 003 M 48 CP, CPGTC 800 12
C 016 F 65 CP, CPGTC 800 12
C 017 F 43 CP, CPGTC 800 12
C 018 M 46 SGTC 400 12
C 019 M 56 SP, SPCP 600 8
C 020 M 39 CP, CPGTC 600 24
C 021 F 57 SGTC 400 12
C 022 F 46 SP, SPCP, 
SPCPGTC
1200 12
C 023 M 57 SP, SPCP, 
SPCPGTC
800 12
C 024 F 51 PGTC 800 12
C 025 F 40 CP, CPGTC 1200 24
C 027 F 40 PGTC 1600 12
CBZ= carbamazepine CP=complex partial, CPGTC=complex partial 
with secondary generalisation, SP=simple partial, SPGTC=simple 
partial with secondary generalisation, SGTC=secondary generalised 
tonic clonic seizures, SPCP=simple partial evolving into complex 
partial seizures, PGTC=primary generalised seizures.____________
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are included in the summary of adverse events, but not in the pharmacokinetic 
analysis.
Carbamazepine pharmacokinetics
There were no changes in mean carbamazepine pharmacokinetic parameters 
following a single dose of remacemide hydrochloride (Figure 6 and Table 3). 
Following 14 days’ treatment, however, the mean AUC0-i2h of carbamazepine 
was increased by 22% (p = 0.12), the mean Cmax by 27% (p = 0.07), and the 
mean Cmin by 22% (p = 0.29). Unsurprisingly, Tmax was unchanged following 
both single and multi-dose remacemide hydrochloride.
Comparison of mean trough carbamazepine levels 5, 12, and 15 days after 
the start of active treatment (40.1, 34.4 and 40.4 umol/L respectively) with 
those on placebo (32.7, 30.5 and 34.5 umol/L respectively) showed a 
statistically significant increase (p=0.0013). Four patients had at least one of 
the pharmacokinetic parameters of carbamazepine increased by more than 
30% during the remacemide hydrochloride treatment phase. None of these 
patients, however, reported any symptoms suggestive of carbamazepine 
toxicity.
CBZ-E pharmacokinetics
The mean AUC, Cmax, and Cmin for CBZ-E (Table 3) were not significantly 
altered by concomitant remacemide hydrochloride following single or multiple 
dosing (Figure 7). After 14 days' treatment, two patients had an increase in 
AUC or Cmax of more than 30%, one being a rise in AUC of 177% and in
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Figure 6: Mean plasma concentrations of carbamazepine in 10 patients with 
epilepsy over a 12 hour period following single (300mg) or multiple (300mg 
BD for 14 days) dosing with remacemide hydrochloride or placebo.
Table 3
Mean carbamazepine pharmacokinetic parameters (SD) after single and 
multiple doses of remacemide hydrochloride and placebo in 10 epileptic 
patients.
AUC Cmax Tmax Cmin
(umol.hr.M) (umol.M) (hours) (umol.M)
Placebo 367.8 (135.2) 40.5 (8.7) 4.8 (4.6) 34.7 (8.2)
Single dose 392.3(161.1) 43.3(10.1) 7.1 (4.2) 34.0 (7.2)
Multiple doses 425.4 (156.9) 50.6 (12.2) 5.1 (3.5) 40.8(11.6)
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Figure 7
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Figure 7: Mean plasma concentrations of carbamazepine10,11 -epoxide in 10 
patients over a 12 hour period following single (300mg) or multiple (300mg BD 
for 14 days) dosing with remacemide or placebo.
Table 4
Mean carbamazepine 10,11 epoxide pharmacokinetic parameters (SD) after 
single and multiple dose of remacemide hydrochloride and placebo in 10 
epileptic patients
AUC Cmax Tmax Cmin
(umol.hr.M) (umol.M) (hours) (umol.M)
Placebo 53.8 (32.7) 5.6 (2.6) 6.2 (5.1) 5.0 (2.4)
Single dose 46.7 (26.9) 5.0 (2.2) 4.6 (4.6) 4.5 (2.2)
Multiple doses 48.4 (27.5) 5.9 (2.4) 5.2 (4.6) 4.9 (2.2)
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Cmax of 153%. These patients, however, remained symptom-free. There was 
no significant difference in Tmax following acute or chronic remacemide 
hydrochloride dosing. Comparison of mean trough CBZ-E levels 5, 12, and 15 
days after the start of active treatment (5.1, 4.4 and 5.0 umol/L respectively) 
with those during placebo treatment (4.9, 4.1, and 5.0 umol/L respectively) 
showed no significant differences (p = 0.62).
Remacemide and ARL12495XX pharmacokinetics
Mean plasma concentrations following single and multiple dosing are 
illustrated for remacemide in Figure 8, for ARL12495XX in Figure 9, and for 
both in table 5. As anticipated from a drug with a considerably shorter half-life 
than dosing interval, there was little carry-over of remacemide from dose to 
dose, and the steady-state profiles attained were at only slightly higher levels 
than those following the single dose (Figure 8 and Table 5). For 
ARL12495XX, however, consistent with its longer terminal half life, there was 
a greater carry-over during multiple dosing, and the maximum concentrations 
attained at steady-state were approximately twice those following the single 
dose (Figure 9 and Table 5). Steady state peak (Cmax) to trough (Cmin) 
oscillations were much smaller for ARL12495XX than for remacemide.
With both remacemide and ARL12495XX, there was good predictability of 
multiple dose profiles compared with single dose profiles based on linear 
superposition of the concentration data and comparisons of AUCs following
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Mean pharmacokinetic parameters (SD) of remacemide hydrochloride and 
ARL12495XX in 10 carbamazepine treated patients following acute and 
chronic dosing.
Cmax
(ng.mr1)
Cmin
(ng.ml"1)
Tmax
(hours)
AUC**
(ng.hr.ml-1)
t1/2
(hours)
Single Dose
Remacemide 783 (229) NA 1.5(1.0) 2266 (1344) 3.6 (1.3)
ARL12495XX 30.2 (7.6) NA 2.0 (0.7) 395 (125) 10.4 (0.6)
Multiple Dose
Remacemide 1006 (411) 60.9 (74.8) 1.1 (0.4) 2644 (1376) 3.5 (1.4)
ARL12495XX 64.8 (23.2) 25.2 (7.9) 1.6 (0.9) 427 (108) 11.2 (4.1)
**AUC00for single dose profiles, AUC0-i2h for multiple dose profiles 
NA = not applicable
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Figure 8
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Figure 8: Mean (+/-SD) single dose and steady state plasma concentrations of 
remacemide in 10 patients taking carbamazepine who received a single dose 
(300mg) or multiple doses (300mg BD for 14 days) remacemide hydrochloride.
Figure  9
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Figure 9: Mean (+/-SD) single dose and steady state plasma concentrations of 
ARL12495 in 10 patients taking carbamazepine who received a single dose (300mg) 
or multiple doses (300mg BD for 14 days) remacemide hydrochloride.
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single and multiple dosing. This suggests that there was no autoinduction of 
remacemide or ARL12495XX metabolism.
Adverse events
No major adverse events were reported, and no patients were withdrawn from 
the study due to adverse events, although one patient (C016) had his dose of 
remacemide hydrochloride halved 4 days into the multiple-dose phase 
because of dizziness. Overall, more events were reported while patients were 
on placebo (36 adverse events) than following remacemide hydrochloride 
treatment (26 events reported). Similar numbers of patients reported adverse 
events following multiple dosing with active treatment (10 patients) as were 
reported with placebo (9 patients). There were similar numbers of central 
nervous system events (4 on remacemide hydrochloride versus 3 on 
placebo), and gastrointestinal symptoms reported were equal on both 
treatments (2 each).
Discussion
Carbamazepine is a well-known inducer of the hepatic P450 mono-oxygenase 
enzymes (Brodie 1992). This results in marked intra- and inter-individual 
variations in serum concentrations of other antiepileptic drugs during 
polypharmacy, an unpredictability which is exacerbated by variable 
autoinduction of metabolism (Levy and Wurdland 1995). In addition, many 
other drugs have been shown to interact pharmacokinetically with 
carbamazepine (McKee and Brodie 1994). A major pathway involves oxidation
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of carbamazepine to the 10,11-epoxide (CBZ-E), which is itself 
biotransformed by the enzyme epoxide hydrolase to the inert dihydrodiol 
(Eichelbaum et al 1985). These two processes provide a target for 
interactions between carbamazepine and other antiepileptic drugs (Brodie et 
al 1983, Macphee et al 1988, McKee et al 1992). Changes in the epoxide 
concentration may be important because this CBZ-E contributes to the 
efficacy and adverse events associated with carbamazepine treatment 
(Gillham et al 1988). In one study the majority of patients on co-medication 
with remacemide hydrochloride had dose-related increases in trough 
concentrations of carbamazepine, necessitating a reduction in carbamazepine 
dose in a few patients (Clark et al 1995).
Like carbamazepine, remacemide is also eliminated almost exclusively by 
metabolic transformation. Apart from the active metabolite ARL12495, which 
is formed by the ubiquitous aminopeptidase enzymes, there are a number of 
oxidative biotransformation products. In addition, remacemide hydrochloride 
undergoes direct glucuronidation to form a carbamoyl glucuronide metabolite, 
an important pathway in man (Clark et al 1995).
Following multiple dosing with remacemide hydrochloride, there was an 
overall small inhibition of carbamazepine metabolism during active treatment 
compared with placebo. Three patients demonstrated a rise in carbamazepine 
trough levels of >30%. There were no significant changes overall in CBZ-E 
concentrations during treatment with remacemide hydrochloride, although 
there were marked differences in individual response with one patient 
exhibiting an increase in CBZ-E level of more than 100%. No patients had any
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clinical sequelae.
These findings are consistent with the in-vitro experiments using 6-B- 
hydroxylation of testosterone as a marker of CYP3A4 activity (Riley - 
manuscript in preparation), which showed that remacemide is an inhibitor of 
cytochromal activity associated with this isoform. Since the concentrations of 
remacemide required in the in-vitro mixture to achieve inhibition of CYP3A4 
are in excess of those reached in vivo, it is fair to assume that any increase in 
carbamazepine concentrations will be modest. Remacemide has not been 
shown to affect epoxide hydrolase in vitro, in keeping with the findings in this 
study.
This study also offered the opportunity to provide a pharmacokinetic profile of 
remacemide and ARL12495XX in enzyme-induced patients. For both 
compounds, the multiple dose profile was consistent with that predicted from 
the single dose, indicative of linear disposition and the absence of 
autoinduction of metabolism. The terminal half life of remacemide was similar 
to that found in previous clinical studies in human volunteers (Figure 10), 
whereas that of ARL12495XX in enzyme-induced patients was shorter than in 
untreated healthy volunteers (Clark et al 1995). Exposure to remacemide 
based on AUC values was around 60% of that reported previously in non­
induced subjects taking the same dose of the drug, while that of ARL12495XX 
was about 30% (Figure 10).
The most common adverse events reported with remacemide hydrochloride 
were dizziness and mild to moderate gastrointestinal upset (Clark et al 1995).
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Figure 10: Mean pharmacokinetics of remacemide and ARL12495 in patients 
pretreated with carbamazepine versus healthy untreated volunteers (Data on 
file Astra Pharmaceuticals)
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There were no adverse events precipitating withdrawal from the study, 
although one patient reported dizziness, necessitating a decrease in 
remacemide hydrochloride dose. A greater number of adverse events were 
reported during the placebo phase. In healthy, untreated volunteers, the AUC 
following similar dosing with remacemide hydrochloride (600mg/day) was 
between two and three times higher than the doses used in patients taking 
carbamazepine in this study. Consequently, 600mg per day is unlikely to be 
the maximum tolerated dose of remacemide hydrochloride in patients 
receiving treatment with carbamazepine.
There was considerable inter-patient variability in the pharmacokinetic 
response following the introduction of remacemide hydrochloride suggesting 
differences in individual susceptibility to the interaction. Although vigilance 
should be exercised in adding remacemide hydrochloride to antiepileptic drug 
regimes containing carbamazepine, it is questionable whether a reduction in 
carbamazepine dosage will be required in most patients. Since the presence 
of carbamazepine will result in lower bioavailability of remacemide and 
ARL12495XX, patients pre-treated with an enzyme-inducer such as 
carbamazepine will require higher doses of remacemide hydrochloride than 
non-induced patients. In addition, the remacemide concentration can be 
expected to rise when carbamazepine is withdrawn. Since remacemide and 
ARL12495XX exhibit predictable and linear kinetics in carbamazepine 
patients, with no evidence of autoinduction, there should be little need for 
routine therapeutic monitoring of either drug in this clinical setting. The mutual 
interaction between carbamazepine and remacemide hydrochloride is
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predictable and modest, and should not present a barrier to their clinical use 
in combination.
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Results from phenvtoin-treated patients 
Patients
Of the 11 patients recruited (Table 6), 10 completed the study as per protocol. 
One patient (P011) withdrew consent one day into the second multiple dosing 
phase for social reasons. Patient number P013 underwent single dosing with 
remacemide but was subsequently withdrawn from the trial because one of his 
pre-trial phenytoin levels was found to be below the target range. After 
dosage adjustment, the patient recommenced the study as patient P014.
Phenytoin pharmacokinetics
There were no changes in phenytoin pharmacokinetic parameters following a 
single dose of remacemide hydrochloride (Figure 11 and Table 6). Following 
14 days’ treatment, however, there was a trend towards an increase in the 
mean AU C 0-i2h of phenytoin by 11.5% (p=0.33), the mean Cmax by 13.7 % 
(p=0.32), and the mean Cmin by 22 % (p=0.12). Tmax was unchanged 
following both single and multi-dose remacemide hydrochloride. Comparison 
of mean trough phenytoin levels 5, 12, and 15 days after the start of active 
treatment (76.8, 95.4 and 90.6 ng/ml respectively) with those on placebo 
(72.1, 73.0 and 74.7 ng/ml respectively) showed a treatment associated 
increase which reached statistical significance (p=0.02). No patients, 
however, reported any symptoms suggestive of phenytoin toxicity.
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Table 6
Demographic characteristics of phenytoin-treated population
Patient Sex Age
(years)
Phenytoin dose 
(mg/day)
Dosage interva 
(hours)
P001 M 59 450 12
P 007 M 28 350 24
P 008 M 28 300 12
P 009 M 58 400 12
P010 M 27 300 24
P011* M 22 275 24
P 012 M 31 200 12
P 014** M 54 500 12
P 015 M 26 600 12
P 016 F 41 325 12
P 017 F 24 350 12
* Did not complete study
**Was initially included as Patient number 13, withdrawn and re­
entered as 014.
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Table 7
Mean phenytoin pharmacokinetic parameters (SD) after single and multiple 
doses of remacemide hydrochloride and placebo in 10 epileptic patients
AUC Cmax Tmax Cmin 
(nmol.hr.mr1) (nmol.ml'1) (hours) (nmol.ml'1)
Placebo 
Single dose 
Multiple doses
944 (459) 98.3 (57.3) 4.7 (3.6) 74.7 (34.4) 
917 (315) 90.9(30.2) 3.3 (3.6) 80.0(31.4) 
1047 (533) 108 (55.1) 3.9 (3.6) 87.8(44.2)
Fiaure 11
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Figure 11: Mean plasma concentrations of phenytoin in 10 patients following 
treatment with single (300mg) or multiple (300mg BD for 14 days) dose of 
remacemide hydrochloride.
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Remacemide and ARL12495XX pharmacokinetics
Mean pharmacokinetic parameters for remacemide hydrochloride and 
ARL12495XX following single and multiple dosing are shown in Table 8, and 
are similar to the parameters demonstrated in carbamazepine-treated 
individuals. As anticipated from a drug with a considerably shorter half-life 
than dosing interval, there was little carry-over of remacemide from dose to 
dose, and the steady-state profiles attained only slightly higher levels than 
those following the single dose. For ARL12495XX, consistent with its longer 
terminal half life, there was a greater carry-over during multiple dosing, and at 
steady-state the maximum concentrations attained were almost twice those 
following the single dose. With both remacemide and ARL12495 (Figure 12 
and 13), there was good predictability of multiple dose profiles compared with 
single dose profiles based on linear superposition of the concentration data 
suggesting a lack of autoinduction of remacemide or ARL12495XX 
metabolism.
Adverse events
No major adverse events occurred, and noone required withdrawal from the 
study due to intolerable adverse events. Similar numbers of adverse events 
were reported while patients were on placebo (10 adverse events) as were 
reported during remacemide treatment (9 events reported). An identical 
number of patients (six) reported adverse events following multiple dosing 
with active treatment as occurred on placebo, and there were similar numbers 
of
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Table 8
Mean pharmacokinetic parameters (SD) of remacemide hydrochloride and 
ARL12495XX in 10 phenytoin-treated patients following acute and chronic 
dosing.
Cmax Cmin Tmax A U C * t1/2
(ng.ml'1) (ng.ml"1) (minutes) (ng.hr.ml"1) (hours)
Single Dose
Remacemide 660 (191) NA 60 (20) 1424 (511) 3.0 (0.9)
ARL12495XX 35.5(11.5 ) NA 96 (37) 210 (70 ) 9.1 (1.9)
Multiple Dose
Remacemide 666 (159) 25.1 (15.4) 63 (26) 1651 (529) 2.6 (0.3)
ARL12495XX 52.7 (18.1) 25.7 (12.2) 225 (447) 372 (128) 10.1 (4.9)
* AU C * for single dose profiles, AU C0-i2h for multiple dose profiles 
NA = not applicable
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Figure 12: Mean (+/-SD) single dose and steady state plasma concentrations of 
remacemide in 10 patients taking phenytoin who received a single dose (300mg) or 
multiple doses (300mg BD for 14 days) remacemide hydrochloride.
Figure 13
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Figure 13: Mean (+/-SD) single dose and steady state plasma concentrations of 
ARL12495 in 10 patients taking phenytoin who received a single dose (300mg) or 
multiple doses (300mg BD for 14 days) remacemide hydrochloride.
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central nervous system events (8 on remacemide versus 6 on placebo). No 
gastrointestinal symptoms were reported during this study.
Discussion
Phenytoin is a well-known inducer of the hepatic P450 mono-oxygenase 
enzymes (Brodie 1992). This results in marked intra- and inter-individual 
variations in serum concentrations of other antiepileptic drugs during 
polypharmacy. In addition, many other drugs have been shown to interact with 
phenytoin (McKee and Brodie 1995). Its clearance in man is almost 
exclusively by hepatic metabolic transformation, a major pathway involving the 
action of CYP2C9 and CYP2C19 (Levy 1995). In one study a proportion of 
patients on co-medication with remacemide and phenytoin had dose-related 
increases in trough concentrations of phenytoin, although no one required a 
reduction in phenytoin dose (Clark et al 1995).
Following multiple dosing with remacemide hydrochloride, there was a trend 
towards inhibition of phenytoin metabolism during active treatment compared 
with placebo which did not reach statistical significance. No patients 
demonstrated any clinical signs or symptoms of phenytoin toxicity.
This study confirms the effects of enzyme induction on the pharmacokinetic 
profile of remacemide and ARL12495XX. For both compounds, the multiple 
dose profile was consistent with that predicted from the single dose, indicative 
of linear disposition and the absence of autoinduction of metabolism. The 
terminal half life of remacemide was similar to that found in previous clinical 
studies in human volunteers, whereas that of ARL12495XX in enzyme-
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induced patients was shorter than in untreated volunteers (Palmer et al 1993). 
In healthy volunteers, the AUC following similar dosing with remacemide 
hydrochloride was between two and three times higher that in patients on 
phenytoin in this study. Consequently, 600mg per day is unlikely to be the 
maximum tolerated dose of remacemide hydrochloride in patients receiving 
treatment with phenytoin.
The combination of phenytoin with remacemide was well tolerated, with few 
adverse events reported, and no patients requiring withdrawal from the study. 
A similar number of adverse events were reported during the active treatment 
and placebo phases.
There was considerable inter-patient variability in the pharmacokinetic 
response following the introduction of remacemide hydrochloride, suggesting 
differences in individual susceptibility to the phenytoin / remacemide 
interaction. Although vigilance should be exercised in adding remacemide 
hydrochloride to antiepileptic drug regimes containing phenytoin, it is unlikely 
that a reduction in phenytoin dosage will be required in many patients. Since 
the presence of phenytoin will result in lower bioavailability of remacemide 
and ARL12495XX, patients pre-treated with an enzyme-inducer such as 
phenytoin will require higher doses of remacemide hydrochloride than non­
induced patients. In addition, the remacemide concentration can be expected 
to rise when phenytoin is withdrawn. Since remacemide and ARL12495XX 
exhibit predictable and linear kinetics in phenytoin patients, with no evidence 
of autoinduction, there should be little need for routine therapeutic monitoring 
of either drug in this clinical setting. The mutual interaction between phenytoin
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and remacemide hydrochloride is predictable and modest, and should not 
present a barrier to their widespread clinical use in combination.
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Valproate-treated patients
Sixteen valproate-treated patients were recruited (Table 9), each on a regime 
which had been stable for at least three months. All patients had at least one 
plasma measurement of valproate within the target range (345-695umol/L) 
during that period.
Patients
Of the 16 patients recruited (Table 9), 4 completed the study at the higher 
dose of remacemide (see protocol) with ten patients completing the trial 
having received 150mg for at least 9 days. Two patients withdrew from the 
trial due to the onset of adverse events (one at each dose level). One patient 
who was withdrawn during the placebo phase because of intercurrent illness, 
restarted the study and completed the trial at the lower dose.
Valproate pharmacokinetics
Analysis of those patients stabilised on 150mg BD remacemide shows no 
changes in valproate pharmacokinetic parameters following administration of 
single or multiple dosing of remacemide hydrochloride (Figure 14 and Table 
10).
Demographic characteristics of Valproate-treated patients treated with 
remacemide.
Patient Sex Age
(years)
Daily valproate 
intake 
over 2 divided 
doses (mg)
V 002 M 38 2000
V 004 M 20 3000
V 008 F 45 1200
V 009 M 43 2000
V010 M 24 800
V011 M 37 1200
V 012 M 41 2500
V 022 F 24 1000
V 023 F 52 2400
V 024 M 33 3500
V0031 M 54 2600
V0052 M 57 1700
V0072 F 19 700
V0162 F 19 2000
V0013 F 62 1800
V0064 M 45 2000
Completed high dose (300mg BD Remacemide) but results uninterpretable. 
2Completed high dose remacemide regimen 
3Withdrew due to adverse events at 300mg BD 
4Withdrew due to adverse events at 150mg BD
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Table 10
Mean valproate pharmacokinetic parameters (SD) after single and multiple 
doses of remacemide hydrochloride and placebo in 10 epileptic patients 
receiving 300mg final dose after multiple dosing with 150mg BD.
AUC Cmax Tmax Cmin
(ng.hr.mr1) (ng.ml"1) (hours) (ng.ml'1)
Placebo 
Single dose 
Multiple doses
6492.9 (1857.4)
6704.1 (2252.1)
6451.2 (1348.5)
836.3(219.5) 
775.8 (255.7) 
793.1 (193.7)
2.6 (1.4)
4.5 (2.0)
3.6 (2.0)
491.4 (102.9) 
533.0(158.7) 
482.8 (72.6)
Figure 14
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Figure 14: Mean plasma concentrations of sodium valproate in 10 patients 
following treatment with single (300mg) or multiple (14 days) dose of 
remacemide hydrochloride.
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Remacemide and metabolite pharmacokinetics
Mean pharmacokinetic parameters for remacemide hydrochloride and 
ARL12495XX following single and multiple dosing are shown in Table 3V. 
After 14 days treatment, there was no significant difference in any of the 
pharmacokinetic parameters of remacemide or ARL12495XX (Figures 15 and 
16).
Based on linear superposition of the concentration data, there was good 
predictability of multiple dose profiles of both remacemide and ARL12495XX 
compared with single dose profiles, suggesting a lack of autoinduction of 
remacemide or ARL12495XX metabolism.
The half life of both remacemide and ARL12495XX was lower in the 3 
evaluable patients completing the multiple dose phase on 300mg BD (Table 
12) compared to those intolerant of the high dose, although with small 
numbers involved, this did not reach statistical significance.
Adverse events
Of the nine patients started on remacemide hydrochloride 300mg BD, two 
were withdrawn from the study: one immediately, and one following a 
reduction in remacemide hydrochloride dose to 150mg BD. Two other patients 
had the dose reduced to 150mg BD after 4 days, and completed the trial 
satisfactorily at this dose level. The side effects experienced at 300mg BD, 
were central nervous system related (dizziness, drowsiness, headache) with 
one patient experiencing dyspepsia which failed to resolve on reduction of the 
remacemide hydrochloride dose.
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Mean pharmacokinetic parameters (SD) of remacemide hydrochloride and 
ARL12495XX in 10 valproate-treated patients following acute and chronic 
dosing.
Cmax Cmin Tmax AUC* t1/2
(ng.ml"1) (ng.ml-1) (Hours) (ng.hr.ml-1) (hours)
Single Dose
Remacemide 817(257) NA 1.3(0.8) 3282 (899) 4.2 (0.7)
ARL12495XX 76.7 (25) NA 5.2 (2.7) 1310(7583) 15.5 (3.8)
Multiple Dose
Remacemide 706 (380) 46.7 (25.0) 1.2 (0.3) 2644 (1347) 4.2 (0.9)
ARL12495XX 104 (41) 46.4 (14.1) 2.8(1.2) 924 (364) 15.0 (5.6)
* AUCoc for single dose profiles, AU C0-i2h for multiple dose profiles 
NA = not applicable
Mean pharmacokinetic parameters (SD) of remacemide hydrochloride and 
ARL12495XX in 3 valproate-treated patients following acute and chronic 
dosing with 300mg BD.
Cmax Cmin Tmax AUC* t1/2
(ng.ml-1) (ng.ml-1) (Hours) (ng.hr.ml-1) (hours)
Single Dose
Remacemide 934 (408) NA 1.5 (0.5) 3167 (748) 4.3 (2.1)
ARL12495XX 123 (45) NA 3.5 (2.3) 1487 (286) 13.8 (5.9)
Multiple Dose
Remacemide 803 (242) 61.8(50.0) 10(0.5) 2791 (572) 3.5 (0.5)
ARL12495XX 159 (39) 85.4 (15.5) 18(0.3) 1351 (155) 10.3(2.4)
* AUCoc for single dose profiles, AU C0-i2h for multiple dose profiles 
NA = not applicable
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Figure 15: Mean (+/-SD) single dose and steady state plasma concentrations of 
remacemide in 10 patients taking sodium valproate who received a single dose 
(300mg) or multiple doses (300mg BD for 14 days) remacemide hydrochloride.
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Figure 16: Mean (+/-SD) single dose and steady state plasma concentrations of 
ARL12495 in 10 patients taking sodium valproate who received a single dose 
(300mg) or multiple doses (300mg BD for 14 days) remacemide hydrochloride.
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While on 150mg twice daily, no new major adverse events were reported, and 
as stated, only one patient was withdrawn from the study while on 150mg BD, 
because of an adverse event which had begun while on the higher dose (see 
above).
A similar number of patients on 150mg BD reported adverse events during 
dosing with active treatment (7 patients) as reported events while on placebo 
(5 patients). More adverse events were reported while patients were on 
remacemide treatment (21 events reported) compared to placebo (8 events 
reported), with more CNS side effects during active treatment (10 events) 
compared to the placebo treatment phase (1 event). Two gastrointestinal 
symptoms were reported during active treatment phase, with none occuring 
on placebo.
Discussion
Sodium valproate is a known hepatic enzyme inhibitor (Brodie 1992). This 
results in marked intra- and inter-individual variations in serum concentrations 
of other antiepileptic drugs during polypharmacy (McKee et al 1993). In 
addition, many other drugs have been shown to interact pharmacokinetically 
with valproate (McKee and Brodie 1995).
This interaction study used a placebo-controlled design in order to investigate 
the potential interaction between remacemide hydrochloride and valproate. 
Following multiple or single dosing with remacemide hydrochloride, there was 
no significant effect seen on valproate metabolism.
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This study also offered the opportunity to provide a pharmacokinetic profile of 
remacemide and ARL12495XX in valproate-treated patients. For both 
compounds, the multiple dose profile was consistent with that predicted from 
the single dose, indicative of linear disposition and the absence of 
autoinduction of metabolism. The pharmacokinetic parameters of remacemide 
and ARL12495XX in a valproate-treated population were similar to that found 
in human volunteers (Palmer et al 1993). The mean terminal half life of both 
remacemide and ARL12495XX in valproate-treated patients after chronic 
dosing (4.16 and 15.03 hours respectively) are not significantly different from 
those in healthy volunteers (3.35 and 12.86 hours respectively) (Palmer et al 
1993).
At 150mg twice daily of remacemide hydrochloride, the drug was well 
tolerated compared to placebo. There was a minor degree of inter-patient 
variability in the pharmacokinetic response following the introduction of 
remacemide hydrochloride suggesting differences in individual susceptibility 
to the interaction. Interestingly, although it did not reach statistical 
significance, patients who completed the study at the higher dose of 
remacemide displayed a shorter half life of both remacemide and 
ARL12495XX than those requiring dose reduction. The kinetics of 
remacemide and ARL12495XX, therefore, are not saturable at anticonvulsant 
doses. A proportion of valproate-treated patients may tolerate remacemide at 
the higher dose.
In this study, a higher number of adverse events were reported during the 
active treatment phase than during the placebo phase. Given the
158
pharmacokinetic data, the adverse events reported during remacemide 
treatment may be the result of a pharmacodynamic rather than 
pharmacokinetic interaction. A more complex interaction between remacemide 
and the various long-acting metabolites of valproate cannot, however, be 
excluded at this point.
Although vigilance should be exercised in adding remacemide hydrochloride 
to antiepileptic drug regimes containing valproate, it is likely that when started 
at an adequately low dose, remacemide would be well-tolerated when used 
with concomitant valproate.
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Conclusions
As discussed, the pharmacokinetics of remacemide and its active metabolite 
ARL12495XX are significantly different in a population that is receiving 
enzyme-inducing anticonvulsant medication. There is a trend towards an 
increase in the mean half life of remacemide in those on valproate (4.16 
hours) compared to patients pretreated with carbamazepine (3.39 hours) or 
phenytoin (2.59 hours) which reached statistical significance only in the latter 
case. The half life of ARL12495XX in valproate-treated patients, however, 
was significantly raised compared to patients on monotherapy with either 
carbamazepine (9.06 hours) or phenytoin (9.15 hours).
The effect of remacemide co-treatment on the established AEDs is variable. 
No significant differences were seen in phenytoin or valproate metabolism 
during treatment with remacemide. There was an increase in phenytoin 
concentrations trough concentrations which became significant after the first 
week.
Levels of CBZ-E are also unchanged by concomitant remacemide, but 
carbamazepine pharmacokinetics, are less predictable. Some patients 
experienced a moderate rise in peak and trough carbamazepine 
concentrations. It should be remembered, however, that no patients reported 
symptoms of carbamazepine toxicity, probably as a result of the unchanged 
CBZ-E levels. Further studies which are already underway, which involve 
potential dose altering by an unblinded observer may further elucidate the 
relationship between carbamazepine and remacemide.
Those patients on valproate, although lacking any significant alterations in
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metabolism of remacemide and ARL124954XX are probably more susceptible 
to adverse events than untreated volunteers. This may be due to a 
pharmacodynamic interaction between valproate and remacemide, or it may 
conceivably be a result of a pharmacokinetic interaction between remacemide 
and a long-lasting metabolite of valproate.
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The effects of the new AEDs on rodent whole
brain biochemistry
The use of whole brain biochemistry to examine the new AEDs
As our experience with the new AEDs grows, it is becoming more apparent 
that their effects are more wide ranging than was previously thought. Since 
the metabolism of amino acids is part of a large metabolic loop, and since 
enzyme substrates are structurally similar, it may be naive to think that a 
compound will have significant effects at one point in the chain without 
producing significant effects elsewhere.
In this respect, investigation of enzyme and substrate effects of AEDs needs 
to take a wide view. Further expansion of the enzymes and amino acids 
assayed would be desirable in the investigation of effects on glutamine 
synthase. The model may allow further manipulation to assess the role of 
different combinations of AEDs.
The effects of vigabatrin on levels of whole brain GABA concentrations and 
GABA-T activity have been well documented (Schechter et al 1991). The 
extent of the in-vivo GAD inhibition is less well described. With tiagabine 
possibly working well in combination with vigabatrin (Leach and Brodie 1994), 
we were keen to ascertain if the biochemical effects of combining the two 
compounds may give a rationale for further clinical combinations. Having 
initially used this method to assess these two drugs in combination, we 
subsequently extended the scope of investigation of other AEDs to include 
glutamate and glutamine, both essential precursors to GABA formation. The 
lesson having been learnt with vigabatrin in cell culture, that drugs can often
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have surprising neurophysiological effects, we decided to investigate the 
effects of two new AEDs, gabapentin and remacemide, on the enzymes and 
precursors of the GABA shunt.
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Effect of ARL12495XX on whole brain biochemistry
Remacemide has been thought to have one single mode of action, but as with 
lamotrigine and vigabatrin (Leach and Brodie 1995), the anticonvulsant 
effects may be augmented by related neurochemical effects. The 
neurochemical properties of remacemide have already been discussed, but 
given our experience of other new AEDs, we would contend that it is important 
to assess the effect of remacemide on neuronal amino acid metabolism in- 
vivo. This gives us a fuller understanding of the drug and its possible usage in 
combination.
The desglycinyl derivative, ARL12495, is an important active metabolite of 
remacemide. Routinely, this is the compound that is used in in-vitro 
experiments of remacemide.
This experiment looks at the effect of single and multiple i.p. injections of 
ARL12495AA on GABA metabolism in whole brain. Metabolism of GABA was 
monitored by measuring it’s precursors (glutamate, glutamine), total GABA 
levels, and the activity of the enzymes responsible for the formation (GAD) 
and breakdown (GABA-T) of GABA.
Study design
Acute studies
The first set of mice were given a single dose of either normal saline solution 
or ARL12495AA by i.p. injection. Each treatment group consisted of six mice. 
The dose of ARL12495AA used was 10, 25, 50, or 75mg/Kg. Six hours after
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injection, the brains were removed and assayed for the parameters of GABA 
metabolism as described below.
Chronic Studies
The second set were given a single injection of saline or ARL12495AA at 
identical doses to that described above, for 5 consecutive days. Six hours 
after the final dose, identical procedures were undertaken.
Statistics
Calculations were carried out using the Minitab V10 software package. 
Results were compared using ANOVA with Dunnet correction, to compensate 
for multiple comparisons with control.
RESULTS 
Glutamine levels
No differences were found on comparing glutamine levels of control animals, 
with those receiving ARL12495AA for one or more days (Figure 17).
Glutamate levels
No differences were found on comparing glutamate levels of control animals, 
with those receiving ARL12495AA as a single dose (Figure 18). After 
administration of the higher doses for 5 days, there was a trend towards a 
reduction in glutamate levels, although this narrowly failed to achieve 
statistical significance.
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Figure 17
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Figure 17: Mean (±SEM) glutamine concentrations in mouse whole brain after 
single and multiple doses of ARL12495
Figure 18
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Figure 18: Mean (+SEM) glutamate concentrations in mouse whole brain after 
single and multiple doses of ARL12495,
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GABA Levels
No differences were found on comparing GABA levels of control animals, with 
those receiving ARL12495AA chronically or acutely (Figure 19).
Iij
s
I GAD activity
| After a single dose there were no significant differences in GAD activity
ii
(Figure 20). When ARL12495AA had been administered for 5 days, however, 
at doses of 50 and 75 mg/Kg/day, a significant decrease was noted in activity 
of the enzyme.
GABA-T activity
Following single dose ARL12495AA, no change was noted in GABA-T activity 
(Figure 21). After 5 days' administration, however, at the two highest dose 
levels (50 and 75 mg/Kg/day), the activity of GABA-T was significantly 
increased.
Discussion
The enzyme effects of ARL12495AA have not been previously described for a 
compound that is an effective anticonvulsant. Both the decrease in GAD and 
the increase in GABA-T could be construed as being conducive to a decrease 
in GABAergic inhibition, and at first sight, this might not be the best secondary 
effect for a potential AED to have. We would argue, however, that these
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Figure 19
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Figure 19: GABA concentrations in mouse whole brain after single and 
multiple doses of ARL12495
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Figure 20
GAD Activity 
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Figure 20: Activity of GAD in mouse whole brain after single and multiple 
doses of ARL12495
Fiaure 21
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Figure 21: Activity of GABA-T in mouse whole brain after single and multiple 
doses of ARL12495
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effects are rendered less important because the levels of whole brain GABA 
remain unchanged by ARL12495AA. Although measurement of whole brain 
GABA is not always a reliable indicator of GABAergic inhibitory tone, the lack 
of a fall in GABA levels is somewhat reassuring.
That the highest doses of ARL12495AA should affect GAD and GABA-T 
activity is perhaps not overly surprising, given it's effects on the hepatic 
cytochrome P450 system in-vitro (Riley et al 1995) and in-vivo (Leach et al, 
submitted). It should be noted that the effects on GABA-T occur only at doses 
approaching those maximally tolerated in rodents (Muir and Palmer 1991).
The diminished GAD activity at higher dose may be related to the decrease in 
concentrations of it’s substrate, glutamate. This decrease in whole brain 
glutamate, though not statistically significant, is of some interest. Glutamate is 
a well recognised excitotoxin (Meldrum 1990). This neurotoxicity is mediated 
mainly by it’s actions at the NMDA receptor (Choi et al 1991). Activation of 
this glutamate receptor predisposes to cationic influx which can cause cell 
death, and ARL12495XX has already been shown to inhibit release of 
glutamate (Srinivasan et al 1995). If further work can confirm that remacemide 
and its metabolites have effects not only on glutamate receptors and 
glutamate release, but also on glutamate levels, then it may form a rational 
basis for the use of the drug in other areas where excitotoxins are thought to 
be of importance, such as ischaemia, Parkinson’s disease, and motor 
neurone disease.
Conclusion
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Like other novel anticonvulsants, remacemide is now being shown to have 
wider neurochemical effects than was first thought. The nature of the effects 
on GABA-T and GAD were unexpected, although their significance may be 
tempered by the lack of an effect on total GABA levels.
Whether the enzyme changes in mice following a short duration of treatment 
are of any relevance to a human population treated for longer periods with 
relatively lower doses is, at the moment, unclear.
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Effects of gabapentin on whole brain biochemistry
This paper looks at the effect on GABA metabolism of different doses of 
gabapentin on rodent brain following single and multiple dosing. GABA 
metabolism was monitored by measuring it’s precursors (glutamate, 
glutamine), total GABA levels, and the activities of GAD and the enzyme 
responsible for GABA breakdown, GABA-transaminase (GABA-T).
Study design
Acute studies
One set of mice was given a single dose of either normal saline solution or 
gabapentin by i.p. injection. Each treatment group consisted of six mice. The 
dose of gabapentin administered was 5, 10, 25, 50, or 75mg/Kg. Four hours 
after injection, brains were removed and assays carried out for GABA, 
glutamate, glutamine, and the activities of GABA-T and GAD.
Chronic Studies
A second set was given twice daily i.p. injections of gabapentin, to a daily total 
as described above, for 8 consecutive days. Four hours after the final dose, 
identical procedures were undertaken.
Statistics
As with the previous study, calculations were carried out using the Minitab 
V10 software package. Results were compared using ANOVA with Dunnet 
correction, to compensate for multiple comparisons with control.
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RESULTS 
Glutamine levels
No differences were found on comparing glutamine levels of control animals 
following chronic administration (Figure 22). Acute administration showed a 
significant increase in glutamine levels after injection of 50mg/Kg, with no 
trends seen at other doses. This would cast doubt upon the importance of this 
single result.
Glutamate levels
Single dose of gabapentin had no effect on glutamate concentrations at any 
dose. After seven days, however, there was a clear trend towards reduction in 
glutamate concentrations, the reduction reaching statistical significance at 
25mg/Kg (Figure 23).
GABA Levels
No significant changes were seen in GABA concentrations after either single 
or multiple dosing (Figure 24).
GAD activity
Measurement of GAD activity showed wide variability throughout all groups. 
There were no trends visible after single or multiple dosing (Figure 25).
GABA-T activity
Acute administration of gabapentin caused no statistically significant 
increases in GABA-T activity (Figure 26). After seven days, there was a clear 
trend towards reduction in GABA-T activity, which became significant at doses 
of 10mg/Kg and above (with the exception of 25mg/Kg, which narrowly failed 
to achieve statistical significance).
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Figure 22
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Figure 22: Mean (±SEM) glutamine concentrations in mouse whole brain 
following single or multiple doses of gabapentin.
Figure 23
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Figure 23: Mean (±SEM) glutamate concentrations in mouse whole brain 
following single or multiple doses of gabapentin.
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Figure 24: Mean (±SEM) GABA concentrations in mouse whole brain 
following single or multiple doses of gabapentin.
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Figure 25: Mean (+SEM) GAD activity in mouse whole brain following single 
or multiple doses of gabapentin.
Figure 26
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Figure 26: Mean (+SEM) GABA-T activity in mouse whole brain following 
single or multiple doses of gabapentin.
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Discussion
Gabapentin is an efficacious and well tolerated anticonvulsant (Chapter 2 - 
The new AEDs) which has been widely used as add-on treatment for 
refractory epilepsy. Despite widespread searches, the exact mode of action 
remains unclear (Taylor 1995).
Previous in-vivo studies (Ben Menachem et al 1992) have looked at the 
effects of single dose gabapentin on CSF amino acids in humans, showing 
only that by 72 hours post-dose, the CSF levels of homovanillic acid and 5- 
Hydroxyindoleacetic acid were increased. The significance of these changes 
is unclear. Using MRI spectroscopy, gabapentin is said to increase GABA 
concentrations in human brain (Petroff et al, 1996). This contrasts with our 
findings.
We know that gabapentin does not act as a direct GABA agonist, does not 
bind to GABA receptors (Bartosyck et al 1986), and in fact, appears to have 
it’s own specific binding sites as shown on autoradiography (Hill et al 1993). 
This may be related to a subunit of the calcium channel (Warner Lambert - 
Unpublished Data).
Gabapentin has been associated with various actions on the GABAergic 
inhibitory system. As previously discussed (Goldlust et al 1995) gabapentin 
was known to inhibit both GABA-T and Branched Chain Amino Acid 
Transaminase (BCAA-T), while Kocsis and Honmou (1994) showed that 
gabapentin increased non-synaptic GABA release. Induction of GAD, the 
enzyme responsible for production of GABA and the breakdown of glutamate, 
has also been thought to be of potential importance as a mode of action
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(Silverman et al 1991, Taylor et al 1993, Loscher et al 1991). We found no 
evidence of GAD induction, and can only surmise that the aminooxyacetic 
acid-induced GABA accumulation demonstrated in the presence of 
gabapentin by Silverman and colleagues (1991) was due to an additional 
degree of GABA-T inhibition.
It is widely agreed that gabapentin has the potential to have many effects on 
GABA turnover, and our study is one attempt to further elucidate their relative 
importance. If we can understand how gabapentin alters the GABA shunt, 
then its clinical use alongside other AEDs may be better directed.
Significant inhibition of GABA-T by gabapentin may suggest that it may 
usefully be combined with other GABA-T inhibitors. At higher doses, 
vigabatrin causes an inhibition of both GAD and GABA-T activity (Leach - 
paper submitted). This may account for the plateau of anticonvulsant efficacy 
that has been shown in some trials (McKee et al 1993), and may also account 
for the increase in adverse events at higher doses (Grant and Heel 1992). 
Combination of gabapentin with vigabatrin may allow for optimal inhibition of 
GABA-T with less GAD inhibition, potentially improving anticonvulsant effect. 
The trend towards decrease in glutamate concentrations on treatment with 
gabapentin may be linked to its effect on glutamate dehydrogenase discussed 
in earlier chapters. This decrease in glutamate levels is a desirable effect in 
terms of anticonvulsant and neuroprotective activity, and further work is 
needed to elucidate further the clinical importance, if any, of this effect.
These other associated actions of gabapentin on GABA metabolism are of 
great interest, and may imply that gabapentin has other wider ranging effects
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on the production and breakdown of amino acids in the brain.
Conclusion
Gabapentin is an important new AED, whose mode of action is not yet fully 
understood. This study looks at the effect of gabapentin on the key enzymes 
and substrates of amino acid metabolism which are involved in the 
metabolism of the main inhibitory neurotransmitter GABA.
Although no changes were seen in whole brain levels of GABA during this 
work, gabapentin was shown to have important effects on GABA-T activity. 
There were significant changes in levels of glutamate after chronic dosing 
with gabapentin, which may be of importance in helping to lessen the negative 
effects of chronic refractory epilepsy.
The biochemical actions of gabapentin may allow for useful combination with 
other proven AEDs, particularly vigabatrin. Further clinical and laboratory 
studies are required to investigate the potential for use of gabapentin as part 
of a rational polypharmacy plan for chronic epilepsy.
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Effects of tiaqabine and vigabatrin on cortical biochemistry 
following multiple doses
Both tiagabine and vigabatrin are known to augment GABAergic inhibition. As 
is discussed in previous sections, there may be some additive effect on GABA 
uptake inhibition when both drugs are used together. During one of 
tiagabine’s efficacy trials, we and other investigators felt that those already 
receiving vigabatrin tended to have a greater reduction in seizure frequency 
than other patients once tiagabine was added to their regime. This prompted 
a successful addition of sub-therapeutic doses of vigabatrin in two patients 
who had partially responded to tiagabine (Leach and Brodie 1994).
This experiment examines the effect on GABA metabolism of different 
combinations of tiagabine and vigabatrin in mice. Three parameters of GABA 
metabolism monitored were assayed: total GABA levels, GABA-T activity and 
GAD activity.
Study design
A first set of mice were split into four groups, each receiving once-daily intra- 
peritoneal injection with low dose vigabatrin (10 mg/Kg), low dose tiagabine 
(0.4mg/Kg), a combination of both drugs, or saline. Each treatment group 
consisted of six mice. Two further sets of mice were again subdivided into four 
groups and treated with similar treatment regimes at medium dose (vigabatrin 
50mg/Kg, tiagabine 2mg/Kg), or high dose (vigabatrin 250mg/Kg, tiagabine 
10mg/Kg). After eight days treatment the cerebral cortices were removed and
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assayed for both enzymes and GABA itself.
Statistics
Calculations were carried out using the Minitab V10 software package. 
Results were compared using ANOVA with Dunnet correction, to compensate 
for multiple comparisons with control.
RESULTS
Low Dose Study
Vigabatrin and tiagabine were without effect on cortical GABA concentrations 
when used alone. Combination of the two at low doses however significantly 
increased GABA levels compared to control, although not on comparison with 
vigabatrin alone (Fig WC1). All other low dose treatments were without effect 
on the activities of GABA-T (Fig WC3) and GAD (Fig WC2).
Medium Dose Study
Both vigabatrin and combination significantly increased cortical GABA 
concentrations (Figure 27) compared to control, while tiagabine alone at 
medium dose had no effect. Vigabatrin significantly reduced GABA-T activity 
compared to control (Figure 28). Interestingly tiagabine caused an increase in 
GABA-T activity, while the combination treatment had no significant effect on
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Figure 27: Mean (+/-SEM) GABA levels in mouse brain following treatment 
with different doses of vigabatrin, tiagabine, and a combination for 5 days.
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Figure 28: Mean (+/-SEM) GAD Activity in mouse brain following treatment 
with vigabatrin, tiagabine or a combination of the two for five days.
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Figure 29: Mean (+/-SEM) GABA-T activity in mouse brain after treatment 
with various doses of vigabatrin, tiagabine or a combination for 5 days.
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GABA-T activity. GAD activity was significantly reduced (Figure 28) by both 
vigabatrin and combination therapy at medium dose, while tiagabine alone 
had no effect.
High Dose Study
High dose vigabatrin and high dose combination significantly increased 
cortical GABA concentrations (Figure 27) and significantly reduced activity of 
both GABA-T (Figure 29) and GAD (Figure 28). Tiagabine at high dose was 
without effect on any of the parameters.
Discussion
If rational polypharmacy is to become the norm, the combined use of two 
GABAergic anticonvulsants would seem a reasonable first step. We have 
used this animal model in an attempt to delineate the biochemical effects of 
vigabatrin and tiagabine when used alone and in combination. Doses for this 
study were defined as high, medium, or low on the basis of response to 
chronic dosing in laboratory seizure models. Medium doses were those which 
were found to be optimally therapeutic, while the high and low doses were 
increased or decreased respectively by a factor of five. Low doses were 
previously shown to be subtherapeutic in our laboratories against MES and 
PTZ-induced seizures in mice.
Despite our earlier beliefs, vigabatrin probably has a number of effects on 
GABAergic function, while tiagabine is currently believed to be more specific. 
The finding that both may act in inhibiting GABA uptake (Leach et al 1996 -
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submitted) may explain the previously noted clinical additive effect (Leach and 
Brodie 1994).
That low dose combination had no effect on enzyme activity, but that it 
increased GABA concentrations compared to control is a curious 
phenomenon. The observation may suggest some interaction between 
vigabatrin and tiagabine at low dose which underpins the additive effect seen 
clinically. Tiagabine has been shown to preferentially block the GAT-1 GABA 
uptake mechanism (Borden et al 1994), and it is not known which uptake 
mechanism, if any, is responsible for vigabatrin uptake. If selective GAT-1 
blockade led to an upregulation of other GABA transport mechanisms, then 
this could theoretically enhance the intracellular uptake of vigabatrin, 
rendering lower doses of vigabatrin efficacious.
Medium dose vigabatrin increased GABA concentrations and decreased 
activity of GABA-T and GAD. The decrease in GAD activity was thought to be 
a result of feedback by increased levels of GABA, although this has not been 
thought to be a factor in mammalian brain (Horton 1989). Some authors, in 
contrast have suggested that vigabatrin has a direct inhibitory effect on GAD 
(Jung et al, 1979). It has been postulated that the effect on GAD may 
contribute to the development of tolerance (Neal and Shah 1990) or the 
limitation of effect of higher doses (McKee et al 1994) of vigabatrin. Medium 
dose tiagabine failed to significantly affect GABA concentrations or GAD 
activity, but caused a significant increase in GABA-T activity when compared 
to control.
At high dose, vigabatrin had a more pronounced inhibition of GABA-T, GAD,
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and increase in GABA than happened at other doses. High dose combination 
did not differ from the actions of vigabatrin alone, suggesting that no 
interactions occur between the two drugs at this high dose level.
Conclusion
Tiagabine and vigabatrin are both effective novel anticonvulsants, which were 
thought to have different, single actions on the GABAergic inhibitory system. 
Both have anticonvulsant efficacy when used with other anticonvulsant 
agents, and some clinical experience has suggested that there is a particular 
benefit in the combination of both compounds. Combining these drugs at low 
dose may avoid the need for high doses to be used, and so decrease the 
incidence of adverse effects.
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The effects of vigabatrin and tiagabine on GABA 
uptake in primary cultures of rodent astrocytes.
The role of glial cell and neuronal culture in the elucidation of basic
mechanisms
Culture of glial cells has been essential in helping to elucidate their normal 
physiological function. As our techniques have been refined, it has now 
become apparent that the two morphological types of astrocytes Type I and II 
have differing biochemical functions.
As a result of the techniques used, most astrocyte cultures have usually 
consisted almost exclusively of Type II astrocytes. Since culture techniques 
can now be carried out to culture either type preferentially (Juurlink and Hertz
1992), there are greater possibilities for further basic research into drug 
mechanisms. The role of tiagabine or vigabatrin in altering GABA uptake in 
each astrocyte type may be important. Could gabapentin affect GABA 
production selectively in one or other astrocyte type?
Neuronal culture is also carried out at our Unit. Preliminary studies have 
confirmed that, like the nipecotic acid derivatives, vigabatrin affects GABA 
uptake into both neurones and astrocytes. Neuronal culture is a more 
challenging procedure in many respects: harvest being required from rodent 
fetal material, cell yield being lower, and the culture failure rate being higher. 
Despite these difficulties, neuronal culture may be as relevant as astrocytes in 
assessing the basic mechanisms of the new AEDs.
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The effect of vigabatrin and tiagabine on GABA uptake in 
cultured astrocytes.
Cell cultures are a well established way of examining the in-vitro biochemistry 
of neurones and astrocytes. Although no-one would argue that any 
conclusions should be directly extrapolated to human populations, these 
techniques can provide useful clues to the mode of action of new drugs. As 
previously discussed, earlier work from our laboratories suggested that 
GABA-uptake in cultured cells may be affected by vigabatrin (Sills et al,
1993).
Aims
Our primary objective was to confirm, and if possible quantify the effect of 
vigabatrin and tiagabine on the rate of GABA uptake by cultured astrocytes. 
The doses at which this process is affected, the rapidity of onset and the 
duration of action will also be examined. The possibility that vigabatrin and 
tiagabine could act synergistically in the inhibition of GABA uptake is also to 
be investigated.
Methods
These are described in detail in an earlier chapter (Materials and Methods). 
The drugs and their doses used are as follows:
1) Tiagabine dose-ranging
Tiagabine at concentrations of 10, 50, 100, 200, 300, 400, or 500 rimol for 
four hours.
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2) Vigabatrin dose-ranging
Vigabatrin at concentrations of 1, 10, 50, 100, 250, 500 pmolar for four hours.
3) Tiagabine time-ranging
200r|mol tiagabine for between 0.5 hours and 24 hours.
4) Vigabatrin time ranging
100p moles vigabatrin solution for times varying from 1 to 24 hours.
5) Combination regimes
Combination of optimal combinations of vigabatrin and tiagabine, with GABA 
uptake measured 4 hours after exposure.
Statistical methods
The experiment was carried out over several batches. Combination of the 
groups was carried out once all results were expressed as a proportion of 
mean control values ± the standard error of the mean. Analysis of variance 
was done, where appropriate using Dunnet (comparison against control data) 
or Tukey's corrections (comparison of variance of each group with all others).
Results
1) Tiagabine dose ranging study
Following four hour exposure of astrocytes to tiagabine at concentrations 
between 100 and 300r|mol, there was a significant reduction in GABA uptake 
into primary cultures of rat cortical astrocytes (Figure 30). Doses outwith this 
range were without effect on GABA uptake.
2) Vigabatrin dose-ranging study
Vigabatrin significantly reduced GABA uptake into astrocytes at 
concentrations between 100 and 250pmol after four hours’ exposure (Figure 
31). All other doses of vigabatrin were without effect.
Figure 30
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Figure 30: Mean GABA uptake (±SEM) in primary cultures of rat astrocytes in 
response to tiagabine for four hours.
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Figure 31: Mean GABA uptake (±SEM) in primary cultures of rat astrocytes in 
response to tiagabine for four hours.
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3) Tiagabine time ranging
Tiagabine (200r|mol) significantly reduced GABA uptake four, eight, and 
twenty four hours post exposure (Figure 32). No effect was seen at earlier 
time points.
4) Vigabatrin time ranging study
Vigabatrin (100nmol) had no effect on GABA uptake at any of the time points 
tested (Figure 33).
5) Combination testing
Tiagabine (200r|mol), vigabatrin (100jamol) and combination treatments 
significantly reduced GABA into primary cultures of rat astrocytes compared to 
control (Figure 34). Analysis showed that combination of the two compounds 
was more effective than either of the drugs used singly.
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Figure 32
GABA uptake 
(%age of control) 
140
120 
100 - 
80 - 
60 - 
40 - 
20 -  
o -
*p<0.05
“l '-------1------- '------- 1------- 1— i-------1-------1
0 4 8 12 16 20 24
Time exposed to tiagabine 200nmol (hours)
Figure 32: Mean GABA uptake (±SEM) in primary cultures of rat astrocytes.
Figure 33
GABA uptake 
(%age control)
140 -  
120 -  
100 -  
80 -  
60 -  
40 -  
20 -  
0 -
0 4  8 12 16 20 24
Time exposed to vigabatrin 100umol (hours)
Figure 33: Mean GABA uptake (±SEM) in primary cultures of rat astrocytes.
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Figure 34
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Figure 34: Mean GABA uptake (±SEM) in primary cultures of rat astrocytes 
exposed to GABAergic drugs at optimum concentrations for 4 hours.
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Discussion
Both vigabatrin and tiagabine are significant advances in the treatment of 
epilepsy over the last 5 years (Leach and Brodie 1995). We have previously 
suggested that the combination of both drugs may be particularly beneficial 
(Leach and Brodie 1994), and this has also been noted by other clinicians (Dr 
Pam Crawford - Personal communication).
We have shown that the effect of tiagabine on GABA uptake is dose 
dependent. The concentration-effect profile would appear to be U-shaped, 
which makes determination of an IC50 impossible. A similar U-shaped curve 
has been reported using tiagabine in animal seizure models (Nielsen et al, 
1991). Why higher doses of tiagabine are ineffective is unclear, although they 
may be cytotoxic to some degree. No sign of cell death, such as a decrease in 
protein yield was seen at any dose during these studies.
The delay in initiation of tiagabine-related GABA uptake inhibition was 
surprising. In whole animal studies, the anti-seizure effects are soon evident 
following parenteral administration (Nielsen et al, 1991). Further work is 
warranted soon after tiagabine administration to primary cell cultures to 
investigate this anomaly.
The demonstrated inhibitory effect of vigabatrin on GABA uptake confirms our 
earlier work (Sills et al 1993). Strangely, this effect was present at doses 
between 100 and 250 umol, with no effect visible at higher doses. The 
effective concentrations are close to the IC50 for GABA-T inhibition in similar 
models (Larsson et al, 1986). This secondary action might partly explain the 
wide range of animal models in which GABA-T inhibitors are effective 
(Schechter et al, 1979), and may also explain the difference in the time of
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optimal GABA-T inhibition and that of maximal anticonvulsant in animal 
seizure models (Bernasconi et al, 1988).
Given the lack of response at higher doses, the inhibition of GABA uptake by 
vigabatrin is unlikely to be a result of a simple competitive block, despite their 
structural similarity. Previous studies have suggested that vigabatrin is not a 
substrate for any GABA transporter, but is believed to enter cells via some 
high affinity uptake system (Grant and Heel, 1991). With the appearance of 
work defining multiple GABA uptake carriers (Borden et al, 1994) however, it 
is possible to speculate that vigabatrin may have an action at one or more of 
these specific targets. GAT-3 may be a more likely candidate, since a 
secondary substrate of GABA-T, p-alanine (Benuck and Lajtha, 1975) 
selectively blocks this carrier (Clark and Amara, 1994). The structural 
similarities of GABA, p-alanine and vigabatrin may facilitate a common 
binding at active sites of GABA-T and the GAT-3 GABA transporter.
Tiagabine and vigabatrin did show some additive effect on GABA uptake 
inhibition when given in combination. The drugs may have a similar site of 
action, since the increased effect is infra-additive. This may support the 
possibility that the uptake inhibition may occur at GAT-3, since tiagabine has 
a minor role in blocking this transporter (Borden et al 1994).
Conclusions
Clinical experience with tiagabine had suggested that it's effect may be 
enhanced in patients already on vigabatrin therapy, and further studies are 
underway to investigate this. This effect of vigabatrin on GABA uptake may be
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a partial explanation for the usefulness of this combination.
Further characterisation of vigabatrin’s GABA uptake blocking properties may 
help to determine its relative importance as an additional mechanism of 
action. This is one situation where an improved definition of each drug’s 
biochemical actions may pave the way towards a more rational and beneficial 
approach to polypharmacy.
One of the deficiencies in the study is the lack of investigation into the effect 
of these drugs on the levels of cortical glutamate. Further work directly 
correlating this would be justified, particularly following administration of 
vigabatrin. One other direction in which research should be undertaken is in 
the investigation of smaller doses of vigabatrin and tiagabine. Since whole 
brain biochemistry is changed significantly by combined low doses where the 
drugs used singly are ineffective, would the combined use of low dose have 
significant GABA-uptake blocking activity?
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Clinical study of the efficacy and tolerabilitv of 
adjunctive gabapentin in refractory partial
seizures.
Cognition and gabapentin: a double-blind, placebo-controlled 
study in refractory epilepsy
The doses of gabapentin used in previous double-blinded studies are lower 
than would now be commonly used in clinical practice, and in these trials most 
adverse events reported with gabapentin usage are transient and minor 
(Browne 1993). The most common side effects include somnolence, 
dizziness, ataxia and fatigue (Browne 1993).
Using a battery of tests, we have previously shown that treatment with other 
anticonvulsants can alter psychomotor and cognitive testing in a dose-related 
manner (Macphee et al 1986, Brodie et al 1987, Gillham et al 1988, 1990, 
1991, 1993). If newer AEDs such as gabapentin are to attain a satisfactory 
market share, they will have to prove that they are at least as well tolerated as 
the older agents.
Aims
The aim of the study was to assess the efficacy and tolerability of different 
doses of gabapentin in patients with treated refractory epilepsy.
Methods
Twenty seven patients were recruited from the Epilepsy Research Unit at the 
Western Infirmary in Glasgow (Table 13). Details of the study were approved 
by the local Ethical Committee and all patients gave full, informed, written 
consent to their participation. All had epilepsy refractory to at least one of the
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currently available AEDs. Seizures were localisation-related, and all patients 
had a history of adequate compliance, were able to follow dosage 
instructions, and were able to have their seizures fully documented for the 
duration of the trial. All patients were receiving at least one standard AED at a 
dose that had remained stable for at least three months.
Protocol
The study was a double-blind, random-order, crossover, comparison of three 
increasing doses of gabapentin with matched placebo (Figure 35). One month 
after a screening visit, patients were entered into the first 12-week treatment 
phase. Psychomotor and cognitive testing was carried out every four weeks, 
prior to the increase in gabapentin/placebo dose.
After three dose levels had been tested during the first treatment phase, 
patients entered a 4-week washout period prior to commencing the second 
treatment phase. Patients were given individual appointment times, and each 
visit was at a similar time of day to minimise variability in drug levels at each 
visit. Throughout the trial, tablet compliance was checked by tablet counts 
and on history from the patient at each visit. On completion or following 
premature withdrawal from the trial, each patient was given the opportunity to 
continue gabapentin treatment.
Test Battery
A total of eight tests and three self-assessment scales were administered at 
each four-weekly visit. The tests included three psychomotor tests, and five
199
memory tests, while the self-assessment scales involved SEALS 
questionnaires, an AED related symptom score, and a visual analogue score 
(VAS) for drowsiness.
Psychomotor tests
The decision time was the time in milliseconds to respond to a light coming on 
by removing the finger from the base button in a choice time reaction task. 
The mean of 30 trials was recorded. The movement time was the time in 
milliseconds to move the finger from the base button to extinguish a light. The 
mean of thirty trials was recorded. Decision and movement times were carried 
out using the Leeds psychomotor tester.
In the threshold detection test, an array of small rectangles was displayed on 
a computer screen. After a brief time, an extra rectangle was added to the 
array. The patient was required to indicate which it was. The ‘threshold’ was 
the minimum time gap in frame units between the presentation of the arrayand 
the additional stimulus that the patient required to perceive that an extra 
rectangle had been added. This test was administered using an Apple lie 
microcomputer.
The stroop test assessed the patients decision making and flexibility. Patients 
were given a card with a list of words written on it, printed in inks of varying 
colours. They were then asked to go through the lists, stating the colour of ink 
used in each word, ignoring what the word says. The number of colours stated 
correctly within two minutes of starting was the basis of the score.
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Memory tests
All memory tests except for the paired associated learning, were performed at 
every visit. The forward digit span test measured the maximum number of 
digits the patient could recall immediately following oral presentation. Patients 
were allowed two trials at each level. The backward digit span measured the 
maximum number of digits that the patient could recall in reverse order 
immediately following oral presentation. Both digit span tests are discontinued 
when two tests at the same level were failed. The forward visual span 
measures the maximum number of squares correctly reproduced in sequence 
as demonstrated by the examiner. The backward visual span assesses the 
maximum number of squares correctly reproduced in reverse order to that 
demonstrated by the examiner. The visual span tests are terminated when two 
consecutive tests are failed.
The paired associate learning test gives a score up to 18 depending on the 
number of attempts required by the patient to name three sets of correctly 
paired words. In the Rivermead behavioural memory test the ‘screen score’ of 
this standardised psychometric battery was used.
Self reporting scales
SEALS I involves 50 questions which the subject answers in order to 
assesses subjective feelings of specific symptoms such as cognitive slowing, 
dysphoria, irritability, fatigue, and worry. The period under assessment was 
the 7-day period immediately prior to the visit.
To calculate the Drowsiness score patients were asked to demonstrate, with
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the help of a visual analogue scale, their degree of alertness. The measured 
distance along the line chosen by the patient was recorded at each visit.
The AED-Related Symptom Score is constructed from patients’ responses to 
a four-point grading score for 10 adverse effects (dizziness, dry mouth, 
flushing, headache, nausea, double vision, ankle swelling, tremor, 
unsteadiness, and palpitations). Only six are associated with AED use, the 
other four being controls.
Drug Assays
Carbamazepine, sodium valproate, phenytoin and phenobarbitone 
concentrations were measured by enzyme immunoassay (Emit, Syva, Palo 
Alto, USA). Vigabatrin was extracted from plasma into ethylacetate, heated 
with dansyl chloride at high pH to form a fluorescent derivative, and measured 
by HPLC with phenylGABA as internal standard. The interassay coefficient of 
variation (CV) over the range 1-100mg/L was 5% and the lower limit of 
detection was 0.1mg/L. Lamotrigine was extracted into ethinylacetate from 
plasma with 2M sodium hydroxide and measured by HPLC with BWA 725C 
(Wellcome Laboratories, UK) as internal standard. The interassay CV over 
the range 0-5mg/L was 6% with a lower limit of detection of 0.25mg/L. A 
recently devised gabapentin assay using HPLC with fluorimetric detection 
(Forrest - in press) was utilised in our laboratories. The inter- and intra-assay 
variations of this method were 3.8% and 2.6% respectively at 5ug/ml, and the 
detection limits were 1 and 10ug/ml.
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Table 13
Demographic data of evaluable patients in gabapentin study
Patient
Number
Sex Age Duration
of
epilepsy
(years)
Baseline 
seizure 
frequency 
(n/28 days)
Treatment Seizure
type
1 M 26 24 5 CBZ, VGB CP/ GTC
2 F 16 13 91 CBZ, SP / GTC
3 F 37 36 42 CBZ, LTG SP / GTC
4 M 35 10 0 CBZ, PHT SP / GTC
5 F 27 19 5 VPA, PRM SPCP
6 M 54 3 5 PHT CP / GTC
7 F 31 17 8 CBZ, PHB CP
8 M 38 24 7 CBZ, VGB CP / GTC
9 F 25 23 212 CBZ, VPA CP/ GTC
11 F 38 36 6 CBZ, PRM CP
12 M 35 18 0 VGB, LTG CP / GTC
13 M 40 5 15 CBZ SP / GTC
15 F 67 62 0 CBZ, CZP CP / GTC
16 M 41 9 28 OCB, SPCP/GTC
18 M 41 34 6 VGB, PHT SPCP/GTC
19 M 46 7 3 CBZ CP/ GTC
20 F 25 13 71 CBZ, VGB CP/ GTC
21 M 44 2 7 VPA CP/ GTC
22 F 39 30 4 CBZ, VGB SPCP/GTC
23 F 30 13 30 CBZ, VPA SPCP
26 F 32 18 7 VPA CP/ GTC
28 F 39 34 8 CBZ, PHT CP
CBZ = carbamazepine, VGB = vigabatrin, LTG = lamotrigine, PHT = phenytoin, PRM 
= primidone, PHB = phenobarbital.VPA = sodium valproate.
CP / GTC = complex partial with occasional secondary generalisation.
SP / GTC = simple partial with occasional secondary generalisation.
SPCP = Simple partial seizure evolving into complex partial.
CP = complex partial.
SPCPGTC = simple partial evolving into complex partial with occasional secondary 
generalisation.
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Statistics
Statistical analysis was carried out by the biometrics unit at Parke Davis Ltd 
using the SAS statistical package. The primary measure of seizure control is 
the comparison of seizure frequency during active (gabapentin) treatment with 
that during placebo treatment phase. Seizure frequencies were normalised 
using a log transformation prior to analysis. Changes from baseline in 
individual cognitive function tests were analysed using the Wilcoxon signed 
ranks test. In addition to the analysis of individual tests, composite scores for 
memory and psychomotor performance were constructed by summation of the 
normalised scores for related assessments.
Composite memory and psychomotor scores were compared using analysis of 
variance. The five SEALS subscores and the visual analogue scale of 
drowsiness were explored using analysis of covariance with the baseline 
measure as covariate. Data for each dose level was assessed separately.
Results
Twenty of the 27 patients completed the study (Table 13). Five patients 
withdrew because of the onset of adverse events (4 on placebo, 1 on 
gabapentin), and two requested withdrawal due to lack of efficacy (1 each on 
placebo and gabapentin). Five of these patients withdrew prior to the onset of 
the second phase, leaving 22 patients who had been exposed to both 
treatment phases and were eligible for analysis.
Seizure frequency
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The frequency of all seizures combined was significantly reduced by 
gabapentin treatment (p=0.02) throughout the active treatment period (Table 
14). Of the 21 patients exposed to all doses, nine (43%) had their total seizure 
frequency reduced by at least 50% while on concomitant gabapentin. Efficacy 
was greatest at 1800 and 2400mg/day of gabapentin. Two patients were 
seizure-free throughout the active treatment phase with none responding 
similarly to placebo.
Seven patients experienced simple partial seizures without secondary 
generalisation during the study. Simple partial seizures were not significantly 
affected by gabapentin, although 2 patients (29%) had the seizure frequency 
reduced by at least half i.e. ‘responded’ to treatment. Complex partial seizures 
without secondary generalisation, noted in 17 patients, were also reduced on 
gabapentin, with 5 patients (29%) ‘responding’ to treatment, although the 
overall reduction did not reach statistical significance. Ten (59%) of 17 
patients experiencing secondary generalised seizures ‘responded’ to 
gabapentin treatment, with the median monthly frequency of this type 
significantly reduced from 1 to 0.3 per month on gabapentin (p=0.01).
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Table 14
Effect of gabapentin treatment on median frequency and interquartile 
range of each seizure type.
n Gabapentin Placebo P
value
Simple Partial 7 Frequency
Range
1.7
0-14.3
1.7
0-14.3
0.80
Complex Partial 17 Frequency
Range
3.0 
2.0-4.3
3.7
1.3-6
0.62
Secondary Generalised 17 Frequency
Range
0.3 
0.3-3.3
1.0 
0.3-7.3
0.01
Total Seizures 21 Frequency
Range
4.3
2.3-16.7
7.0
3.7-19.7
0.02
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Neuropsychological assessment
No order effect was seen in any parameter of psychomotor or cognitive testing 
i.e. there was no improvement in the tests as the trial progressed.
Psychomotor testing
Composite scores of psychomotor function were not altered by gabapentin 
treatment (Table 15). Comparison of composite psychomotor scores and 
individual tests at each treatment level with the corresponding placebo phase 
fails to show any significant difference. Mean psychomotor function results 
during the placebo treatment phase were plotted against seizure frequency, 
showing an interesting negative correlation between frequency of ictal events 
and psychomotor capabilities (Figure 36) which reached statistical 
significance.
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Table 15
Mean (SD) comparative psychomotor, memory and visual analogue
drowsiness scores.
Gabapentin Placebo
Composite Psychomotor Score 0.0 (3.6) 0.0 (2.7)
Composite memory Score 0.2 (3.6) -0.3 (3.6)
Visual Analogue Fatigue Score 43 (28) 39 (28)
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Figure 36: Correlation between seizure frequency and composite 
psychomotor scores throughout placebo treatment phase.
☆
r=0.49
p=0.02
1--------- '---------1---------'---------1---------r
208
Memory testing
Composite memory scores showed no impairment on gabapentin (Table 15), 
even at highest dose. Comparison of individual test results between the two 
treatment phases showed only two tests to be significantly altered: the paired 
associate learning test being significantly improved on active treatment 
(p=0.02), while the backward visual was better on placebo treatment (p<0.05). 
No correlation was found between seizure frequency and memory function 
testing (Figure 37).
SEALS-1
SEALS scores were compared for each patient throughout both treatment 
phases. Further comparisons were carried out at each dose level and 
compared with the corresponding placebo dose level. Of the five subscores, 
none were significantly affected by gabapentin even at highest dose, although 
the increases in subscores for tiredness and cognition narrowly failed to reach 
statistical significance (p=0.06, and 0.08 respectively) (Table 16).
Fatigue algorithm
The VAS drowsiness score was significantly greater during treatment with 
2400mg/day of gabapentin compared to the corresponding placebo dosing 
phase (p=0.03) (Table 15). Interestingly, there was a stronger, statistically 
significant correlation between the degree of fatigue reported and seizure 
frequency (r=0.47) (Figure 38).
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Figure 37
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Figure 37: Correlation between composite memory scores and seizure 
frequency throughout placebo-treatment phase.
Table 16
Mean (SD) SEALS Subscores during treatment with 2400mg/day
gabapentin or placebo.
Gabapentin Placebo P value
Cognition 49(12) 51 (13) 0.08
Dysphoria 17(5) 17(5) 0.25
Temper 12(4) 12(3) 0.61
Tiredness 13(3) 14(4) 0.06
Worry 10(4) 10(3) 0.58
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Adverse events
Similar numbers of patients reported adverse events on gabapentin and 
placebo. Five patients withdrew because of the onset of adverse events, four 
while on placebo, and one while on gabapentin (because of a rash). Nineteen 
patients (79%) reported 47 adverse events on gabapentin, compared to the 
placebo phase where 15 patients (63%) reported 30 adverse events.
The AED symptom scores which were constructed showed a statistically 
significant change while on the highest dose of gabapentin (p=0.006). No 
significant differences were seen at the lower two doses. Interestingly, there 
was again a stronger correlation between AED symptom score (Figure 39) 
and seizure frequency (r=-0.72, p=0.0002) than with any form of drug 
treatment.
Drug Concentrations
The median plasma level of gabapentin increased with each dose increase: 
mean levels at 1200, 1800, and 2400mg/day were 4.7+2.6, 6.8±3.8, and 
8.6±3.3mg/L respectively. As would be expected from previous studies, there 
was no change in other AED levels following gabapentin treatment (Table 17).
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Figure 38: Correlation of VAS scores for fatigue and seizure frequency.
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Figure 39: Correlation of composite adverse event score and seizure 
frequency.
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Table 17
Mean antiepileptic drug concentrations (mg/L) during placebo or 
gabapentin dosing phase.
n Gabapentin Placebo
Carbamazepine 16 8.7 8.0
Lamotrigine 2 6.6 6.1
Phenobarbital 1 27.4 26.1
Phenytoin 4 14.3 15.4
Primidone 2 9.6* 9.6
Sodium valproate 5 77.1 82.5
Vigabatrin 6 25.1 26.0
*Only one patient exposed to gabapentin and primidone.
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Discussion
Cognitive function is an important issue in the treatment of epilepsy. Many 
patients complain of impaired memory and slowed thinking while receiving 
long-term anticonvulsant therapy, and the recent literature on psychomotor 
testing in epilepsy patients is testimony to doctors’ attempts to quantify the 
extent of any drug-related cognitive impairment (Vermeulen and Aldenkamp 
1995). This delineation of the higher mental effects of AEDs is vital: if the 
newer drugs are to thrive, they will have to prove to be better, or at least as 
well tolerated as the established AEDs.
This study has used higher doses of gabapentin than other double-blind trials. 
Despite the refractory nature of the study cohort, the response rates were 
comparable with those in the best of the efficacy studies (Anhut et al 1994, 
Crawford et al 1987, UK Gabapentin Study Group 1990, US Gabapentin study 
group 1992). As with other studies, the effect on secondary generalised 
seizures has been greater than on other seizure types (McLean 1995).
The lack of interaction with other AEDs confirms the findings of other studies 
(Hooper et al 1991, Radulovic et al 1994, Tyndel et al 1994), and is another 
advantage of gabapentin. This is particularly true in a setting where for the 
moment at least, use in the UK is only as add-on therapy.
At doses high enough to produce a significant reduction in seizure frequency, 
gabapentin has demonstrated a relative lack of psychomotor or memory 
impairment. Findings of a lack of psychomotor adverse events with 
gabapentin are consistent with previous reports of gabapentin’s clinical 
tolerability (Browne 1993). There were two measures of fatigue that were
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increased with gabapentin treatment; the fatigue visual analogue scale was 
significantly increased throughout the treatment phase while the SEALS 
subscore for tiredness narrowly failed to achieve statistical significance. 
Although multiple comparisons have a higher chance of providing some 
isolated statistically significant results, the fact that the scores were 
measuring closely allied symptoms may lead us to believe that the findings 
are clinically as well as statistically significant. Other similarly designed trials 
(Gillham et al 1993, Macphee et al 1986) have shown that tolerance can 
develop to fatigue and drowsiness. Were the highest dose levels to be 
observed for longer, the same tolerance may have been observed.
The correlation between seizure frequency and both VAS tiredness and 
composite psychomotor testing is interesting. That patients with more frequent 
seizures have more symptoms and signs of impairment may arise from 
several factors. Whether this change in response represents the workings of 
an innately more ‘damaged’ brain, or the impairment secondary to more 
frequent seizures will be difficult to assess. That the correlation between 
seizure frequency and these two variables was much stronger than the 
correlation with gabapentin levels or gabapentin dosage may imply, however, 
that the paramount consideration in improving cognitive function should be a 
reduction in seizure frequency.
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General conclusions and discussion
General discussion
The last five years have seen welcome additions to our pharmacological 
armamentarium. Prior to the late eighties there were five anticonvulsant 
compounds in common use in the UK. By the end of this century it appears 
likely that there will be up to eleven new AEDs licensed. Meanwhile, progress 
in neuro-imaging and epilepsy surgery also continues apace. In all of history, 
there has never been a time when we could survey the unconquered lands of 
refractory epilepsy with such optimism.
There has, with justification, been a great deal of interest in the new 
anticonvulsants. Despite their introduction, however, most people would agree 
that a significant proportion of our patients remain unsatisfactorily controlled. 
Where the new AEDs have probably been of most benefit is in reducing the 
number of adverse events experienced. If their efficacy continues to equal 
that of the established agents, then, and only then will their future be assured. 
If even our best newest agents leave some seizure types untouched, then 
how are we to increase the number of patients in whom full control is 
achieved? Given the nature of the new AEDs, perhaps it is time to re-evaluate 
the role of combination therapy for epilepsy. As previously argued, the 
rational combinations will require a greater knowledge of the drugs’ actions. 
Do the studies described in this thesis help us in this regard?
Vigabatrin
When tested in cultured cells and whole brain, vigabatrin demonstrated some 
effects other than GABA-T inhibition. GABA uptake was significantly reduced
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in a dose-dependent manner. If vigabatrin increases the optimal GABA uptake 
inhibition in combination with tiagabine, then this may explain the possible 
additive effect noted when the two drugs are given together. When used in 
mice, the effective inhibition of whole brain GABA-T activity was 
demonstrated alongside an equally significant rise in GABA concentrations, 
and a comparable decrease in GAD activity.
Gabapentin
The double-blind clinical study has confirmed earlier impressions that at 
anticonvulsant doses, even as add-on therapy, gabapentin has little 
discernible effect on psychomotor function or on memory. Interestingly, under 
controlled conditions in our study, there was a significant relationship between 
seizure frequency and performance in psychomotor testing.
The effects of gabapentin on whole brain biochemistry failed to show any 
increase in GABA concentrations or GAD activity, but did show significant 
decreases in GABA-T activity and a trend towards a reduction in glutamate 
concentrations after multiple dosing. When placed alongside other in-vitro 
work suggesting positive effects on GABA release and GABA concentrations, 
it seems likely that gabapentin depends, at least in part, on its GABAergic 
effects for its anticonvulsant activity.
Tiagabine
The effect of tiagabine on GABA uptake in cultured astrocytes was quantified, 
and the dose-response curve found to be ‘U’-shaped. Tiagabine had no effect
217
on cortical biochemistry when used alone, aside from an increase in GABA-T 
activity of dubious significance. When used in combination with vigabatrin at 
low dose, there was an increase in GABA concentrations demonstrated which 
was not obvious with either drug used alone. At medium and high dose, there 
was no significant difference between the biochemical effects of vigabatrin 
alone and in combination with tiagabine.
Remacemide
The potential for interactions with the older AEDs was investigated in patients. 
Remacemide did not significantly affect the concentrations of valproate, or the 
carbamazepine metabolite CBZ-E. While on oral remacemide, there was a 
trend towards an increase in phenytoin concentrations, which failed to reach 
significance except in the case of the trough concentrations during the 
multiple dose treatment phase. In a minority of patients on carbamazepine, 
co-administration of remacemide hydrochloride significantly increased 
concentrations of the baseline AED. These interactions may be important, but 
are unlikely to be a significant impediment to the use of remacemide 
alongside established agents.
Among valproate-treated patients, the half-life and AUC of remacemide 
hydrochloride and its main metabolite ARL12495XX were similar to that of 
untreated volunteers. In contrast, patients pretreated with an enzyme-inducing 
AED had a significantly lower exposure to remacemide hydrochloride and 
ARL12495XX as measured by AUC, and this patient group may require higher 
doses of remacemide to achieve equivalent plasma concentrations of the two
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compounds.
On assessment of the effect of ARL12495XX on GABA metabolism in mouse 
whole brain, some surprising findings were made. In addition to the effects on 
sodium channels and NMDA receptors, ARL12495XX would also appear to 
have effects on GABA metabolism. Multiple dosing with ARL12495XX 
appeared to cause a significant decrease in GAD activity and increase in 
GABA-T activity, although the clinical relevance of these actions is unclear.
How can we formulate a rational plan for development of rational 
polypharmacy?
1. Chance observation 
This is traditionally the method by which useful combinations have been 
developed in other branches of medicine. So far, in terms of AEDs, no specific 
drug combinations have been shown to be better than any others. The 
combinations involving the newer agents that have been (incompletely) tested 
are those that have been noted by chance to work in a limited number of 
patients (eg. lamotrigine and valproate, vigabatrin and tiagabine).
All new AEDs have to undergo extensive clinical testing as add-on therapy. It 
would be efficient, and potentially productive if pharmaceutical companies 
testing new AEDs as adjunctive therapy were compelled to carry out further 
analyses to assess the relative benefits in groups of patients receiving 
different baseline AEDs. This type of analysis will not be without its bias, each 
drug being used predominately in different seizure types, but it may provide 
some useful clues for future drug use. The pharmaceutical industry, would
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argue that this would be impractical: every company is understandably keen 
that their new product is seen as a ‘cutting edge’ compound rather than a 
mere cofactor. Meta-analysis of large trials, or of a number of trials, however 
could have advantages with which even the pharmaceutical industry could 
sympathise. Such meta-analyses may, for example, help forewarn us at an 
earlier stage of any important pharmacokinetic interactions involving the new 
compounds.
Y we are to rely on clinical observation to give us hints as to ideal drug 
combinations, then we need regular reviews to improve our yield. For this 
reason among others, it would be helpful if the data upon which drug licensing 
applications are based were made available at an early stage in peer- 
reviewed journals. On researching the chapter on the new AEDs, it became 
apparent that there was a paucity of freely available clinical and pre-clinical 
data, even for those drugs whose licence had been granted. It is far from ideal 
that clinical and biochemical data of compounds on general release have to 
be gleaned from journal abstracts pending full publication of the study data. It 
is unrealistic, and probably unhealthy, for our understanding of such drugs to 
be based solely on the subjective, and often selective data provided by the 
pharmaceutical industry.
2 Rational planning of useful combinations 
In this scientific age, it would be sensible to base our choice of AED 
combinations on the information available to us. With our increasing 
knowledge of neurophysiology and neurobiochemistry, is it more likely that we
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should be able to make that choice?
Perhaps not yet. Despite the fact that we are better informed than ever before, 
there are still large gaps in our knowledge. It would have been naive to 
assume, for example, that remacemide would have no effect on the GABA 
shunt merely because it had already proven to have effects on glutamatergic 
neurotransmission. What we learn from this experiment may be that in terms 
of basic mechanisms of action of the AEDs, nothing should be taken for 
granted.
How will we determine what is best for our patients?
The knowledge of basic mechanisms of action, however complete, does not 
answer all of our questions about anticonvulsant treatment. Even if all the 
neurochemical and neurophysiological effects of all AEDs can be elicited, will 
that help us to decide how drugs should be paired? Should compounds be 
combined with drugs on the same side of the fence (eg two GABAergic drugs) 
or should we be using each one alongside others with actions on different 
systems? Some would argue that multiplicity of action is what has bedevilled 
the use of the older AEDs: according to this view, we should be searching for 
a drug that has one single anticonvulsant effect. In this view, combining drugs 
with different actions merely simulates the administration of an established 
drug.
In answer, having a combination of drugs producing a variety of effects is an 
improvement on having a single multi-active drug. The combination of more 
specific drugs offers a greater flexibility of manoeuvre in response to any
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clinical improvement or the onset of adverse events. For a patient on 
lamotrigine / valproate combination, for example, the relative doses would be 
determined by the patient’s response. If weight gain is a problem, valproate 
dose could be adjusted, whereas the temporary reduction of lamotrigine dose 
may suffice in the prevention of headache.
Just as importantly, could we combine drugs according to their biochemical 
‘side effects’? The pairing of vigabatrin and gabapentin, for example may 
allow for a greater inhibition of GABA-T with little GAD inhibition, so perhaps 
removing the ceiling to effective dosing of vigabatrin’s efficacy (McKee et al 
1993), or minimising any adverse events (Grant and Heel 1991).
Knowledge of the AEDs’ biochemical effects may also warn us of 
combinations to avoid. It would be interesting to assess the effect of a 
remacemide / vigabatrin combination on whole brain GABA-T. Would this 
combination have any efficacy in animal seizure models? Would the dual 
depression of GAD activity produce a high incidence of side effects?
While we concentrate on the novel drugs’ actions in in-vitro experiments, it is 
important that we do not forget the established AEDs. That lamotrigine and 
valproate combine so effectively is probably more than a result of the well- 
recognised pharmacokinetic interaction . Are there any particular aspects of 
lamotrigine’s action(s) that mesh particularly well with the actions of 
valproate? Further work on the established AEDs to further delineate their 
neurophysiological effects would be useful, not only in terms of helping to 
formulate treatment plans, but also in helping to augment our knowledge of
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the basic processes underlying epileptogenesis.
Synergy is an attractive proposition for doctors in all areas of medicine. To 
have drugs producing effects in combination that are supra-additive seems to 
be the biological equivalent of getting something for nothing. Once a 
potentially beneficial combination comes to our attention, by whatever means, 
how can we test its efficacy and tolerability, or determine if any synergism is 
effected? Pharmacologically, use of the isobologram first espoused by Loewe 
in 1953, may be the most effective way forward (Mawer and Pleuvry 1995) 
(Figure 40). The straight line isobologram (A’) charts doses of each drug
required to exert a particular effect if their actions are additive. If there is 
synergy or potentiation, the doses required to produce the same effect will be 
lower, and the curve for potentiation (S’) will be below the straight line. If the
ED50
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drug effects are antagonistic, the doses of each drug required will be higher, 
and the curve (IVT) will be above the line.
In theory this principle is useful, and in practice, it has been used 
(unsuccessfully) in the assessment of possible potentiation between 
felbamate and phenytoin (Swinyard et 1989). There are no clinical examples 
where isobolograms have been used to look at seizure effects, but in patients, 
isobolograms were used to examine the additive hypoglycaemic effect 
between salicylates and sulphonylureas. One of the problems in patients 
would be the determination of these ‘equivalent’ doses. Since epilepsy study 
populations are so variable, it would be difficult to decide which dose of 
valproate was equivalent, for example, to a specified dose of lamotrigine. Any 
pharmacokinetic interactions would have to be compensated for using blood 
levels, and yet there is no good correlation between serum levels of 
lamotrigine and its clinical efficacy.
In simpler terms, controlled clinical trials have been suggested (Richens 
1995) which use a double-dummy design, comparing each drug singly with 
placebo, and with a combination of the two active treatments. Having four 
treatment arms, these trials will require large numbers of patients, one quarter 
of which will be receiving placebo. In most countries except the USA, there 
seems to (rightly) be some problems with placebo-controlled monotherapy 
studies. Elsewhere there may also be ethical problems if either of the drugs is 
not licensed for use as monotherapy. Where a drug dose differs between 
arms because of pharmacokinetic interactions (eg lamotrigine and valproate), 
this dose variance could cause some difficulty in interpreting the trial results.
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There has been a fashion for recent reviews to assess the role of drug 
combinations in the treatment of epilepsy (Schmidt and Gram 1995, Richens 
1995, Lammers 1995). That opinion in the last twenty years has tended to 
oppose combination therapy has also meant that little work went into planning 
of rational polypharmacy even before the introduction of the newer AEDs. 
While there are many reasons why the established AEDs don’t mix well, it is 
sad, to say the least, that little effort has been made to provide an objective 
basis to support the use of various drug combinations.
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Suggested Combinations for future investigation.
We now have a shortlist of combinations which would appear to have 
particular promise.
• Valproate \ lamotrigine
The clinical benefits of valproateMamotrigine has been widely noted, and 
further investigation of this additive effect is essential. Both drugs are licensed 
for use as monotherapy in the UK, and there should be no ethical problem in 
having some patients on either of these drugs as monotherapy. The 
pharmacokinetic interaction between the two, however, may necessitate the 
provision of an unblinded observer to intervene where necessary, ensuring 
that plasma levels of lamotrigine, in particular, are comparable between 
groups.
• Lamotrigine and Vigabatrin
This is one of the few drug combinations tested under controlled clinical 
conditions that exclusively involves new AEDs. Previously, before lamotrigine 
had been granted approval for use as monotherapy, there were logistical 
problems in testing this combination. Stolarek et al (1994) used a placebo- 
controlled design and concluded that addition of a new drug was better than 
placebo. Further work by Schapel et al (1993), however confirmed the 
suggestion that the combination may have particular benefit. Studies of these 
two drugs in animal seizure models are being performed in our unit to test the 
efficacy against PTZ and MES-induced seizures in mice. Despite the efforts of 
the investigators mentioned, no properly controlled studies have been carried 
out which gives any scientific evidence of synergism.
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• Vigabatrin and tiagabine
Our in vitro work, alongside clinical observations in our unit and further afield 
(Dr Pam Crawford - personal communication), would suggest that an 
investigation of the use of combined vigabatrin and tiagabine may yield some 
interesting results. Tiagabine will probably be granted a license for use in the 
UK in the near future, which would ease the logistical problems in organising 
this, although the lack of a monotherapy license for either drug would mean 
that the combination may initially'at least be used only in addition to other 
AEDs.
• Gabapentin and vigabatrin
No clinical reports have yet been made to suggest particular clinical benefit in 
combination of these drugs, but our whole brain work may suggest that the 
combined use may lead to more complete inhibition of GABA-T activity while 
GAD inhibition may be kept to a minimum. Again, once one or either of these 
drugs gains a monotherapy license, the required double-dummy trial will be 
easier to design.
• Gabapentin and Tiagabine
Unsurprisingly, given that gabapentin received its license in the UK after the 
main studies of tiagabine efficacy had begun, there are no clinical reports of 
the particular efficacy of this compound. In-vitro studies, however (Honmou et 
al 1995), and the results of our small pilot study, would appear to suggest that 
gabapentin and tiagabine could be of particular benefit in some patients. The 
results of our whole brain biochemistry work might suggest that combinations 
of gabapentin and vigabatrin could be of interest.
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So far, most of these suggested combinations would appear to concentrate 
largely on the GABAergic system. Perhaps as more drugs of uncertain mode 
of action come into daily use, there may be more opportunity for manipulation 
of the excitatory system, which so far is only served by remacemide, 
lamotrigine, and to some degree, topiramate. The formulation of a rational 
plan for the use of AEDs in combination will take many years, and this thesis 
is only a very small step in that right direction.
Conclusions
The history of epilepsy therapy is littered with the remnants of chance 
observations. To a degree they have served us well, and for a majority of 
newly diagnosed patients we have drugs which will control their seizures with 
no or negligible side effects. For a significant minority, however, things are not 
so rosy. The advent of the newer drugs may help a few patients gain control 
of their epilepsy, but as the continued existence of specialist epilepsy clinics 
will testify, the challenge of refractory epilepsy will remain with us for the 
foreseeable future. There is much work to be done in investigating the new 
AEDs, including that needed to investigate their use in combination. The trials 
required will not be easy. They will present difficult logistical problems, such 
as the use of placebo as monotherapy, large numbers of patients, or possibly 
the exclusion of patients who have received either of the constituent drugs. 
Not least among these problems will be funding difficulties. At the moment, it 
seems unlikely that any major pharmaceutical company will be willing to
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subsidise such work, and the cost of setting up such a huge multicentre study 
may be prohibitive for grant funding bodies. Until the clinical studies can get 
underway, then research into AED combinations may need to either involve 
smaller numbers or concentrate on preparing the groundwork by assessing 
the effects of the all AEDs in a wide range of in-vivo and in-vitro studies.
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The low therapeutic index of established antiepileptic drugs coupled with a better understanding of the 
pathophysiology of seizure production has led to the development of a range of new therapeutic agents for the 
treatment of epilepsy. In this review, the three drugs recently licensed in the UK (vigabatrin, lamotrigine and 
gabapentin) are profiled, together with several of the more promising up-and-coming compounds (oxcarbaze­
pine, felbamate, tiagabine, stiripentol, remacemide and topiramate). Future avenues for clinical research in 
the pharmacological management of the epilepsies involve their rational use both singly and in combination.
Key words: antiepileptic drugs; epilepsy; interactions; neuropharmacology; side-efects.
INTRODUCTION
Epilepsy is a common condition with a point 
prevalence of just under 1% of a given popu­
lation1. There are, by implication, around 
500 000 people in the UK  alone who have epi­
leptic seizures, fewer than 70% of whom will 
have them fully controlled with the currently 
available antiepileptic drugs2. Many patients, 
particularly those with underlying anatomical 
lesions, respond poorly to monotherapy and are 
treated with combinations of anticonvulsants 
that often cause disabling side-effects with 
only an outside chance of significantly im­
proved seizure control.
Dose-related side-effects and idiosyncratic 
reactions are all too common with existing 
anticonvulsants. The tendency to produce 
headache, nausea, dizziness, drowsiness, cogni­
tive impairment and other central nervous 
system side-effects is almost universal2. Their 
potential for teratogenicity3,4 and for deleteri­
ous drug interactions5 make their long-term 
use problematical. The last few years have 
been exciting times for epileptologists. There 
has been a rush of interesting new antiepilep­
tic drugs into clinical development.
THE BASIS OF SEIZURES
Histologically, epileptic neuronal tissue often 
shows only non-specific changes such as gliosis 
or dendritic degeneration6,7. The biochemical 
interplay at the site of epileptogenesis is more 
interesting, and an understanding of the 
pathogenesis may lead us to alter successfully 
the subtle biochemical imbalances responsible 
for seizure generation and propagation. Recent 
advances in drug development have focused on 
the therapeutic potential of manipulating 
brain neurotransmitters.
Endogenous substances such as gamma ami- 
nobutyric acid (GABA), adenosine and glycine 
are thought to be of importance in inhibiting 
seizure spread7. Stimulation of the GABAa 
receptor results in an influx of chloride ions, 
stabilizing the neuronal membrane and pre­
venting seizure activity. Work in primates has 
demonstrated a selective loss of such terminals 
in epileptogenic foci8, implying a local deficit in 
inhibition. There is decreased binding, also, to 
the GABA/benzodiazepine receptor complex in 
temporal lobe lesions9.
The role of the excitatory amino acids, es­
pecially glutamate and aspartate, has been 
well recognized for a number of years. Recep­
tors for these and other dicarboxylic acids are 
present in altered density in patients with
1059-1311/95/010005+04 $08 00/0 ©  1995 British Epilepsy Association
6Table 1: Pharmacological profile of a range of new antiepileptic drugs
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Drug Mode of action H alf life 
(hours)
Elimination Concentrations 
affected by...
Effect on other 
AEDs
Felbamate ? Glycine antagonist 
at NMDA receptor
14-22 Hepatic metabolism, 
some renal excretion
Enzyme inducers PHT, VPA j  
CBZ i
Gabapentin ? Inhibition of L-amino 
acid transport
5 -7 Renal excretion N il N il
Lamotrigine Blocks Na channels 
decreasing EAA 
release
25-29 Hepatic glucuroni- 
dation
Enzyme inducers 
and inhibitors
CBZ
(pharmacodynamic
interaction)
Remacemide Non-competitive 
NMDA antagonist
3 -5
(metabolite
12-18)
Hepatic metabolism 
(active metabolite)
Enzyme inducers 
and inhibitors
PHT, CBZ, t
Stiripentol ? Inhibition of GABA 
uptake and 
metabolism
Variable
(saturation
kinetics)
Hepatic metabolism Enzyme inducers 
and inhibitors
PHT, CBZ, PB f
Tiagabine Decreases GABA 
reuptake
4-13 Hepatic metabolism ? N il ? N il
Topiramate Unknown 18-23 Renal excretion, some 
hepatic metabolism
Unknown Unknown
Vigabatrin Decreases GABA 
metabolism
5 -7 Renal excretion N il PHT 1
NMDA, n-methyl-D-aspartate; EAA, excitatory amino acid; AED, antiepileptic drugs; GABA, gamma aminobutyric acid; 
PHT, phenytoin; VPA, sodium valproate; CBZ, carbamazepine; PB, phenobarbitone.
either generalized10 or temporal lobe11 seiz­
ures. This implicates the excitatory system in 
producing a micro-environment conducive to 
epileptogenesis. These processes and their 
interplay are important factors in determining 
the extent of the neurological instability 
underlying the ictal diathesis12.
ESTABLISHED ANTICONVULSANTS
The last two first-line anticonvulsants to be 
introduced in the UK were carbamazepine in 
1967 and sodium valproate in 1974. These are 
still the best drugs for controlling most types of 
seizures. There remains, however, a great deal 
of scope for improving our treatment of epi­
lepsy. Fewer than 70% of patients are ad­
equately controlled with antiepileptic mono­
therapy13. The addition of a second or third 
drug w ill provide substantial improvement in 
only around 10% of the remainder2. The more 
antiepileptic drugs the patient takes, the 
greater the incidence of adverse effects, par­
ticularly cognitive impairment and teratoge- 
nesis.
The modes of action of established antiepi­
leptic drugs are multiple, complex and overlap­
ping14. Their effects on the central nervous 
system are widespread and rather indiscrimi­
nate— a neuropharmacological blunderbuss 
rather than a laser! The introduction of three
new anticonvulsants with novel mechanisms of)'
action in the UK over the last 5 years has revo­
lutionized our approach to refractory epilepsy. 
Vigabatrin, lamotrigine and gabapentin have 
led the way for a plethora of newer agents that 
are being extensively tested in scienifically- 
based studies world-wide.
This review w ill deal with the compounds 
that are breaking through in the routine man­
agement of epilepsy, and will focus also on the 
most promising drugs currently undergoing 
clinical trials. The pharmacological profiles of 
the anticonvulsants featured in this paper are 
summarized in Table 1. Their potential ranges 
of efficacy are outlined in Table 2.
NEW ANTIEPILEPTIC DRUGS 
Vigabatrin
Vigabatrin was licensed in the UK for use as 
add-on therapy for refractory epilepsy in 1989. 
It  is being increasingly used in Europe, Africa 
and Asia, but still awaits regulatory approval 
in North America.
Mode of action
Vigabatrin is a GABA analogue which acts as 
a ‘suicide’ inhibitor of GABA-transaminase 
(Fig. 1). It  binds irrevocably to its target 
enzyme, and so facilitates GABA-ergic inhi-
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and, thus, stabilizing neuronal membranes28. 
This, however, is unlikely to be the whole 
story29
Pharmacokinetics and interactions
Oral administration of lamotrigine leads to its 
rapid and near complete absorption. The elim­
ination half-life is around 29 hours with 
metabolism largely by hepatic glucuronida- 
tion30. Interestingly, patients with Gilbert’s 
disease have a longer half-life due to a decrease 
in the activity of the enzyme bilirubin uridine 
diphosphate glucuronyl transferase31.
Lamotrigine does not itself induce or inhibit 
hepatic enzymes. Consequently, it has no influ­
ence on the metabolism of other lipid soluble 
drugs, including the oral contraceptive pill and 
warfarin. Sodium valproate has been shown to 
lengthen its half-life to around 59 hours, and 
the enzyme-inducing anticonvulsants, carba­
mazepine, phenytoin and phenobarbitone 
reduce it to around 12 hours32. There have 
been reports of symptoms of neurotoxicity 
(headache, nausea, dizziness, diplopia, ataxia) 
in patients taking carbamazepine in whom 
lamotrigine has been introduced33. These dis­
appear when the dose of either drug is reduced. 
This is thought to be the clinical represen­
tation of a pharmacodynamic interaction34.
h 2n
Fig. 2: Structure of lamotrigine.
Sedation is not a prominent manifestation of 
lamotrigine toxicity49.
Double-blind trials to assess the usefulness 
of lamotrigine as monotherapy, using carba­
mazepine and phenytoin as comparators have 
just been completed. Preliminary results 
suggest equal efficacy to carbamazepine and 
phenytoin with better tolerability. Other com­
parative studies in children, in the primary 
generalized epilepsies and in the elderly are 
underway. The starting dose and titration rate 
w ill depend on existing treatment50 when the 
drug is used as adjunctive therapy (Table 3). 
Lamotrigine is usually prescribed twice daily, 
but a single daily dose can be used if  the drug is 
combined with sodium valproate or as mono­
therapy. A low, slow introduction schedule w ill 
reduce the likelihood of rash.
Efficacy and tolerability
Ten double-blind, placebo-controlled, add-on 
studies have been carried out with lamotri- 
gine35^ 44, nine of which reported success 
against partial seizures with or without 
secondary generalization. Many open studies 
have confirmed these findings45. Clinical ex­
perience also suggests that lamotrigine is ef­
fective for the primary generalized epilep­
sies46. There is anecdotal evidence too to 
support its value in Lennox-Gastaut syn­
drome47. These observations have not yet been 
substantiated in controlled clinical trials.
Lamotrigine is a well-tolerated drug, with 
skin rash being the most common reason for 
withdrawal. This occurs in approximately 3% 
of patients and depends on the rate of introduc­
tion of the drug48. Side-effects such as dizzi­
ness, headache, nausea and vomiting, ataxia, 
diplopia and tremor are other minor problems 
associated with lamotrigine administration.
Table 3: Lamotrigine dosage and titration schedules
1. Add-on in treated adults and adolescents
Valproate Others
Weeks 1-2 25 mg alt die 50 mg daily.
Weeks 3 -4  25 mg daily 50 mg twice
daily
Maintenance 50-100 mg twice 100-200 mg twice
daily daily
2. Add-on in treated children
Valproate Others
Weeks 1-2  0.2 mg/kg 2 mg/kg
Weeks 3 -4  0.5 mg/kg 5 mg/kg
Maintenance 1-5 mg/kg 5-15 mg/kg
3. Monotherapy in newly diagnosed epilepsy
Adults Children
Weeks 1-2 25 mg daily 0.5 mg/kg
Weeks 3 -4  25 mg twice 1 mg/kg
daily
Maintenance 50-100 mg twice 2 -8  mg/kg
daily
Higher doses can be tried if seizures persist and the 
patient is tolerating the drug without complaint.
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Gabapentin
Gabapentin, a chemical analogue of GABA, 
was intended to act as a GABA agonist (Fig. 3). 
It was thought too that, being hydrophilic, 
blood-brain barrier penetration would be fa­
cilitated.
h 3n + C 02"
Fig. 3: Structure of gabapentin.
Mode of action
Interestingly, the. anticonvulsant properties of 
gabapentin are not dependent on any direct 
action on the GABA-ergic system51. The drug 
appears to bind to a membrane site near the 
glutamate receptor, which may represent a 
transport system for L-amino acids52,53. A 
recent study suggests that gabapentin may 
also lim it the rate of firing of sodium-depen­
dent action potentials54.
Pharmacokinetics and interactions
Oral dosing of gabapentin results in rapid 
absorption, and the drug has a bioavailability 
of 60%. A saturable transport mechanism in 
the gut explains the lack of proportionality be­
tween increased doses and levels in plasma55. 
Maximum concentrations occur 2 -3  hours 
after administration and the elimination half- 
life approximates 5 -7  hours56. There is no sig­
nificant protein binding, and the drug is 
excreted unchanged in the urine with clear­
ance rates equivalent to those for creatinine. 
The lack of important drug interactions with 
gabapentin has been widely reported57.
Efficacy and tolerability
A small, dose-ranging, double-blind cross-over 
study was the first to provide evidence for
gabapentin’s efficacy against partial seiz­
ures58. A clear-cut dose-response relationship 
in reducing partial and secondary generalized 
seizures has been demonstrated with the 
drug59. In a large double-blind, parallel group, 
placebo-controlled study involving 127 
patients with drug-resistant partial seizures, 
25% of these taking gabapentin experienced a 
reduction in seizure frequency exceeding 
50%60. The therapeutic effect of gabapentin 
has been shown to persist for up to 24 
months61.
Adverse events with gabapentin are gener­
ally mild and transient62. The most common 
are somnolence, fatigue, dizziness and weight 
gain. Other problems include diplopia, head­
ache, ataxia and nausea. No idiosyncratic reac­
tions have been reported to date. Early reports 
are reassuring also regarding its lack of terato­
genic potential63.
The recommended schedule for prescribing 
gabapentin involves thrice daily adminis­
tration. However, some patients appear to re­
spond to a morning and evening dose. The drug 
should be introduced over the first week at low 
dosage (e.g. 300 mg twice daily) and thereafter 
can be increased more rapidly as necessary to a 
maximum of 2700 mg daily or thereabouts. Its 
use is not currently recommended in children 
under 12 years of age.
Oxcarbazepine
Oxcarbazepine, the 10-keto analogue of carba­
mazepine (Fig. 4), has been licensed for use in a 
number of countries worldwide. Its metabolism 
differs from that of the parent compound and 
this holds out the possibility of a more benign 
side-effect profile with fewer drug interac­
tions64.
NH
Fig. 4: Structure of oxcarbazepine.
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Mode of action
The mode of action of oxcarbazepine is similar 
but not identical to that of carbamazepine65. 
Its major effect, therefore, is in preventing 
burst firing of neurones by blocking voltage- 
dependent sodium channels.
Pharmacokinetics and interactions
Oxcarbazepine is a pro-drug, the main active 
principle being 10,ll-dihydro-10-hydroxy-car- 
bamazepine which is largely eliminated by 
hepatic glucuronidation63. This moiety is 55% 
bound to ^ plasma proteins and has an elimin­
ation half-life approximating 9 hours. Unlike 
carbamazepine, oxcarbazepine does not 
undergo autoinduction of metabolism66. The 
drug has no effect on the metabolism of other 
anticonvulsants67. However, the area under 
the concentration-time curve of the active 
metabolite is lower in patients taking carba­
mazepine, phenytoin and phenobarbitone than 
in controls suggesting a small, probably clini­
cally irrelevant, induction effect of these drugs 
on its elimination67,68.
Oxcarbazepine has less potential than carba­
mazepine to induce liver enzymes and so influ­
ence the metabolism of other drugs. It  appears 
to induce selectively a single isoform of cyto­
chrome P450, namely IIIA 69. Volunteer studies 
have suggested that it does not interfere with 
warfarin metabolism70, nor w ill cimetidine71 
or dextropoxyphene72 inhibit its breakdown. 
However, decreased bioavailability of the oral 
contraceptive pill has been noted in some 
patients treated with oxcarbazepine73.
Efficacy and tolerability
Several double-blind, add-on studies have con­
firmed comparable efficacy between oxcarbaze­
pine and carbamazepine74"76. In addition, no 
difference in anticonvulsant effect was found 
between oxcarbazepine and carbamazepine in 
patients with newly diagnosed epilepsy77. Like 
carbamazepine, oxcarbazepine has no place in 
the treatment of absence seizures and myo­
clonic jerks69.
Comparisons with carbamazepine have sug­
gested a lower incidence of minor side- 
effects75”77. Those most commonly associated 
with oxcarbazepine are diplopia, nausea, head­
ache, dizziness, drowsiness and ataxia69.
Oxcarbazepine, like carbamazepine, has a pro­
pensity to cause hyponatraemia in some 
patients78. However, it produces fewer rashes 
than carbamazepine79 and perhaps other idio­
syncratic reactions69.
Felbamate
Felbamate is a dicarbamate derivative (Fig. 5) 
which is licensed in the United States and has 
recently gained approval for use in partial seiz­
ures and Lennox-Gastaut syndrome in some 
European countries. It  has been reported in 
animal models as having an unique profile of 
anticonvulsant activity, with little tendency to 
cause neurotoxicity80.
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Fig. 5: Structure of felbamate.
Mode of action
Felbamate has an interesting effect in de­
creasing the binding of ligands at the glycine 
site of the n-methyl-d-aspartate (NMDA) 
receptor81. This implies that it may act as a 
glycine antagonist, possibly diminishing the 
deleterious influence on neuronal function of 
excitatory amino acids. Several other modes of 
action have also been suggested82.
Pharmacokinetics and interactions
Oral administration of felbamate leads to com­
plete and rapid absorption. Following a single 
dose, the half-life ranges between 14 and 22 
hours in epileptic patients82. A proportion of 
absorbed drug is excreted unchanged in the 
urine, with the rest undergoing hydroxylation 
and conjugation in the liver.
On addition of felbamate, phenytoin, val­
proate and phenobarbitone levels w ill rise by 
around 20-30%, whereas serum carbamaze­
pine will fall by a similar amount83. However, 
this latter effect is offset by greater production 
of the active metabolite, carbamazepine 10,11
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epoxide84. Enzyme-inducing antiepileptic 
drugs will increase the rate of clearance of fel­
bamate85. The effect of valproate on felbamate 
levels is less clear-cut86.
Efficacy and tolerability
The efficacy of felbamate has been established 
in six major clinical trials involving around 
370 patients87-92. Five of these were under­
taken in patients with partial seizures with or 
without secondary generalization. The final 
piece of evidence consists of a major placebo- 
controlled trial in 73 children with Lennox- 
Gastaut syndrome, each of whom had at least 
90 atonic or atypical absence seizures per 
month despite treatment with one or two 
established antiepileptic drugs. Felbamate 
reduced the frequency of atonic seizures as well 
as atypical absences90. Preliminary results in 
the primary generalized epilepsies are also 
promising. Long-term efficacy data with the 
drug, however, are still limited, although early 
observations are encouraging93.
The most frequent side effects with felba­
mate originate from the central nervous 
system and include diplopia, dizziness, head­
ache, nausea and vomiting, diarrhoea and 
ataxia82. Weight loss of around 5% body weight 
has been reported in some patients, probably 
secondary to anorexia and nausea. Both insom­
nia and somnolence have been associated with 
felbamate administration83.
Mode of action
Tiagabine acts by inhibiting GABA re-uptake 
by glial cells and presynaptic neurones95. The 
resultant increase in synaptic GABA concen­
trations is thought to be responsible for its 
anticonvulsant action96.
Pharmacokinetics and interactions
Tiagabine is well-absorbed orally with peak 
levels occurring around an hour after dosing94. 
The elimination half-life varies between 4 and 
13 hours. Elimination is mainly by hepatic 
metabolism, which appears not to be 
influenced by concomitant anticonvulsant 
treatment.
Efficacy and tolerability
Double-blind studies suggest useful efficacy for 
tiagabine against partial and secondary gener­
alised seizures97,98. Monotherapy trials are 
also currently being undertaken99. Side-effects 
so far have been largely confined to headache, 
dizziness and sedation.
Remacemide
Remacemide was designed to affect the excit­
atory component of epileptogenesis. It  has 
recently entered phase I I I  clinical trials in epi­
leptic patients.
Tiagabine
Tiagabine, a nipecotic acid derivative (Fig. 6), 
has a powerful anticonvulsant effect in animal 
seizure models94.
Fig. 6: Structure of tiagabine.
Mode of action
Remacemide is chemically unrelated to any 
other anticonvulsant (Fig. 7) and has been 
shown to be a weak, non-competitive NMDA  
antagonist100. At least part of remacemide’s 
anticonvulsant action is thought to be due to 
its main metabolite, the desglycinate.
Pharmacokinetics and interactions
Oral dosing of healthy volunteers shows 
absorption to be rapid, peak levels being 
attained around 1 hour after administration. 
The parent drug has an elimination half-life 
approximating 4 hours, whereas the active 
desglycinate metabolite has a longer half-life
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Fig. 7: Structure of remacemide.
in the region of 12-18 hours100. This difference 
in pharmacokinetics between parent drug and 
active metabolite is important in determining 
the optimum frequency of dosing.
Though not yet complete, interactions 
studies with remacemide suggest that it may 
act as an enzyme inhibitor, slowing the metab­
olism of both phenytoin and carbamazepine101. 
Clearance of remacemide is increased in 
patients taking phenytoin and carbamazepine 
compared with those treated with sodium val­
proate102.
Efficacy and tolerability
Preliminary results with remacemide suggest 
useful efficacy against partial and secondary 
generalized seizures103,104. In common with 
other centrally acting drugs, lightheadedness, 
diplopia and dizziness have been reported as 
well as gastro-intestinal symptoms such as 
dyspepsia, nausea and vomiting. Aggressive 
behaviour has been noted on rare occasions. No 
evidence of idiosyncratic reaction to the drug 
has so far emerged.
Stiripentol
Stiripentol (Fig. 8) has been shown to be an 
effective anticonvulsant in many animal seiz­
ure models105-107.
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Mode of action
No precise mechanism of action has been deter­
mined, but laboratory studies suggest that 
stiripentol increases GABA levels either by in­
hibiting synaptosomal uptake or by decreasing 
its metabolism108
Pharmacokinetics and interactions
The drug is slowly distributed rendering its 
elimination curve multiphasic. It  is highly pro­
tein bound and undergoes non-linear kin­
etics109. Stiripentol is biotransformed mainly 
by hepatic metabolism110, and this can be ac­
celerated by other antiepileptic drugs111. It  
strongly inhibits the metabolism of other anti­
convulsants, causing a rise in concomitant phe­
nytoin, carbamazepine, sodium valproate and 
phenobarbitone112,113.
Efficacy and tolerability
Most of the studies carried out so far have been 
open label design in patients with partial seiz­
ures with or without secondary generaliz­
ation111,114. A preliminary report supports effi­
cacy in children with atypical absences115. 
Overall, stiripentol is well tolerated with only 
ataxia, nausea, vomiting and lethargy cur­
rently complicating its clinical use.
Topiramate
Topiramate (Fig. 9) is yet another antiepileptic 
compound, which is structurally distinct from 
all other comparable drugs!
33
Fig. 8: Structure of stiripentol. Fig. 9: Structure of topiramate.
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Mode of action
As with many of the new anticonvulsants, this 
is presently uncertain. One study suggests that 
it may enhance GABA-mediated chloride ion 
influx116.
Pharmacokinetics and interactions
Topiramate is slowly absorbed after oral dos­
ing, peak concentrations in plasma occurring 
between 1 and 4 hours after administration. 
The drug is excreted largely unchanged in the 
urine, with an elimination half-life ranging
- from 19 to 23 hours117. Around 5% of a dose
- undergoes hepatic metabolism. Interactions
- with other anticonvulsants have still to be 
fully delineated.
Efficacy and tolerability
~ A number of double-blind, placebo-controlled
* studies have been completed with topiramate 
in adults with refractory partial seizures with
- or without secondary generalization118,119. 
These have shown a good response (defined as a
’ reduction of >50% in seizure frequency) in
* more than half of the patients taking more
- than 200 mg of the drug per day120,121. Prelimi­
nary data also suggest efficacy in the Lennox- 
Gastaut syndrome122. Topiramate appears 
likely to be a valuable add-on treatment in 
refractory epilepsy123.
The most frequently reported side-effects 
with topiramate include ataxia, cognitive dys­
function, dizziness, headache, nausea, nystag-
- mus, tremor and visual disturbance. Less 
common problems include mood lability and 
weight loss. Animal toxicity studies suggest 
that topiramate may be teratogenic.
CONCLUSIONS
- The recent developments in the pharmacother-
- apy of epilepsy are providing formidable chal­
lenges to the clinician. Which patients should
’ receive which drug and for which seizure type?
* So far, most is known about lamotrigine and 
vigabatrin, as these have been in general use
* for some years. Felbamate and gabapentin 
■ have been licensed more recently in the USA 
’ and approved for licensing in some European
countries. Oxcarbazepine, also generally avail-
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able in some countries, appears to be better 
tolerated than carbamazepine. These drugs are 
undoubtedly valuable in the treatment of 
refractory epilepsy. The early clinical promise 
of tiagabine and remacemide are indicators 
that these compounds too will make the tran­
sition from interesting chemicals to useful 
therapeutic agents. Stiripentol and topiramate 
show a few more problems, but may well prove 
valuable as second-line therapy in refractory 
epilepsy. The drugs touched on in this review 
are merely the tip of a growing iceberg.
For an antiepileptic drug to demonstrate 
efficacy in refractory epilepsy is impressive. 
Their use as adjunctive therapy, however, is 
likely to exaggerate their side-effect profiles. 
The level playing field of double-blind, con­
trolled trials in previously untreated patients 
will demonstrate the true worth of these new 
drugs in comparison with the much less expen­
sive and more established compounds. Mono­
therapy may well prove the newer crop of anti­
convulsants more benign. So far, only 
felbamate has been licensed for this indication, 
although lamotrigipe is likely to be available 
soon as monotherapy in Europe.
The ultimate goal for everyone involved in 
the development of antiepileptic drugs is the 
discovery of effective and safe agents with 
well-defined mechanisms of action. We may 
find it a useful strategy to combine drugs that 
independently influence either excitatory or 
inhibitory processes. As time passes, the best 
combinations are likely to be discovered seren- 
dipitously. The use of two agents acting on the 
‘same side of the fence’, such as vigabatrin and 
tiagabine, may be a logical approach in refrac­
tory single seizure types. Those with different 
modes of action, such as vigabatrin and lamo­
trigine, may be best combined for patients ex­
periencing more than one seizure type. A nar­
rower range of biochemical effects may lead to 
enhanced tolerability during such dual ther­
apy, and ‘selective’ co-prescribing could be the 
key to improving seizure control with . fewer 
side effects. This approach should supersede 
the current empiricism, and lead to the 
rational evolution of combination therapy for 
the treatment of refractory epilepsy.
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Lamotrigine
Clinical Use
John P. Leach and Martin J. Brodie
ia.the 1960s, some anticonvulsants were observed to 
give rise to abnormalities in folate metabolism and a 
lil'le later folate itself was shown to be proconvulsant 
in rodents (17). Around that time, Reynolds and his 
colleagues (30) proposed that antifolate drugs would 
Lye anticonvulsant properties. Lamotrigine, a phenyl- 
triazine compound, was born out of this suggestion 
after a search by Wellcome Laboratories for an appro­
bate folate antagonist. However, its anticonvulsant 
cficacy has proved far greater than its effect on folate. 
These properties are now known to be independent.
At the time of writing, lamotrigine is licensed for use 
as add-on therapy in more than 2 0  countries worldwide 
and is undergoing clinical trials to ascertain its suitabil­
ity for use as monotherapy.
PLACEBO-CONTROLLED T R IA L S
E lev en  placebo-controlled, double-blind trials 
(Table 1), involving almost 1,000 patients, have con­
firmed the efficacy of lamotrigine for partial seizures 
Mh o r  without secondary generalization (6,7,13, 
1922,23,32,35,37,38,40). Most were of crossover 
design, whereas three involved parallel groups (13, 
2337). in some of the early studies (6,7,19), unblinded 
observers were used to control the dose of lamotrigine, 
keeping the circulating concentration within a preset 
ffige. Not all these trials have as yet been published
in M l.
th e  preliminary report by Binnie (6), ten patients 
Wh treatment-resistant partial seizures were recruited 
' Wall completed the study. There was a significant 
^crease in seizure counts with lamotrigine compared 
0p la c e b o . Six noted a decrease in seizure frequency
Antiepileptic Drugs, Fourth Edition, 
edited by R. H. Levy, R. H. Mattson, and
B. S. Meldrum. Raven Press, Ltd.,
New York © 1995.
of at least 50% on lamotrigine, with one patient remain­
ing seizure-free throughout the 7-day treatment period. 
The active drug was well tolerated; side effects oc­
curred in three patients at concentrations above 3 mg/ 
liter and abated following a reduction in lamotrigine 
dosage.
Jawad and colleagues (19) maintained trough levels 
of lamotrigine between 1.5-2 mg/liter. They found a 
significant reduction in seizure days and number of sei­
zures among their 21 patients over 12 weeks of therapy. 
This was most marked after the first month. Two thirds 
of patients had their total seizure count more than 
halved. Seventy-five percent of patients with partial 
seizures responded to lamotrigine, compared with 44% 
with secondary generalization. This reduction was sta­
tistically significant for both seizure types. Lamotrig­
ine was well tolerated, with seven adverse events docu­
mented, two of which occurred during placebo 
administration. Four were reported by one patient, 
who (unsurprisingly!) was withdrawn from the study. 
The most common side effects were headache, diplo­
pia, drowsiness, and ataxia.
In Binnie’s later study (7), 30 patients were given 
lamotrigine as add-on therapy. Although two patients 
reported side effects with lamotrigine, seven experi­
enced these while taking the placebo. Only one patient 
was withdrawn as a result of an adverse event, a macu- 
Iopapular rash. In seven patients the lamotrigine dose 
was reduced, mostly because of headache and dizzi­
ness. The efficacy of lamotrigine was confirmed, with 
12 patients having their total seizure count reduced by 
more than 25% on lamotrigine compared with only four 
on placebo. Twenty of the 22 patients with partial sei-
889
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TABLE 1, Placebo-controlled trials with lamotrigine
Decrease in
Duration total Patients with Patients with
of seizure Patients with >50% decrease >50% decrease
Reference Patients Patients treatment Dose range frequency >50% decrease in partial in generalized 
number recruited completing (weeks) (mg/day) (%) in total seizures seizures seizures
, 6 10s 10 1 50-400
13 24a 21 12 75-400
7 34a 30 12 75-200
22 25a 23 8 75-300
32 88a NA 12 100-400
35 21a 18 12 100-300
13 • 216b NA 24 500
300
placebo
‘ 37 446b NA 24 NA
38 41a 41 12 300 (non-VPA) 
150 (VPA)
- 40 81a 62 18 100-400
23 191b NA 24 500 (non-VPA) 
300 (VPA) 
Placebo
* Crossover trials. 
b Parallel groups.
NA, data not available.
) zures noted an improvement in seizure numbers. This
■* exceeded 50% in just two.
Loiseau and coworkers (22) found that over an 8- 
week period, 15 of 23 patients reported a reduction in
'■ total seizures while taking lamotrigine compared with 
placebo. Fourteen had the frequency of their partial
- seizures reduced, eight by more than 50%. Three pa­
tients noted vertigo and two experienced some ner­
vousness. Seven other minor self-limiting adverse 
events were documented with lamotrigine, compared
1 with four during the placebo phase. The mean trough 
lamotrigine concentration in patients who responded 
to the drug was 1.5 mg/liter, and, unusually, there was 
a hint of a correlation between efficacy and circulating 
concentration.
Risner (32) and Messenheimer et al. (23a) reported 
) the results of a placebo-controlled, double-blind study 
in 98 patients recruited in seven centers across the U.S. 
Most patients received a lamotrigine dose of 400 mg/
- day. During the 14-week treatment period, the overall 
median seizure frequency decreased 25%, with 20% of 
the patients having a 50% or greater reduction in sei­
zure frequency.
* The results from Sander’s study (35) were the least 
conclusive. Eighteen patients completed the trial. 
Three were withdrawn, one due to a complication of 
a seizure and another following an overdose of baseline 
anticonvulsant. The third patient developed symptoms
1 that eventually resolved on valproate withdrawal. 
There was an overall reduction in seizure numbers, 
which was greater for secondarily generalized events 
in the latter stages of the lamotrigine treatment period.
* Partial seizures appeared unaffected. A maximum of 
I 200 mg lamotrigine daily was prescribed if concomitant
NA 60% 5/8 (62.5%) 5/5 (100%)
59 (median) 67% 12/17 (71%) 7/15 (47%)
17 (median) 7% 2/20 (10%) 2/19 (9%)
23 (median) 30% 8/23 (35%) NA
25 (median) 20% NA NA
18 (mean) 11% NA NA
32 (median) 34%
23 (median) 20% NA NA
14 (median) NA
NA NA NA NA
24 (median) 22% 8/41 (20%) 9/32 (28%)
30 (mean) 18% 12/62 (19%) 10/36 (28%)
36 (median) 34%
20 (median) 20% NA NA
8 (median) 18%
treatment included an enzyme-inducing anticonvul­
sant. Trough plasma levels of lamotrigine were mea­
sured. No dose-response relationship was noted, un­
surprisingly perhaps, given the low concentrations. 
Tolerability was not a problem, with similar numbers 
of adverse events reported on lamotrigine and placebo. 
The lack of efficacy, however, was most likely due 
to a combination of low lamotrigine dosage and the 
refractory nature of the seizure disorder. All recruited 
patients were undergoing institutionalized care. 
Around 50% took at least three anticonvulsant drugs 
daily before entering the study, and 11 had a structural 
brain lesion.
Results from a large parallel-group study of 216 pa­
tients were reported by Dren et al. (13) and Matsuo et 
al. (23). A statistically significant decrease in seizure 
frequency was obtained with a lamotrigine dose of 500 
, mg per day compared with 300 mg daily and placebo. 
The beneficial effect persisted throughout the 24-week 
treatment period, with one third of patients taking 500 
mg lamotrigine daily experiencing a 50% or greater re­
duction in seizures. The overall median reduction was 
36% with the 500 mg dose compared with 20% for the 
300 mg dose and 8% for placebo. No useful correlation 
was found between lamotrigine concentrations and ef­
ficacy.
Schachter and coworkers (37) conducted the largest 
American parallel group study on 446 patients, 112 of 
whom received placebo. The remaining 334 took up to 
500 mg lamotrigine daily for 6 months. The efficacy 
data presented to date are scanty, although 65% of pa­
tients were said to have improved (unspecified criteria) 
on lamotrigine compared with 35% on placebo. More 
details are awaited. The withdrawal rate was 8% f°r
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both groups, all because of side effects, the commonest 
of which was nystagmus, which occurred in 18% of 
patients taking lamotrigine against 11% on placebo. 
Adverse events requiring withdrawal of lamotrigine 
were dizziness (3%), blurred vision, headache, and 
rash (1% each).
Schapel and colleagues (38) undertook 12-week 
treatment with lamotrigine and matched placebo in 41 
patients, all of whom completed the study. The dose 
of lamotrigine was dependent on concomitant anticon­
vulsant therapy. Twenty-six patients reported a de­
crease in total seizure numbers, by more than 50% in 
nine (22%). The median reduction in partial and sec­
ondary generalized seizures was 20% and 46% respec­
tively. Overall, 20% and 47% of patients with partial 
and secondary generalized seizures had these reduced 
by more than 50% with lamotrigine compared with 16% 
on placebo. Although the fall in secondary generalized 
seizures did not reach statistical significance, it became 
more marked when patients with less than four seizures 
a month were excluded. Only one serious adverse 
event was reported, which was thought to be a compli­
cation of a seizure. The mean lamotrigine plasma con­
centrations were 1.95 mg/liter in enzyme-induced pa­
tients and 2.37 mg/liter in those who were not taking 
an inducer. A concentration-effect relationship was 
suggested by comparing levels in responders (>50%  
reduction) and nonresponders.
Smith and colleagues (40) reported on 18-week lamo­
trigine and placebo treatment periods. O f 81 patients 
recruited, 62 completed the trial. Lamotrigine doses 
were relatively high compared with other crossover 
studies— 200 mg daily for those on nonenzyme-induc­
ing drugs and 400 mg for those taking enzyme-inducing 
anticonvulsants. Eleven patients withdrew because of 
adverse events, mostly headache, diplopia, and dizzi­
ness. Eighteen of the completing patients had a modest 
j re s p o n se , reporting a reduction in total seizures of be­
tween 25% and 49% when compared with placebo. A 
fu rther 11 could be regarded as responders (reduction 
> 5 0 % ). On analysis by seizure type, 12 of 62 experi­
enced a marked reduction in partial seizures, with 10 
of 36 demonstrating a similar response in secondary 
generalized seizure frequency. Both observations were 
statistically significant. Seizure severity was amelio­
rated by lamotrigine. This change was thought to be 
independent of the positive effect of the drug on seizure 
fre q u e n c y .
For the first time, “ quality of life” factors were mon­
itored throughout an antiepileptic drug study. Al­
though most of the tests revealed no difference be­
tween lamotrigine and placebo, there were significant 
improvements in “ mastery” (perceived internal con- 
trot) and “ happiness.” Forty-two of the completing pa­
tients chose to remain on lamotrigine, some despite 
little change in their seizure pattern. This was inter­
preted by the investigators as supporting the case for 
psychotropic benefit with the drug.
OPEN-LABEL TRIALS AND CASE REPORTS
A  number of open-label trials with lamotrigine have 
been carried out, and these have played a valuable role 
in exploring the dose requirements and identifying 
common side effects (31). Jawad and coworkers (20) 
gave 23 patients lamotrigine in addition to their usual 
medication for 7 days. Of the 20 who completed the 
study, 18 took two other drugs, the remainder receiving 
three. Eight of the patients (40%) had a reduction in 
seizure frequency exceeding 50%, whereas a similar 
number noted a less striking improvement.
Sander’s open-label study (36) also supported effi­
cacy for lamotrigine in patients already taking one or 
two antiepileptic drugs. A total of 104 patients com­
pleted 12 months of treatment with lamotrigine; 25% 
experienced a reduction in seizure count by more than 
half. Those who developed side effects did so at vary­
ing concentrations. This study did not support the con­
cept of a useful target range of plasma lamotrigine con­
centrations. The drop-out rate was 15%. Of these 19 
patients, 15 experienced side effects associated with 
lamotrigine. As in other studies, the commonest prob­
lems were headache, diplopia, drowsiness, and ataxia.
Betts (4) pooled the results of 27 similar open-label 
studies involving a total of 572 patients. Lamotrigine 
doses varied between 200-400 mg daily in induced pa­
tients and 100-200 mg in noninduced patients. The 
changes in seizure frequency were compared over four 
12-week periods with a 3-month baseline. Of the 211 
patients with secondary generalized seizures, 40% 
showed a substantial reduction in seizure frequency 
after 12 weeks of lamotrigine treatment, with 13% be­
coming seizure-free. The 361 patients with partial sei­
zures did slightly less well, but 29% had their seizure 
numbers cut by more than half.
A report of its intravenous use in status epilepticus 
suggests that the drug also possesses acute anticonvul­
sant properties (28).
Anecdotal reports support benefit for lamotrigine in 
patients with primary generalized tonic-clonic sei­
zures (34,41,44), typical and atypical absences (3), 
atonic (29), and myoclonic seizures (46).
EFFICACY IN CHILDREN
There are few studies with lamotrigine in children 
(50). Current evidence, however, supports similar effi­
cacy in this patient population to that documented in
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| TABLE 2. Percentage of patients with ^50% seizure j reduction during the first 12 weeks of lamotrigine
therapy
Seizure type
Children 
(n = 285) Adult (n = 677)
■Total seizures 34 32All partial 31 30Simple partial 14 24Complex partial 34 31Secondary generalized 33 42
Typical absence 53 34Atypical absence 50 61Myoclonic 31 31Clonic 24 36Tonic-clonic 30 38Atonic 38 60
! Data on file at Wellcome Laboratories.
weeks with marked or moderate overall improvement 
seen in eight. A further report suggests that atypical 
absence and complex partial seizures respond best to 
lamotrigine (15). A few children have been established 
on lamotrigine monotherapy (24).
The use of lamotrigine in Lennox-Gastaut syndrome 
has been investigated by three groups (25,39,45). A 
total of 45 affected patients have been treated. Promis­
ingly, 33% demonstrated complete disappearance of 
seizures for up to 2 years of follow-up. Overall, 50% 
of patients reported a decrease in seizure numbers ex­
ceeding 50%. Double-blind studies with the drug in 
therapy-resistant Lennox-Gastaut syndrome are 
awaited. A preliminary report also suggests benefit 
with lamotrigine in children with Rett’s syndrome (47).
adults (Table 2). Chaves and colleagues (11) included 
36 patients aged between 5 and 15 years in a single­
blind trial of lamotrigine preceded by a placebo base­
line phase. Among the 31 completing patients, 12 had 
their seizure counts reduced by at least 50%. An in­
crease in seizure frequency was noted in two children 
and in 17 there was no change.
A total of 249 children aged 2-16 years with refrac­
tory epilepsy were included in an assessment of adju­
vant lamotrigine by Hosking and Spencer (18). The 
drug was well tolerated, with only 26 patients with- 
| drawn due to lack of efficacy or deterioration in seizure 
control. Ten patients experienced a rash, all within the 
first few months of treatment. O f the first 36 patients 
to complete 12 weeks treatment, 15 had their seizure 
numbers cut by more than half. The best responses 
were seen with myoclonic jerks and absence, tonic, 
and atonic seizures. There was a suggestion of im­
proved behavior in some of the children successfully 
treated.
In a review of 59 students attending a special residen- 
| tial school, further details were given regarding 12 chil­
dren who had spike-wave discharges suitable for auto­
matic monitoring (3). Six of these showed a dramatic 
reduction in their spike-wave events with lamotrigine 
I treatment. In some patients this was not accompanied 
I by reduction in overt seizures, but nevertheless con- 
' ferred considerable benefit in terms of improved alert­
ness and behavior.
A review of 120 children treated in Paris (39) re­
ported 40% experiencing at least a 50% reduction in 
total seizures; 10% became seizure-free. The best re­
sults were obtained in patients with generalized sei­
zures, including absences, Lennox-Gastaut syndrome, 
and other types of symptomatic generalized epilepsy. 
In another open study, 18 children between the ages 
of 5 and 11 were given lamotrigine as add-on therapy 
(48). Fifteen remained on the treatment for at least 24
MONOTHERAPY
Eight patients with partial epilepsy, who had com­
pleted a double-blind, placebo-controlled, add-on trial 
with lamotrigine had their concomitant antiepileptic 
medication withdrawn (2). This was successfully 
achieved in seven, who had a reduction or, at least, 
no change in seizure frequency. Only one patient was 
returned to polytherapy. Among the others, the inci­
dence of side effects was much reduced. Avrutsky (1) 
looked at patients at the end of a 6-month lamotrigine 
treatment period. Of the 36 who stayed on the drug, 
eight had their other antiepileptic drugs discontinued.
Timmings and Richens (46) undertook a pilot trial 
in 17 patients with juvenile myoclonic epilepsy, all of 
whom were receiving sodium valproate. After a 4-week 
single-blind, placebo-controlled, add-on period, pa­
tients were randomized to receive either lamotrigine 
or valproate as monotherapy for a further 12 weeks. 
One patient dropped out in the add-on phase due to 
the onset of dizziness. Three patients withdrew during 
the crossover to lamotrigine, one with increased sei­
zure frequency and the other two with rash. Otherwise, 
seizure control was comparable between valproate and 
lamotrigine monotherapy.
A multicenter, open-label trial of lamotrigine as 
monotherapy was conducted in patients whose sei­
zures were uncontrolled by carbamazepine, phenytoin, 
or sodium valproate (10). After a 4-week lamotrigine 
titration phase, the patients were followed up for 12 
weeks to assess the clinical response. The other antiep­
ileptic drug was withdrawn if the addition of lamotrig­
ine produced a decrease in seizure frequency of more 
than 50%. Patients on lamotrigine monotherapy were 
followed up for 12 additional weeks. Eighty-one per­
cent of these patients were sustained successfully on 
lamotrigine monotherapy. On the negative side, there 
were 127 drop-outs. Thirty of these were for lack of 
lamotrigine efficacy and 48 for side effects severe
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enough to warrant lamotrigine withdrawal, 16 of whom 
developed rashes (12).
Preliminary analysis has been made of an open, mul­
ticenter monotherapy trial of lamotrigine versus carba­
mazepine (10). Suitable patients for inclusion were 
aged 16-65 years. They had suffered two or more par­
tial or secondary generalized tonic-clonic seizures 
during the previous 6 months with at least one within 
the past three months. Randomisation was blinded to 
lamotrigine or carbamazepine. Three parallel treat- 
! ment schedules were available. Following a 6-week 
dosage escalation phase, patients were established on 
lamotrigine 100 mg or 200 mg daily or carbamazepine 
600 mg daily. They were regarded as having completed 
the study if they had a further seizure on maintenance 
treatment, or if they finished the 24-week follow-up 
period seizure-free.
Similar numbers of patients have remained seizure- 
I free on all three schedules. Seven receiving carbamaz­
epine were withdrawn due to adverse events compared 
with one on lamotrigine. This latter patient developed 
a rash on the higher lamotrigine dose. Four patients 
treated with carbamazepine also had rashes. Nausea 
and tiredness, ataxia and dizziness, and abnormal men­
struation were the reasons given by the other three 
patients for being unable to tolerate carbamazepine.
Lamotrigine is presently undergoing a program of 
double-blind trials as monotherapy in newly diagnosed 
epilepsy. More than 250 patients have completed com­
parative studies against carbamazepine and phenytoin 
and definitive reports o f these important studies will 
be available soon.
| USEFUL COMBINATIONS
The development of rational schemes for combining 
antiepileptic drugs may be one of the positive spin-offs 
of developing agents with single and specific mecha­
nisms of action. The possibility of manipulating oppo­
site sides of the neurotransmitter balance, involving 
neuronal inhibition and excitation, with, for example, 
vigabatrin enhancing inhibition and lamotrigine antago­
nizing excitation, is an exciting one. Whether this will 
be more effective than combining drugs that influence 
the same side at two different points, such as by using 
lamotrigine with remacemide, will become apparent on 
appropriate clinical testing.
The beneficial effect of combining sodium valproate 
and lamotrigine (26,27) was marked following failure 
of both drugs individually in treatment of a small num­
ber of patients with intractable typical absence and par- 
| tial seizures.
Similarly, increased efficacy has been reported anec­
dotally when lamotrigine was tried with vigabatrin 
(21,42). Stolarek and colleagues (43) carried out a pla­
cebo-controlled, double-blind, crossover trial of addi­
tional lamotrigine in patients receiving vigabatrin as 
part of their anticonvulsant regime. As neither drug 
had a license for monotherapy, it was not possible to 
combine just lamotrigine and vigabatrin. There was a 
reduction by 37% in overall seizure count during the 
lamotrigine treatment period compared with placebo 
among the 20 patients completing the trial. At the high­
est lamotrigine dose (100 mg twice daily) nine patients 
reported a fall in seizure numbers exceeding 50%. Both 
partial and secondarily generalized seizures were re­
duced. The plasma lamotrigine concentrations did not 
correlate with clinical efficacy in this study, in common 
with most others. By manipulating further the thera­
peutic regimes, five patients were subsequently ren­
dered seizure-free on lamotrigine and vigabatrin alone.
This favorable response was supported by two open- 
label studies using combinations containing vigabatrin 
and lamotrigine (14,33). Robinson and colleagues (33) 
looked at 48 patients. In the total group, there was 
a 54% decrease in mean monthly seizure frequency. 
Seventy-three percent of patients with partial seizures 
experienced a reduction of greater than 50%. Forty- 
five percent of patients with generalized seizures, con­
sisting mainly of Lennox-Gastaut syndrome, had their 
seizure frequency reduced by at least half. Froscher 
(14) tried this combination in 12 patients with refrac­
tory epilepsy. Seven remained on the cpmbination with 
good effect, with three being withdrawn due to lack of 
efficacy and two experiencing side effects.
IN IT IA T IO N  AND MAINTENANCE OF THERAPY
The lamotrigine elimination half-life is substantially 
prolonged in valproate-treated patients (49), an effect 
negated by concomitant enzyme-inducing drugs which 
themselves accelerate lamotrigine metabolism (8). In 
addition, there is good, if anecdotal, evidence that a 
low, slow titration schedule will reduce the likelihood 
of rash (12). Accordingly, the starting dose and rate of 
titration for lamotrigine as adjunctive therapy depends 
on existing treatment.
Tablets containing 25 mg, 50 mg, 100 mg, and 200 
mg lamotrigine are available. Chewable tablets con­
taining 5 mg, 25 mg, and 100 mg lamotrigine provide 
an alternative preparation for children and for patients 
who have difficulty in swallowing. These can also be 
dispersed in a small volume of water. Lamotrigine is 
usually prescribed twice daily, but a single daily dose 
can be used in patients taking the drug along with so­
dium valproate or as monotherapy. A parenteral for­
mulation is in development.
Recommended dosing schedules for lamotrigine are
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TABLE 3. Lamotrigine dosage schedules
1. Add-on in treated adults and adolescents
Valproate Others
Weeks 1-2 25 mg every 50 mg daily
other day
Weeks 3-4 25 mg daily 50 mg twice daily
Maintenance 50-100 mg 100-200 mg
twice daily twice daily
2. Add-on in treated children
: Valproate Others
Weeks 1-2 0.2 mg/kg 2 mg/kg
Weeks 3-4 0.5 mg/kg 5 mg/kg
Maintenance 1-5 mg/kg 5-15 mg/kg
3. Monotherapy in newly diagnosed epilepsy
Adults Children
Weeks 1-2 25 mg daily 0.5 mg/kg
Weeks 3-4 25 mg twice 1 mg/kg
daily
Maintenance 50-100 mg 2-8 mg/kg
twice daily
Higher doses can be tried if seizures persist and the pa­
tient is tolerating the drug without complaint.
outlined in Table 3. Higher doses can be tried if the 
drug is well tolerated. Although no definite evidence 
of teratogenicity has accumulated, caution should be 
employed when using lamotrigine in patients with 
child-bearing potential. The drug should only be used 
when, in the opinion of the attending physician, the 
likely benefit outweighs the potential risks.
Like other antiepileptic drugs, lamotrigine appears 
to exacerbate seizures in a small number of patients in 
whom it should be rapidly withdrawn. Reducing the 
dose by 50-100 mg weekly seems a reasonable policy 
| (9). Because the drug is metabolized in the liver, it is 
j sensible to avoid its use in patients with severe hepatic 
| impairment. There is little formal experience with la­
motrigine in babies, in the elderly, or in patients with 
I renal failure.
( At present, it appears that no clinical benefit can 
be obtained by monitoring plasma lamotrigine levels, 
because the concentrations required to elicit an ade­
quate response vary so much between individuals. 
There is no evidence either that subjective side effects 
are more likely to occur in patients with higher concen­
trations (5). Indeed, some patients will derive benefit 
from as much as a gram of lamotrigine daily without 
complaint, whereas others will develop headache or 
nausea and vomiting with doses as low as 100 mg daily. 
Further studies exploring the concentration-effect-tox- j icity relationship with the drug are warranted.
| INDICATIONS
Lamotrigine is licensed in more than 20 countries 
worldwide as add-on therapy for the treatment of re­
fractory partial and secondarily generalized seizures.
Long-term studies up to 3 years have revealed no evi­
dence of tolerance (16). Anecdotal reports suggest effi­
cacy for the drug across the range of idiopathic general­
ized epilepsies. Lamotrigine might, therefore, be tried 
in patients with refractory absence, tonic-clonic, myo­
clonic, tonic, and clonic seizures. Its use in combina­
tion with sodium valproate and vigabatrin shows par­
ticular promise.
Results from comparative double-blind trials in 
newly diagnosed patients with partial and primary gen­
eralized tonic-clonic seizures are imminent. However, 
lamotrigine can be useful in those few patients unable 
to tolerate, for one reason or other, the first-line 
agents. Its efficacy in the elderly is currently being 
evaluated in a double-blind comparative trial against 
carbamazepine and its promise in primary generalized 
tonic-clonic epilepsy is being formally tested against 
sodium valproate. Double-blind, placebo-controlled 
trials in children are also under way.
CONCLUSIONS
Lamotrigine is a potentially important addition to the 
ranks of available anticonvulsants. It has proven effi­
cacy in adults and adolescents for partial and second­
ary generalized seizures. Anecdotal reports also sup­
port particular efficacy in the idiopathic generalized 
epilepsies. Its broad spectrum of activity is wide 
enough to justify using it in patients with more than 
one seizure type. The next important step is for lamo­
trigine to gain acceptance as a first-line drug for use 
as monotherapy in patients with newly diagnosed epi­
lepsy. Data are still required in children, in the elderly, 
and in the idiopathic generalized epilepsies.
The possibility of rational duotherapy with estab­
lished and novel anticonvulsants provides an exciting 
prospect for future clinical research. Combinations of 
lamotrigine with sodium valproate and vigabatrin ap­
pear particularly promising. This will hopefully be con­
firmed in due course in formal double-blind trials. Stud­
ies looking at lamotrigine along with other drugs that 
affect excitatory amino acid neurotransmission are 
also awaited with interest.
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Deliberate overdose with the novel anticonvulsant 
tiagabine
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Tiagabine is a novel antiepileptic drug which acts by decreasing gamma aminobutyric acid uptake in astrocytes and 
I neurones. Here the first case of deliberate overdose with this compound in a patient on concomitant phenytoin is 
i reported. On admission to hospital his conscious level deteriorated to grade I I I  coma. No changes in the 
electrocardiogram were noted. Recovery from the initial effects was rapid, and there were no sequelae. Plasma 
levels of tiagabine (3.1 f i g / m l) 4 hours after ingestion were 30 times higher than at typical steady state during, 
therapeutic dosing. The effects of poisoning with current first-line antiepileptic drugs are reviewed. The newer 
agents, particularly those with greater biochemical specificity, may be safer in overdose than the more established 
anticonvulsants.
Key words: tiagabine; overdose; epilepsy; self poisoning.
INTRODUCTION
i
Epileptic patients are at greater risk of self 
poisoning than other patient groups1. Safety in 
overdose should, therefore, be an important 
consideration when choosing an antiepileptic 
drug. Tiagabine is a novel anticonvulsant, which 
is currently undergoing phase III trials 
worldwide2. It is a nipecotic acid derivative with a 
lipophilic anchor, which allows it to cross the 
blood-brain barrier. Tiagabine acts by blocking 
the re-uptake of the inhibitory neurotransmitter 
gamma animobutyric acid (GABA) into glial cells 
and neurones3. The resultant increase in synaptic 
GABA concentration is thought to be responsible 
for its anticonvulsant action4. After oral ad­
ministration, it is rapidly absorbed and metabol- 
( ized in the liver with a half-life of between 4 and 
| 13 hours. Although sedation has been reported,
preliminary data suggest that tiagabine does not 
impair cognition at therapeutic dosage5. We 
report the first case of deliberate overdose with 
| tiagabine.
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CASE REPORT
DR is a 30-year-old man who has suffered from 
complex partial and secondary generalized seizures 
of unknown aetiology since the age of three. 
Surface electroencephalography demonstrated 
recurrent focal epileptiform discharge in the right 
fronto-temporal area. Computerized tomography 
of the brain was normal. Prior to this episode he 
had been taking tiagabine (64 mg daily) in 
addition to his usual dose of phenytoin (200 mg 
daily) with substantial benefit under an open 
protocol for the previous 9 months.
Following an argument with his girlfriend, the 
patient took 320 mg of tiagabine together with 
400 mg phenytoin. One hour later, he became 
drowsy and he was admitted to the local hospital. 
His conscious level deteriorated rapidly, reaching 
grade III coma overnight. Routine biochemistry, 
liver function tests and full blood counts were all 
normal. No active intervention was undertaken 
and the patient recovered fully. No neurological 
deficit could be demonstrated 12 hours after 
admission. Serial electrocardiograms showed no
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abnormality through his hospital stay. Tiagabine 
and phenytoin plasms concentrations 4 hours 
after ingestion were 3.1 /xg/ml and 22 /xg/ml, 
respectively. Psychiatric review confirmed that 
this was an impulsive overdose with no suicidal 
intent. He was discharged home after 48 hours’ 
observation.
DISCUSSION
The current first-line antiepileptic drugs are all 
potentially fatal in overdose1, perhaps a conse­
quence of their multiple, non-selective mechan­
isms of action6. In a three-year prospective survey 
of overdoses of non-barbiturate anticonvulsants 
reported to the UK National Poisons Service, 
carbamazepine (48%), phenytoin (33%) and 
sodium valproate were the most frequently 
ingested7, perhaps not surprisingly as they are 
regarded as the antiepileptic drugs of first choice8.
The initial features of carbamazepine poisoning 
are those of cerebellar dysfunction. As the 
concentration increases, central nervous system 
depression becomes dominant, progressing to 
respiratory depression in severe cases9. Antichol­
inergic features appear, presumably as a conse­
quence of carbamazepine’s structural similarity to 
the tricyclic antidepressants. An increase in the 
frequency of convulsions has been noted, perhaps 
related to the production of hyponatraemia10. 
The risk of cardiac arrhythmias necessitates ECG 
monitoring for at least 24 hours11.
The saturation pharmacokinetics of phenytoin 
means that the ingestion of even a small dose can 
produce a substantial increase in circulating 
concentration12. The slow rate of hepatic metabo­
lism can make the recovery period as long as a 
week13. The initial features of acute phenytoin 
toxicity are cerebellar dysfunction including 
nystagmus, incoordination, dysarthria and 
ataxia14. Depression of the central nervous system 
(CNS) is common, often progressing to coma. 
This may be accompanied by hypotension and 
respiratory depression.
With sodium valproate, central nervous system 
depression is predominant, although often 
benign15. Coma, however, can occur after inges­
tion of more than 20 mg/kg body weight. 
Seizures16, respiratory failure, bone marrow 
suppression17 and metabolic adverse effects such 
as acidosis and hypocalcaemia can all occur18. 
Fatalities, although uncommon, have been 
reported17,18.
Our patient was receiving treatment with 
phenytoin and tiagabine prior to the event. The 
tiagabine concentration four hours after ingestion
was 30 times higher than at typical steady state 
following therapeutic dosage (Dr LC Lassen, 
pers. comm.). This is equivalent to around 
300 /x mol/litre of carbamazepine or 450 /x mol/ 
litre of phenytoin. At that time the patient was in 
light coma. The phenytoin concentration just 
exceeded the target range, and so was unlikely to 
contribute to the clinical picture. Induction of 
tiagabine’s metabolism by phenytoin might have 
contributed to the patient’s rapid recovery19.
There are no published cases of self poisoning 
with the GABA transaminase inhibitor vigabat­
rin, but current information suggests that the only 
adverse effect is transient drowsiness (Dr J 
Mumford, pers. comm.). There has been one 
report of lamotrigine overdose, in which neurolo­
gical toxicity was a feature20. This is the first 
report of tiagabine taken in overdose in man, and 
the rapid, uneventful recovery is, we believe, 
reassuring for this vulnerable patient population. 
One of the individual benefits of the newer 
antiepileptic drugs may be that their increased 
biochemical specificity augments existing physiol­
ogical processes, even in overdose, rather than 
producing a ‘blunderbuss’ deleterious effect on a 
range of cerebral functions and peripheral tissues. 
Consequently, anticonvulsants with defined 
mechanisms of action may be safer in overdose 
than the more established agents.
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ABSTRACT
A rapid and simple method for determination of the novel antiepileptic compound 
gabapentin (l-(aminomethyl)-cyclohexaneacetic add) in plasma is described. Blank human 
plasma was spiked with gabapentin (1.0 - 10.0 pg/ml) and internal standard 
(l-(aminomethyl)-cycloheptaneacetic add; 5.0 pg/ml). Individual samples were treated 
with 2M perchloric acid, centrifuged and then derivatised with ophthalaldehyde-3- 
mercaptopropionic add. Separation was achieved on a Beckman Ultrasphere 5p reversed 
phase column with mobile phase consisting of 0.33 M acetate buffer (pH = 3.7; containing 
100 mg/1 EDTA) / methanol / acetonitrile (40:30:30). Eluants were monitored by 
fluorescence spectroscopy with excitation and emission wavelengths of 330 and 440 nm 
respectively. The calibration curve for gabapentin in plasma was linear (r = 0.9997) over 
the concentration range 1.0 - 10.0 pg/mL Recovery was seen to be > 90 %. The inter- and 
intra-assay, variations for three different gabapentin concentrations were < 10 % 
throughout. The lower-limit of quantitation was found to be 0.25 pg/mL Chromatography 
was unaffected by a range of commonly employed antiepileptic drugs or selected amino  
adds.
2
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INTRODUCTION
Gabapentin (GBP) is a novel antiepileptic drug (AED) that has recently been approved in 
the UK and USA for the treatment of partial seizures. It is a hydrophilic analogue of the
N
inhibitory neurotransmitter y-aminobutyric add (GABA) and was designed to act as a 
GABAareceptor agonist that could freely cross the blood-brain barrier [1].
Despite its structural similarity to GABA (figure 1), GBP has demonstrated only limited 
effects on the GABAergic system. It is devoid of effect on GABA-mediated ion 
conductances, GABA receptor binding and GABA metabolism [2,3], Although the 
mechanism of GBP action remains to be frilly characterised, substantial evidence now 
suggests that it may interact spedfically with a plasma membrane site proposed to be the 
system L-amino add transporter [4,5].
GBP has an experimental anticonvulsant profile similar to that of valproic acid [6], It is 
effective against tonic seizures induced by a variety of chemoconvulsants [6] and is also 
active in the maximal electroshock test [6] and several rodent models of genetic reflex 
epilepsy [7], Clinically, the drug has demonstrated efficacy against both partial and 
generalised tonic-clonic seizures [8].
GBP is rapidly absorbed and exhibits a dose-dependent bioavailability as a result of a 
saturable uptake process [9]. Maximum concentrations occur 2 - 3  hours after 
administration and the elimination half-life is approximately 5 -7  hours [10]. There is no
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significant binding to plasma proteins, and the drug is excreted unchanged in the urine 
with a clearance rate equivalent to that for creatinine [11]. Despite extensive 
pharmacokinetic investigations, and the report that GBP is free of important drug 
interactions [9], the requirement for a reliable, routine laboratory assay of GBP 
concentration remains, particularly for those who advocate therapeutic monitoring of this 
drug in the treatment of epilepsy [12],
There are currently two published methods for the laboratory measurement of GBP, a 
high-performance liquid chromatographic (HPLC) assay [13] and a gas chromatographic 
(GC) assay [14]. The routine HPLC method, a modified version of a HPLC assay for 
GABA, would appear, however, to have several significant drawbacks. These include a 
multistep derivatisation involving 2,4,6-trinitrobenzenesulphonic acid (TNBS) followed by 
an extraction into toluene, and a methodology apparently incompatible with the use of 
modem, automated HPLC systems.
We have developed an automatable, one step derivatisation method for the determination 
of GBP in plasma by HPLC with fluorimetric detection. This rapid and reliable assay, 
which obviates the requirement for hazardous chemicals such as TNBS and toluene, is a 
modification of the method of Durkin and colleagues [IS] for analysis of neurotransmitter 
amino adds in brain.
4
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EXPERIMENTAL
Reagents
GBP (l-(aminomethyl)-cyclohexaneacetic add) and the internal standard (1- 
(aminomethyl)-cycloheptaneacetic add) were supplied by Parke-Davis Pharmaceuticals 
Resesarch Division, Ann Arbor, Michigan, USA. Methanol and acetonitrile (HPLC grade) 
were from Rathbum Chemicals, Walkerbum, Scotland. All other chemicals (reagent 
grade) were obtained from Sigma Chemical Co, Poole, Dorset, England.
Standards
Stock solutions of GBP (1 mg/ml) and internal standard (1 mg/ml) were prepared in 
de-ionised water and stored at -20 °C for up to 7 days. Working standard solutions of 
GBP (10 - 100 pg/ml) and internal standard (50 pg/ml) were prepared daily in de-ionised 
water. The derivatisation reagent, ophthalaldehyde-3-mercaptopropionic add (OPA- 
MPA), was prepared weekly by dissolving 50 mg OPA in 4.5 ml of methanol and adding
0.5 ml borate buffer and 50 pi 3-MPA. The borate buffer was prepared on a weekly basis 
by adjusting 0.5 M boric add to pH 9.5 with 1N NaOH
Sample preparation
GBP standards were prepared by die addition of 50 pi of the appropriate working 
standard (10 - 100 pg/ml) and 50 pi of working internal standard to 0.4 ml blank human 
plasma. Samples for analysis were prepared by adding 50 pi of working internal standard 
to 0.45 ml unknown plasma. Pooled plasma, spiked at high (5.0 pg/ml), medium (2.5
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pg/ml), and low (0.5 pg/ml) GBP concentrations was used to determine intra- and inter­
assay variations.
Derivatisation
A 200 pi volume of 2 M perchloric add was added to each standard and sample before 
vortex mixing for 10 seconds and centrifuging for 3 minutes at 15,000g at room 
temperature A 50 p i aliquot of the resulting supernatant was reacted with 200 p i of 
methanol, 200 pi of 0.5 M borate buffer (pH = 9.5) and 50 pi OPA-MPA solution. The 
reaction mixture was allowed to stand at room temperature for 5 minutes prior to injection 
of 20 pi onto the column. The derivatised GBP and internal standard were found to be 
stable for between 4 and 12 minutes prior to injection.
High Performance Liquid Chromatography
Chromatography was carried out at room temperature on a Beckman Ultrasphere 
octadecyl silane (ODS) 5p reversed phase column (250 x 4.6 mm; 80A pore; Beckman 
Instruments Inc., Fullerton, California, USA). The chromatography system consisted of a 
Waters 6000A pump (Waters / Millipore UK, Harrow, Middlesex, England), a Shimadzu 
SIL-9A auto-injector (Dyson Instruments Ltd., Houghton-le-Spring, Tyne and Wear, 
England) and a Perkin-Elmer LS5 fluorescence spectrophotometer (Perkin-Elmer, 
Beaconsfield, Buckinghamshire, England). The excitation and emission wavelengths were 
330 and 440 nm respectively with slitwidths set at 15 and 20 nm respectively. The mobile 
phase consisted of 0.33 M acetate buffer (containing 100 mg/1 EDTA) / methanol /
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acetonitrile (40:30:30). The acetate buffer was prepared by diluting 7.5 ml glacial acetic 
add (approx 17.4 M) to 400ml with water, adding 40 mg EDTA and adjusting the pH to 
3.7 with 3 N NaOH. Flow rates were 1.5 ml/mm throughout.
Calculations
Chromatograms were recorded and integrated on a Jones Chromatography JCL6000 
chromatography data system (Crawford Sdentific, Strathaven, Scotland). GBP 
concentrations were determined by comparison of peak height ratios of analyte to internal 
standard, quantified in relation to volume, and expressed as pg/ml. Pearson’s product 
moment correlation coefficient is quoted.
RESULTS
GBP and the internal standard were well resolved from one another and the solvent fiont 
(figure 2). The calibration line (slope = 296.757, y-intercept = 39.44) was shown to be 
linear fiom 1.0 - 10.0 pg/ml (n = 6; r = 0.9997). The intra-assay variations at 0.5, 2.5, and 
5.0 pg/ml were 4.1, 2.2, and 3.8 % respectively. The inter-assay variations for the same 
samples were 10.0, 2.0, and 2.6 % respectively. Recoveries were shown to be > 90 % 
throughout.
There were no interfering peaks fiom any of the following other AEDs:- phenytoin, 
carbamazepine, sodium valproate, phenobarbital, primidone, clobazam, clonazepam, 
lamotrigine, vigabatrin, oxcarbazepine, felbamate, tiagabine or remacemide.
I
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Similarly, there were no interfering peaks fiom any of the following amino acids:- 
L-alanine, L-arginine, L-aspartic add, L-cystine, L-ghitamic add, glydne, L-histidine, 
I^isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, 
L-threonine, L-tyrosine or L-valine.
\
Typical GBP chromatograms are illustrated in figure 2. Samples were taken fiom a patient 
currently undergoing a double blind, crossover trial with GBP and placebo. One sample 
was taken fiom each treatment arm of this study where the daily GBP dose was 2400 mg.
DISCUSSION
This method employed pre-column derivatisation and fluorimetric detection for the 
quantitation of GBP concentrations in plasma. It facilitated clear detection and resolution 
of the drug, and its appropriate internal standard, with intra- and inter-assay variations of 
: an acceptable degree. Chromatography was unaffected by other commonly employed 
AEDs or a variety of endogenous amino adds.
In contrast to previously published assays [13], the methodology proved to be both rapid 
and simple, obviating several complicated steps including the requirement for pH 
adjustment of a relatively small volume. Another important advantage of this method over 
those previously reported [13] was a reduced requirement for the use of hazardous 
chemicals such as toluene and TNBS. Unlike its predecessors, this method also proved 
compatible with modem HPLC systems which facilitate automated pre-column
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derivatisation, thus reducing the number of technical-hours required to analyse a given 
number of samples.
One potential disadvantage of this new assay was an apparent reduction in sensitivity, with 
the lower limit of quantitation observed here being 0.25 pg/ml compared to 10 ng/ml 
previously reported by Hengy and Kolle [13]. However, in our clinical practise the 
expected plasma concentration on the least effective dose (1200 mg daily) exceeds 2 
pg/ml While saturable absorption must be taken into account, this daily dose of GBP is 
relatively low when compared to those of up to 6400 mg now being administered to 
patients with refractory epilepsy. Thus, it would appear that, with the exception of the 
most sensitive pharmacokinetic requirements, the new assay is more than adequate for the 
routine analysis of plasma GBP concentrations in the epilepsy clinic.
In conclusion, the method reported above represents a significant advance in the 
laboratory analysis of the novel antiepileptic drug GBP. In comparison to previously 
published methods [13], this HPLC assay is rapid, simple, safe and readily automatable. In 
addition, it appears to possess a sensitivity more than adequate for the routine monitoring 
of GBP concentrations in patients with intractable epilepsy.
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LEGENDS TO FIGURES
FIGURE 1 : Comparison of the chemical structures of the inhibitory neurotransmitter 
y-aminobutyric acid (GABA) and the novel antiepileptic compound gabapentin (GBP).
FIGURE 2 : Typical chromatograms highlighting gabapentin (GBP) and internal standard 
(IS.) peaks in one patient sample from each phase of a double blind, crossover trial of 
GBP and placebo. Upper chromatogram represents the placebo phase and the lower 
chromatogram the active phase. Daily GBP dose was 2400 mg.
11
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ABSTRACT
Tiagabine (TGB) and vigabatrin (VGB) are two novel anticonvulsant compounds reported to 
exert their pharmacological effects via an action on the y-aminobutyric acid (GABA) system 
We have investigated the effects of acute exposure of these drugs on the uptake of GABA into 
rat cortical astrocytes in primary culture. Astrocytes were prepared from the cerebral cortices 
of one day-old rat pups by a mechanical dissociation technique and were assayed for GABA 
uptake activity after 21 days in culture. TGB (100 - 300 nM) and VGB (100 pM) reduced 
GABA uptake when compared to control at 4 hours post-exposure. GABA uptake was also 
reduced following 8 and 24 hour exposures to 200 nM TGB. A combination of TGB (200 nM) 
and VGB (100 pM) treatments reduced GABA uptake when compared to both control and 
VGB treated cultures. These results support the efficacy of TGB as a GABA uptake inhibitor 
and suggest that VGB may also exert an effect by this mechanism
Keywords:- Tiagabine, vigabatrin, GABA uptake, cortical astrocytes, cell culture.
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INTRODUCTION
| Epilepsy is one of the most common neurological disorders, affecting an estimated 50 million
j persons world-wide [1]. The majority of the epileptic population can be adequately controlled
| with existing antiepileptic drugs (AEDs), although 20% of patients remain resistant to
currently available treatment [2], Recent additions to the clinician’s armamentarium have, 
however, improved the pharmacological treatment of epilepsy, particularly in terms of side 
effect profiles [3].
I
Two such novel compounds are vigabatrin (VGB) and tiagabine (TGB). Both drugs have been 
| reported to exert their anticonvulsant actions via specific effects on the y-aminobutyric acid
(GABA) system, VGB by an irreversible inhibition of the enzyme GABA-transaminase 
(GABA-T) and TGB by blockade of neuronal and glial GABA uptake [4,5].
While experimental evidence supports a single mechanism of action for TGB [6], a variety of 
reports would suggest otherwise for VGB. The diverse range of experimental anticonvulsant 
profiles exhibited by a variety of neuroactive compounds, all of which are proposed to act as 
inhibitors of brain GABA-T [7], might suggest the contribution of secondary mechanisms of 
action. Similarly, Bemasconi and colleagues [8] demonstrated that the anticonvulsant effects of 
VGB in animal seizure models are not related to the time of maximal GABA-T inhibition 
Perhaps the most pertinent observation, however, is one of rebound seizures immediately upon 
clinical withdrawal of the drug [9], Such an effect would be inconsistent with a compound 
which irreversibly inhibits an enzyme in the brain. As a result of these experimental and clinical
i
observations with VGB, we have investigated its action on GABA uptake into rat cortical 
| astrocytes in primary culture and compared these effects to those obtained with TGB.
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MATERIALS
! One day-old rat pups were obtained from a breeding colony of Sprague Dawley rats housed at
the Joint Animal Facility, University of Glasgow. Dulbecco’s modified Eagle medium 
(DMEM), horse serum (HS), L-glutamine, penicillin and streptomycin were all obtained from 
! Gibco BRL (Paisley, UK). All other chemicals (reagent grade) were obtained from the Sigma
Chemical Company (Poole, UK). Radiolabelled GABA (y-[14C(U)]-aminobutyric add) was 
obtained from NEN Research Products (Stevenage, UK). VGB (D,L-4-aminohex-5-enoic
I
! add) and TGB ((R-)-(-)-l-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidine-carboxylic
I
I acid, hydrochloride) were obtained from Marion Merrell Dow (Winnersh, UK) and Novo 
Nordisk A/S (Bagsvaerd, Denmark) respectively.
METHODS
Primary culture of cerebral cortical astrocytes
This method was devised from modifications of the methods of Larsson and co-workers [10] 
and Bender and Hertz [11], The cerebral cortices of one day-old rat pups were removed under, 
aseptic conditions and cleared of attached olfactory bulbs, basal ganglia, hippocampal 
formations and meningeal membranes. The dissected neopallia were then cut into small cubes 
! (0.5 mm3) by two passes (at 90°) in a Mcflwain tissue chopper (Mickle Laboratory Engineering 
Company Ltd, Gomshall, UK). The chopped tissue was transferred to a sterile glass filter (80 
pm nylon mesh; Lockertex Ltd., Warrington, UK) and the filtrate collected in a sterile beaker.
I The chopped material was washed through the filter with culture medium (DMEM 
I supplemented with 20% (v/v) HS, 2.5 mM L-glutamine, 100 I.U./ml penicillin, and 100 pg/ml
I
streptomycin) to give a final volume of 3 ml per brain. The filtrate was then passed through a 
i sterile needle (BD Microlance 21G 0.8 x 40) three times. The volume of the resulting
>4
I
4
I
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| suspension was adjusted with culture medium to allow a 3 ml aliquot per culture dish in a ratio
| of 1 brain to 3 dishes. A 3 ml volume of the final cell suspension was plated onto 60 x 15 mm
Falcon Primaria culture dishes (A+J Beveridge, Edinburgh, UK). The cultures were maintained 
J at 37°C in an environment of 95% air / 5% CO2 with a humidity of > 90%. The culture
j medium (3 ml) was replaced every 3 -4  days throughout. The HS concentration was reduced
I
to 10% at the first medium change with a final reduction to 5% at the second change. After 14 
I days in culture the medium was supplemented with 0.25 mM 3'5'-dibutyryl cyclic adenosine
| monophosphate (cAMP) to induce cell differentiation. P enicillin and streptomycin were
j omitted from the medium at this stage following reports that penicillin may interfere with
GABAergic function [12]. The cultures were employed for the study of GABA uptake 7 days 
after supplementation with cAMP.
[14C]-GABA uptake into cultured astrocytes
This method was devised from modifications of the methods of Larsson and co-workers [10] 
and Yu and colleagues [13]. A standard balanced salt solution (BSS) was used throughout the 
investigations of [14C]-GABA uptake. Its composition was as follows: 136 mM NaCl, 5 mM 
KC1, 0.8 mM MgS04, 2.6 mM NaHC03, 0.4 mM KH2PO4, 0.34 mM Na2HP04, 1.3 mM 
CaCt, 5.6 mM D-ghicose and 15 mM HEPES. The solution was adjusted to pH 7.4 with 1 M 
NaOH and stored, at 4°C, for up to 1 week. BSS was warmed to 37°C prior to use. Cultures 
for investigation were removed from the incubator and the existing medium aspirated. Cultures 
were washed twice ( 2 x 2  ml) with BSS before being returned to the incubator in a further 
volume of BSS (3 ml) for an equilibration period of 20 minutes. The pre-washed cultures were 
j then removed from the incubator and the existing BSS aspirated. This solution was replaced by
l BSS (2 ml) containing the drug concentrations appropriate to the individual experiment.
Enclosure (v)
Control plates received BSS alone. All culture plates were returned to the incubator for a 
further incubation period (1 - 24 hours). After the incubation period, a further 1 ml of BSS
(with appropriate control / drug treatment) containing 150 pM [14C]-GABA (specific activity =
\
1 mCi/mmol) was added to each plate. Incubation (37°C) was allowed to continue for 5 
minutes before the cultures were washed with 5 volumes (2 ml) of BSS. Cells were removed 
from the plates by scraping in 1 M NaOH (1 ml). Aliquots were taken for protein 
determination by the BIORAD method and liquid scintillation counting in 6 ml of Picofhxor 40 
scintillation fluid (Canberra Packard, Pangboume, UK). A Canberra Packard 2000CA TRI- 
CARB liquid scintillation counter (Pangboume, UK) was employed to analyse GABA uptake 
in individual cultures in comparison to the dpm of standard solutions containing known 
amounts of radioligand. Results were quantified by the relation of GABA uptake to the protein 
concentration and expressed as pmol/min/mg protein in individual cultures.
Determination of protein concentration
Protein concentrations were determined by the sensitive BIORAD method which relies on the 
colour change of a dye (Coomassie Brilliant Blue G-250). Standards were prepared over the 
range 5-20 pg/ml bovine serum albumin and samples o f  unknown protein concentration were 
also diluted into this range. BIORAD dye reagent was diluted 1:1 with water and added to 
standards and samples alike. Tubes were mixed and incubated at room temperature for 5 
minutes and then read at 595 nm in a spectrophotometer (MR5000, Dynatech Ltd., Guernsey). 
Results were corrected for dilution and expressed in mg/mL
T! Enclosure (v)
j EXPERIMENTAL PROTOCOL
The following studies were designed to investigate the dose- and time-dependent effects of 
I both TGB and VGB on GABA uptake into primary cultures of rat cortical astrocytes.
I Individual studies employed control (untreated) groups and between 12 and 20 plates per
i
group.
Study 1:- The effects of TGB dose (50 - 500 nM) on GABA uptake at 4 hours post-treatment, 
j Study 2:- The effects of VGB dose (1 - 500 pM) on GABA uptake at 4 hours post-treatment.
I Study 3:- The effects of200nM TGB on GABA uptake at 1 - 24 hours post-treatment.
I
[ Study 4:- The effects of 100pM VGB on GABA uptake at 1 - 24 hours post-treatment.
- Study 5:- The effects of200nM TGB and lOOpM VGB, alone and in combination, on GABA
uptake at 4 hours post-treatment.
STATISTICAL METHODS
Statistical analysis was performed using MINITAB for Windows statistical package (Version 
10.1) on a Viglen 4DX266 microcomputer. Results were expressed as the mean percentage of 
mean control values for each group ± the standard error of the mean (SEM). In those 
experiments evaluating dose and time related drug actions (Study nos. 1 - 4) ,  results were 
compared to control values by one-way analysis of variance with Dunnett correction for 
I multiple comparisons. In the combination experiment (Study no. 5), results were compared by 
two sample t-test.
7
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RF,STILTS
Study 1:- TGB (100 - 300 nM) significantly reduced GABA uptake into primary cultures of 
rat cortical astrocytes following a four hour exposure (figure 1). All other doses of TGB were 
without effect.
Study 2:- VGB (100 and 250 pM) significantly reduced GABA uptake into primary cultures 
of rat cortical astrocytes following a four hour exposure (figure 2). All other doses of VGB 
were without effect.
Study 3:- TGB (200 nM) significantly reduced GABA uptake into primary cultures of rat 
cortical astrocytes at 4, 8 and 24 hours post-exposure (figure 3). TGB was without effect at all 
other time points investigated.
Study 4:- VGB (100 pM) was without effect on GABA uptake into primary cultures of rat 
cortical astrocytes at all of the time points investigated (figure 4).
Study 5 TGB (200 nM), VGB (100 pM) and combination treatments all significantly 
reduced GABA into primary cultures of rat cortical astrocytes when compared to control 
(figure 5).
DISCUSSION
The aims of these studies were to investigate the effects of TGB and VGB, alone and in 
combination, on the uptake of [I4C]-GABA into rat cortical astrocytes in primary culture.
8
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These drugs have previously been proposed to exert their pharmacological actions via single 
and specific effects on the GABAergic system [4,5].
TGB belongs to a new class of AEDs, derived from nipecotic add and believed to exert their 
anticonvulsant action by blockade of GABA uptake into neurones and glial cells [6]. Recent 
evidence has suggested that GABA uptake is mediated by 4 distinct transporter proteins [14] 
and that TGB is predominantly active at the transporter termed “GAT-1” and weakly active at 
“GAT-3”. TGB is effective against audiogenic seizures in DBA/2 mice [5], the motor 
manifestations of amygdaloid kindled seizures [15] and the tonic and clonic components of 
pentylenetetrazol-induced seizures in both rats and mice [5]. It has also been proposed to have 
efficacy against tonic seizures induced by maximal electroshock [16], TGB is currently 
undergoing phase HI clinical trial for the treatment of epilepsy and initial reports suggest that 
the drug is active against both partial and secondary generalised seizures [3].
In these studies, TGB reduced GABA uptake into rat cortical astrocytes in a dose-specific 
manner. Its concentration - effect profile appeared to be U-shaped, however, making 
determination of an ICso impossible. A similar dose-related pattern has been reported with 
TGB in whole animal seizure models [5], The reason for this phenomenon remains unknown, 
and although higher drug doses are possibly cytotoxic, no parallel reduction in the protein 
content of cultures was observed in the above studies. Another surprising observation from 
these studies was the latency to onset of TGB action on GABA uptake, with the drug only 
being active after at least 4 hours exposure. This would not appear to concur with the rapid 
onset of TGB action in whole animal seizure models following parenteral administration [5]. 
One might speculate that direct application of TGB to the cell surface should result in
I
i Enclosure (v)
| immediate effect. Further studies employing a wider range of time intervals from 0 to 4 hours 
are required in an attempt to clarify this apparent discrepancy.
j VGB was the first drug to enter regular clinical use, having been designed specifically for the
| treatment of epilepsy [17]. It has been proposed to exert its anticonvulsant effects by an
irreversible inhibition of GABA-T [4], the enzyme responsible for the metabolic degradation of 
the inhibitory neurotransmitter GABA. VGB has demonstrated efficacy against a range of
j experimental seizures including those induced by picrotoxin [8] and amygdaloid kindling [18]
I
J and is also effective in genetic models of reflex epilepsy [19].
At concentrations of 100 and 250 pM, VGB significantly blocked astrocytic GABA uptake. 
These concentrations are close to that reported as the I C 5 0  for inhibition of GABA-T in the 
| same cell type [20]. This previously unreported mechanism of VGB action might help to
j explain the diverse range of experimental anticonvulsant profiles exhibited by a variety of
GABA-T inhibitors [7]. It may, also underlie the lack of relationship between the time of 
maximal GABA-T inhibition and the anticonvulsant effects of VGB in animal seizure models 
| [8] and the observation of rebound seizures immediately upon clinical withdrawal of the drug
j P L
I
j If one considers the structural similarity between VGB and GABA, it is possible to speculate
I
I that the blockade of GABA uptake afforded by VGB may be the result of a simple competitive 
J reaction between the two molecules at one or more of the 4 reported GABA uptake carriers
| [14]. Although previous studies have suggested that VGB is not a substrate for the “GABA
I V
I transporter” [21], the drug is believed to enter cells via some high affinity uptake system [17],
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With recent evidence proposing the existence of multiple GABA uptake carriers [14], it is 
possible that VGB has a specific action at one or more of these newly discovered targets. The 
GABA uptake carrier ‘GAT-3” might represent the most likely site of VGB action in this 
respect. Beta-alanine, a specific substrate of GABA-T [22], has been shown to selectively
j block GABA transport via the ‘GAT-3” carrier [23], It is possible that structural similarities
I
| facilitate the binding of GABA, p-alanine and VGB at the active sites of both GABA-T and the 
‘GAT-3” transporter.
I
hi cultures exposed to a combination of both TGB and VGB, the inhibition of GABA uptake 
was greater than that observed when either drug was administered alone. This effect did, 
however, appear to be infra-additive and would thus suggest a similar site of action for both 
drugs. If TGB and VGB were to act at independent uptake sites one would expect to observe 
a total inhibition of GABA uptake equal to the sum of inhibitions observed with both drugs 
alone. This evidence might support a contributory role for VGB on the TGB-mediated 
blockade of GABA uptake at the ‘GAT-3” transporter.
In conclusion, these results suggest that both TGB and VGB block GABA uptake into primary 
cultures of rat cortical astrocytes. Further studies to determine the basis of the U-shaped dose- 
response to TGB and its lack of effect prior to 4 hours are required. In terms of VGB, a more
j detailed evaluation of this novel mechanism is planned. Further investigations of its dose- and
I
I time-dependency and cell specificity, together with evaluation of the relationship between this
l
I and the intracellular effects of VGB are clearly required. Characterisation of the GABA uptake
i blockade observed with VGB may help to determine its relative importance as an additional
I mechanism of anticonvulsant action.
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LEGENDS TO FIGURES
Figure 1 Effects of tiagabine (TGB) concentration on the uptake of [14C]-GABA into rat 
cortical astrocytes in primary culture following a four hour exposure. Results (12 < n > 20) are 
expressed as the mean percentage of the control values and error bars denote the standard 
error of the mean (SEM). Statistical significance (*p<0.05) was determined by one-way 
analysis of variance with Dunnett correction.
Figure 2 Effects of vigabatrin (VGB) concentration on the uptake of [14C]-GABA into rat 
cortical astrocytes in primary culture following a four hour exposure. Results (12 < n > 20) are 
expressed as the mean percentage of the control values and error bars denote the standard 
error of the mean (SEM). Statistical significance (*p<0.05) was determined by one-way 
analysis of variance with Dunnett correction.
Figure 3 :- Effects of exposure time (hours) to tiagabine (TGB; 200 nM) on fire uptake of 
[14C]-GABA into rat cortical astrocytes in primary culture. Results (12 < n > 20) are expressed 
as the mean percentage of the control values and error bars denote the standard error of the 
mean (SEM). Statistical significance (*p<0.05) was determined by one-way analysis of 
variance with Dunnett correction.
Figure 4 :- Effects of exposure time (hours) to vigabatrin (VGB; 100 pM) on the uptake of 
[14C]-GABA into rat cortical astrocytes in primary culture. Results (12 < n > 20) are expressed 
as the mean percentage of the control values and error bars denote the standard error of the 
mean (SEM). Statistical significance (*p<0.05) was determined by one-way analysis of 
variance with Dunnett correction.
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Figure 5 Effects of tiagabine (TGB; 200 nM) and vigabatrin (VGB; 100 pM), alone and in 
combination, on the uptake of [14C]-GABA into rat cortical astrocytes in primary culture 
following a four hour exposure. Results (12 < n > 20) are expressed as the mean percentage of 
the control values and error bars denote the standard error of the mean (SEM). Statistical
s.
significance (*p<0.001) was determined by two-sample t-test.
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SUMMARY
A r a n d o m is e d ,  d o u b le - b l in d ,  p la c e b o - c o n t r o l le d  c r o s s o v e r  s t u d y  o f  a d d - o n  r e m a c e m id e  h y d r o c h lo r id e  
was c a r r ie d  o u t  in  1 0  o u t  o f  1 4  r e c r u i t e d  p a t ie n ts  b e in g  t r e a t e d  w i t h  c a r b a m a z e p in e  ( C B Z )  
m o n o th e ra p y . F o r t y  e ig h t  h o u r  c o n c e n t r a t io n  p r o f i le s  o f  C B Z ,  i ts  a c t iv e  e p o x id e  m e t a b o l i t e  ( C B Z - E ) ,  
re m a c e m id e , a n d  i ts  d e s g ly c in y l  m e t a b o l i t e  ( A R L 1 2 4 9 5 X X )  w e r e  a s s a y e d  f o l l o w i n g  s in g le  a n d  
m u lt ip le  d o s in g .  F o l l o w i n g  1 4  d a y s ’ t r e a t m e n t  w i t h  3 0 0 m g  r e m a c e m id e  h y d r o c h lo r id e  t w i c e  d a i ly ,  t h e  
m ean A U C  o f  c a r b a m a z e p in e  w a s  in c r e a s e d  b y  2 2 %  ( p  =  0 . 1 2 ) ,  C m a x  b y  2 7 %  ( p  =  0 . 0 7 )  a n d  C m in  b y  
2 2 %  ( p  =  0 . 2 9 ) .  T r o u g h  c o n c e n t r a t io n s  o f  C B Z  w e r e  s t a t is t ic a l ly  s ig n i f ic a n t ly  h ig h e r  ( p = 0 . 0 0 1 3 )
i
du rin g  a c t iv e  t r e a t m e n t  c o m p a r e d  w i t h  p la c e b o .  L e v e ls  o f  C B Z - E  w e r e  u n a f f e c t e d .  N o  s y m p t o m s  o f  
c a rb a m a z e p in e  t o x i c i t y  w e r e  r e p o r t e d .  T h e r e  w a s  n o  e v id e n c e  o f  a u t o in d u c t io n  o f  r e m a c e m id e  
m e ta b o lis m . H o w e v e r ,  in  th e s e  C B Z - t r e a t e d  p a t ie n ts ,  e x p o s u r e  t o  r e m a c e m id e  a n d  i ts  a c t iv e  
m e ta b o lite  w a s  6 0 %  a n d  3 0 %  r e s p e c t iv e ly  o f  v a lu e s  o b s e r v e d  in  h e a l t h y  v o lu n t e e r s  t r e a t e d  p r e v io u s ly  
with t h e  s a m e  d o s e .  T h u s ,  r e m a c e m id e  h y d r o c h lo r id e  in h ib i t s  C B Z  m e t a b o l is m ,  w h ic h  i t s e l f  in d u c e s  
that o f  r e m a c e m id e  h y d r o c h lo r id e  a n d  i ts  a c t iv e  m e t a b o l i t e .  T h is  m u t u a l  in t e r a c t io n  b e t w e e n  
re m a c e m id e  h y d r o c h lo r id e  a n d  C B Z  is  p r e d ic t a b le  a n d  m o d e s t  a n d  s h o u ld  n o t  p r e s e n t  a  b a r r i e r  t o  t h e i r  
clinical u s e  in  c o m b in a t io n .
I Enclosure (vi)
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INTRODUCTION
I
R e m a c e m id e  h y d r o c h lo r id e  ( 2 - a m i n o - N - [ l - m e t h y l - l , 2 - d i p h e n y l e t h y l ] - a c e t a m i d e  m o n o h y d r o c h lo r id e ) ,  
ja n o v e l a n t ic o n v u ls a n t ,  is  a  n o n - c o m p e t i t i v e  a n ta g o n is t  a t  N - m e t h y l - D - a s p a r t a t e  ( N M D A )  r e c e p t o r s  
(1). M e t a b o l i s m  in  m a n  in v o lv e s  p r o d u c t io n  o f  a n  a c t iv e  d e s g ly c in y l  m e t a b o l i t e  A R L 1 2 4 9 5 X X  ( 2 ) ,  
w hich  h a s  a  lo n g e r  e l im in a t io n  h a l f - l i f e  ( 1 1 - 1 9  h o u r s  v e r s u s  3 - 4  h o u r s )  t h a n  t h e  p a r e n t  c o m p o u n d  ( 3 ) ,  
and is  a  p o t e n t  a n t a g o n is t  a t  t h e  N M D A  r e c e p t o r  ( 4 ) .  A s  w e l l  a s  b e in g  a n  a n t ic o n v u ls a n t  ( 5 ) ,
.re m a c e m id e  h y d r o c h lo r id e  c o u ld  b e  e f f e c t iv e  in  p r e v e n t in g  c e l l  d a m a g e  ( 6 )  in  t h e  c o u r s e  o f  is c h a e m ic  
jinjury ( 7 )  a n d  in  P a r k in s o n ’ s d is e a s e  ( 8 ) .
C a rb a m a z e p in e  ( C B Z )  is  a  f i r s t  l in e  a n t ic o n v u ls a n t  d r u g  ( 9 ) .  I t s  u s e  is  c o m p l ic a t e d  b y  v a r ia b le  
m to in d u c t io n  o f  m e t a b o l is m  ( 1 0 )  a n d  a  p r o p e n s i t y  f o r  p h a r m a c o k in e t ic  d r u g  in t e r a c t io n s  ( 1 1 ) .
H ep a tic  m e t a b o l is m  o f  C B Z  in  m a n  p r o d u c e s  a n  a c t iv e  1 0 ,1 1  e p o x id e  ( C B Z - E )  m e t a b o l i t e ,  w h i c h  is  
^thought t o  b e  r e s p o n s ib le  f o r  s o m e  o f  i ts  n e u r o t o x ic  s id e - e f f e c t s  ( 1 2 ) .  M e t a b o l i s m  o f  th is  c o m p o u n d  
is a lso  a f f e c t e d  b y  o t h e r  a n t ie p i le p t ic  d r u g s  ( 1 3 ) .  T h e  p r e d i le c t io n  o f  th e  e s ta b l is h e d  a n t ie p i le p t ic  
drugs t o  in t e r a c t  w i t h  o t h e r  c o m p o u n d s  a n d  th e  n e e d  f o r  n o v e l  a g e n ts  t o  b e  u s e d  a s  a d ju v a n t  t h e r a p y  
require e a r ly  a s s e s s m e n t  o f  p o t e n t ia l  p h a r m a c o k in e t ic  in t e r a c t io n s ,  w h ic h  c a n  o b s c u r e  in t e r p r e t a t io n  o f  
trial r e s u lts  a n d  in f lu e n c e  d o s e  s e le c t io n  ( 1 4 ) .  T h is  p h a r m a c o k in e t ic  in t e r a c t io n  s tu d y  w i t h  
rem ace m id e  h y d r o c h lo r id e  w a s  c a r r ie d  o u t  in  p a t ie n ts  o n  C B Z  m o n o t h e r a p y ,  u s in g  a  r a n d o m is e d ,  
d o u b le -b lin d  p la c e b o - c o n t r o l le d  c r o s s o v e r  d e s ig n  ( 1 5 ) .
i
METHODS
P atien ts
\  to ta l o f  1 4  p a t ie n t s  w e r e  r e c r u i t e d  ( T a b l e  1 ) ,  e a c h  o n  a  r e g im e n  o f  C B Z  m o n o t h e r a p y  w h ic h  h a d  
seen s ta b le  f o r  a t  le a s t  t h r e e  m o n th s .  A l l  p a t ie n ts  h a d  a t  le a s t  t w o  p la s m a  m e a s u r e m e n ts  o f  C B Z  
ivithin t h e  t a r g e t  r a n g e  ( 2 0 - 5 0 u m o l / L )  d u r in g  th a t  p e r io d .  T w e l v e  o f  t h e  p a t ie n ts  h a d  p a r t ia l  s e iz u r e s
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w ith  o r  w i t h o u t  s e c o n d a r y  g e n e r a l is a t io n ,  w h i le  2  w e r e  t h o u g h t  t o  h a v e  id io p a t h ic  t o n ic - c lo n ic  
se izu res . T h e  s tu d y  w a s  a p p r o v e d  b y  b o t h  t h e  W e s t  E t h ic a l  C o m m i t t e e  in  G l a s g o w  a n d  t h e  R e s e a r c h  
E th ics  C o m m i t t e e  in  C a r d i f f .  W r i t t e n  in f o r m e d  c o n s e n t  w a s  o b t a in e d  f r o m  e a c h  p a r t ic ip a n t
All p a t ie n ts  w e r e  f r e e  f r o m  h e p a t ic ,  r e n a l ,  o r  h a e m a t o lo g ic a l  d is e a s e . T h e y  w e r e  a s k e d  t o  r e f r a in  
fro m  a lc o h o l  a n d  c a f f e in e  t h r o u g h o u t  t h e  s tu d y .  S o m e  p a t ie n t s  w e r e  o n  s ta b le  d o s e s  o f  o t h e r  
m e d ic a t io n , n o n e  o f  w h ic h  w a s  k n o w n  t o  in t e r a c t  w i t h  C B Z  o r  r e m a c e m id e  h y d r o c h lo r id e .  P a t ie n t s  
w ere  r e q u i r e d  t o  k e e p  a  d ia r y  c a r d  d e t a i l in g  s e iz u r e  t y p e  a n d  f r e q u e n c y  a n d  th e  d u r a t io n  a n d  n a t u r e  o f  
any a d v e r s e  e v e n ts  e x p e r ie n c e d .  C o m p l ia n c e  w a s  c h e c k e d  b y  q u e s t io n in g  t h e  p a t ie n t s  a n d  c a r r y in g  
out a  t a b le t  c o u n t .
Protocol
ij
The s tu d y  h a d  a  d o u b le - b l in d ,  r a n d o m  o r d e r ,  p la c e b o - c o n t r o l le d ,  c r o s s o v e r  d e s ig n ,  p r e c e d e d  b y  a n  
open, s in g le -d o s e  t r e a t m e n t  p h a s e . P a t ie n t s  c o n t in u e d  t o  t a k e  C B Z  in  t h e i r  u s u a l  d o s e  t h r o u g h o u t .
One w e e k  f o l l o w i n g  a  s c r e e n in g  v is i t ,  e a c h  p a t ie n t  r e c e iv e d  a  s in g le  d o s e  o f  3 0 0 m g  r e m a c e m id e  
h y d ro c h lo r id e . P la s m a  le v e ls  o f  C B Z ,  C B Z - E ,  r e m a c e m id e ,  a n d  A R L 1 2 4 9 5 X X ,  w e r e  m e a s u r e d  0 ,
0.5, 1 , 1 .5 ,  2 ,  4 , 6 ,  8 , 1 0 ,  1 2 ,  2 4 ,  a n d  4 8  h o u r s  a f t e r  d o s in g .  O n e  w e e k  la t e r ,  p a t ie n t s  e n t e r e d  t h e  f i r s t  
arm o f  c h r o n ic  t r e a t m e n t ,  r e c e iv in g  e i t h e r  r e m a c e m id e  h y d r o c h lo r id e  ( lO O m g  t w i c e  d a i ly  o n  d a y  1 ,
2 0 0 m g  t w i c e  d a i ly  o n  d a y  2 ,  a n d  3 0 0 m g  t w ic e  d a i ly  t h e r e a f t e r )  o r  m a tc h e d  p la c e b o .  T h e  t o t a l  
tre a tm e n t p e r io d  w a s  1 4  d a y s , a f t e r  w h ic h  t h e  f in a l  d o s e  o f  r e m a c e m id e  h y d r o c h lo r id e  w a s  g iv e n  o n  
the m o r n in g  o f  t h e  1 5 t h  d a y  t o  a l l o w  m e a s u r e m e n t  o f  w a s h o u t  c o n c e n t r a t io n s  a t  t h e  s a m e  t im e s  a f t e r  
dosing a s  b e f o r e .  S e v e n  d a y s  la t e r ,  t h e  s e c o n d  t r e a t m e n t  p h a s e  w a s  c o m m e n c e d  a n d  t h e  w h o l e  
p ro c e d u re  w a s  r e p e a t e d .  M o r n i n g  p r e - d o s e  ( t r o u g h )  s a m p le s  w e r e  t a k e n  o n  t h e  5 t h ,  1 2 t h  a n d  1 5 t h  
day a f t e r  i n i t i a t io n  o f  t r e a t m e n t .  A l l  b lo o d  s a m p le s  w e r e  t a k e n  in t o  h e p a r in is e d  t u b e s  f r o m  a  
can n u la ted  f o r e a r m  v e in ,  w h ic h  w a s  k e p t  p a t e n t  b e t w e e n  a s p ir a t io n s  w i t h  n o r m a l  s a lin e . O n  e a c h
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o c c a s io n , t h e  f i r s t  1 m l w i t h d r a w n  w a s  d is c a r d e d ,  a n d  t h e  s u b s e q u e n t  1 5 m l  w e r e  c h i l le d  u n t i l  
c e n t r i fu g a t io n .  A l l  s a m p le s  w e r e  s p u n  a t  3 , 0 0 0  r p m  f o r  1 0  m in u te s ,  a n d  t h e  s e p a r a t e d  p la s m a  f r o z e n  
at - 4 ° C  f o r  b a t c h  a n a ly s is .
Assays
R e m a c e m id e  a n d  i ts  d e s g ly c in y l  m e t a b o l i t e  ( A R L 1 2 4 9 5 X X )  w e r e  q u a n t i f ie d  b y  h ig h  p e r f o r m a n c e  
liq u id  c h r o m a t o g r a p h y  ( H P L C ) ,  T h js  w a s  a  m o d i f ic a t io n  o f  a  p r e v io u s ly  r e p o r t e d  m e t h o d  ( 1 6 ) ,  
a d ju s te d  t o  a l l o w  a u t o m a t e d  s a m p le  p r e p a r a t io n  a n d  im p r o v e  s e le c t iv i t y .  T h e  m e t h o d  in v o lv e d  s o l id  
phase e x t r a c t io n  f o l l o w e d  b y  s e p a r a t io n  o n  a  r e v e r s e  p h a s e  H P L C  s y s te m  u t i l is in g  a  o c t a d e c y l  ( C - 1 8 )  
H P L C  c o lu m n ,  a n  a c e t o n i t r i l e  b a s e d  e lu e n t ,  a n d  u l t r a v io le t  ( u v )  d e t e c t io n  a t  2 1 0  n m . L i m i t s  o f  
q u a n t i f ic a t io n  f o r  t h e  t w o  a n a ly te s  w e r e  1 0  n g /m l .  O n ly  s a m p le s  f r o m  t h e  a c t iv e  le g  o f  t h e  d o u b le ­
blind p h a s e  w e r e  a n a ly s e d  f o r  r e m a c e m id e  a n d  A R L 1 2 4 9 5 X X .  C B Z  a n d  C B Z - E  w e r e  m e a s u r e d  b y  
l iq u id - l iq u id  e x t r a c t io n  o f  p la s m a  f o l lo w e d  b y  r e v e r s e  p h a s e  H P L C  u t i l is in g  a  C - 8  c o lu m n ,  a  m e t h a n o l -  
based m o b i le  p h a s e , a n d  u v  d e t e c t io n  a t  2 1 0 n m .
Pharmacokinetics
The f o l l o w i n g  n o n - c o m p a r t m e n t a l  p h a r m a c o k in e t ic  p a r a m e t e r s  w e r e  c o m p u t e d  f o r  C B Z  a n d  C B Z - E  
for a l l  t h r e e  p h a s e s  o f  s e r ia l  b lo o d  s a m p lin g :
i
1) a r e a  u n d e r  t h e  c o n c e n t r a t io n - t im e  c u r v e  ( A U C )  o v e r  a  d o s in g  in t e r v a l  ( A U C o-t )  c a lc u la t e d  u s in g
i
th e  l in e a r  t r a p e z o id a l  m e t h o d
!
2) p e a k  c o n c e n t r a t io n  ( C m a x )  o v e r  t h e  d o s in g  in te r v a l
3) t r o u g h /p r e - d o s e  c o n c e n t r a t io n  ( C m i n )  o v e r  t h e  d o s in g  in t e r v a l
4) t im e  t o  m a x im u m  c o n c e n t r a t io n s  ( T m a x )
5) C m in  5 ,  1 2 ,  a n d  1 5  d a y s  a f t e r  in i t i a t io n  o f  m u l t ip le  d o s in g  w i t h  r e m a c e m id e  h y d r o c h lo r id e  o r  
p la c e b o
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F o r  r e m a c e m id e  a n d  A R L 1 2 4 9 5 X X ,  t h e  p a r a m e t e r s  c a lc u la t e d  f o l l o w i n g  s in g le  d o s e  a n d  m u l t ip le  
d osing  w e r e :
1) C m a x
2) T m a x
3) A U C ,  e i t h e r  e x t r a p o la t e d  t o  in f in i t e  t im e  ( A U C * > ) ,  w h ic h  w a s  c a lc u la t e d  f r o m  A U C  =  A U C t  +
C t / k e l  w h e r e  A U C t  =  a r e a  u n d e r  t h e  c u r v e  u p  t o  t h e  la s t  p o in t  a t  w h ic h  th e  c o n c e n t r a t io n  c o u ld  b e  
q u a n t i f ie d ,  a n d  k e l  =  t h e  t e r m in a l  p h a s e  p la s m a  e l im in a t io n  r a t e  c o n s ta n t ,  o r  o v e r  a  1 2  h o u r  d o s in g  
in t e r v a l  ( A U C  o -i2h)
4) E l im in a t io n  h a l f - l i f e ,  ( t « 0  a f t e r  t h e  s in g le  d o s e  a n d  d u r in g  w a s h o u t  o f  t h e  m u l t ip le  d o s e  
r e m a c e m id e  h y d r o c h lo r id e  t r e a t m e n t  p h a s e . T h is  w a s  c a lc u la t e d  f r o m  t<, =  0 . 6 9 3 / k e l .
5) C m in  5 ,  1 2  a n d  1 5  d a y s  in t o  r e m a c e m id e  h y d r o c h lo r id e  t r e a t m e n t .
Statistics
S ta tis tic a l c o m p a r is o n s  o f  t h e  p h a r m a c o k in e t ic  p a r a m e te r s  o b t a in e d  f o r  C B Z  a n d  C B Z - E  a t  t h e  e n d  o f
i
the t w o  m u l t ip le  d o s e  p h a s e s  o f  th e  s tu d y  w e r e  c o m p a r e d  u s in g  a n  a n a ly s is  o f  v a r ia n c e  ( A N O V A )  
jwith t r e a t m e n t ,  p e r io d ,  s e q u e n c e  a n d  p a t ie n t  a s  f a c to r s .  L o g a r i t h m ic a l l y  t r a n s f o r m e d  d a t a  w e r e  u s e d  
■for a n a ly s is  o f  t h e  A U C t , C m a x  a n d  C m in  c o m p a r is o n s .  U n t r a n s f o r m e d  d a t a  w e r e  u s e d  f o r  T  m a x .
A nalys is  o f  t h e  t r o u g h  c o n c e n t r a t io n s  u s e d  A N O V A  f o r  t h e  3  c o n c e n t r a t io n s  p e r  p a t ie n t  ( 5 ,  1 2 ,  a n d  
15 d a y s  a f t e r  in i t i a t io n  o f  m u l t ip le  d o s in g )  w i t h  f a c to r s  o f  t r e a t m e n t ,  p e r io d ,  s e q u e n c e ,  d a y  n u m b e r
land p a t ie n t .  S in g le  a n d  m u l t ip le  d o s e  p h a s e s  w e r e  c o m p a r e d  u s in g  a  n o n - p a r a m e t r ic  p r o c e d u r e ,  t h e
!
W ilc o x o n  m a t c h e d  p a ir s  s ig n e d  r a n k  te s t .  A  p r o b a b i l i t y  le s s  t h a n  5 %  in d ic a t e d  s t a t is t ic a l  s ig n if ic a n c e .
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RESULTS
Patients
O f  t h e  1 4  p a t ie n t s  r e c r u i t e d  ( T a b l e  1 ) ,  1 0  c o m p le t e d  t h e  s t u d y  a s  p e r  p r o t o c o l .  O n e  p a t ie n t  ( 0 1 8  )  
w it h d r e w  a  f e w  h o u r s  f o l l o w i n g  a d m in is t r a t io n  o f  t h e  s in g le  r e m a c e m id e  h y d r o c h lo r id e  d o s e  b e c a u s e  
he d is l ik e d  in t r a v e n o u s  c a n n u la t io n .  A n o t h e r  ( 0 2 1  )  p u l le d  o u t  5  d a y s  a f t e r  s in g le  d o s e  a d m in is t r a t io n  
b e c a u s e  o f  a n  in t e r c u r r e n t  v i r a l  i l ln e s s . O n e  p a t ie n t  ( 0 2 4 )  w a s  w i t h d r a w n  b e c a u s e  o f  s u s p e c te d  p o o r  
c o m p lia n c e ,  w h i l e  t h e  f o u r t h  ( 0 1 6 )  h a d  t h e  d o s e  o f  r e m a c e m id e  h y d r o c h lo r id e  h a lv e d  f o l l o w i n g  t h e  
o n se t o f  a d v e r s e  e v e n ts  s u s p e c te d  t o  b e  d u e  t o  t h e  s tu d y  d r u g .  T h is  p a t ie n t 's  d a t a  w e r e  in c lu d e d  in  t h e  
s u m m a ry  o f  a d v e r s e  e v e n ts ,  b u t  n o t  in  t h e  p h a r m a c o k in e t ic  a n a ly s is .
CBZ pharmacokinetics
T h e re  w e r e  n o  s ta t is t ic a l ly  s ig n i f ic a n t  c h a n g e s  in  m e a n  C B Z  p h a r m a c o k in e t ic  p a r a m e t e r s  f o l l o w i n g  a
i
sing le  d o s e  o f  r e m a c e m id e  h y d r o c h lo r id e  ( F i g u r e  1 a n d  T a b l e  2 ) .  F o l l o w i n g  1 4  d a y s ’ t r e a t m e n t ,  t h e  
m ean AUCo-nh o f  C B Z  w a s  in c r e a s e d  b y  2 2 %  ( p  =  0 . 1 2 ) ,  th e  m e a n  C m a x  b y  2 7 %  ( p  =  0 . 0 7 ) ,  a n d  t h e  
m ean C m in  b y  2 2 %  ( p  =  0 . 2 9 ) .  T m a x  w a s  u n c h a n g e d  f o l l o w i n g  b o t h  s in g le  a n d  m u l t i - d o s e  
re m a c e m id e  h y d r o c h lo r id e .  C o m p a r is o n  o f  m e a n  t r o u g h  C B Z  le v e ls  5 ,  1 2 , a n d  1 5  d a y s  a f t e r  t h e  s ta r t  
of a c t iv e  t r e a t m e n t  ( 4 0 . 1 ,  3 4 . 4  a n d  4 0 . 4  u m o l / L  r e s p e c t iv e ly )  w i t h  th o s e  o n  p la c e b o  ( 3 2 . 7 ,  3 0 . 5  a n d  
34.5 u m o l / L  r e s p e c t iv e ly )  s h o w e d  a  s t a t is t ic a l ly  s ig n i f ic a n t  in c r e a s e  ( p = 0 . 0 0 1 3 ) .  F o u r  p a t ie n t s  h a d  a t  
least o n e  o f  t h e  p h a r m a c o k in e t ic  p a r a m e t e r s  o f  C B Z  in c r e a s e d  b y  m o r e  t h a n  3 0 %  d u r in g  t h e  
re m a c e m id e  h y d r o c h lo r id e  t r e a t m e n t  p h a s e . N o n e  o f  th e s e  p a t ie n ts ,  h o w e v e r ,  r e p o r t e d  a n y  s y m p to m s  
su g g es tive  o f  C B Z  t o x ic i t y .
CBZ-E pharmacokinetics
The m e a n  A U C ,  C m a x ,  a n d  C m in  f o r  C B Z - E  ( T a b l e  3 )  w e r e  n o t  s ig n i f ic a n t ly  a l t e r e d  b y  c o n c o m i t a n t  
re m a c e m id e  h y d r o c h lo r id e  f o l l o w i n g  s in g le  o r  m u l t ip le  d o s in g  ( F i g u r e  2 ) .  A f t e r  1 4  d a y s ' t r e a t m e n t ,
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two patients had an increase in A U C  or Cmax o f more than 30% , one being a rise in A U C  o f 177%  
and in Cmax o f  153%. These patients, however, remained symptom-free. There was no significant 
difference in Tm ax following acute or chronic remacemide hydrochloride dosing. Comparison o f  
mean trough C B Z -E  levels 5, 12, and 15 days after the start o f  active treatment (5 .1 , 4 .4  and 5.0 
umol/L respectively) w ith those during placebo treatment (4.9, 4.1, and 5.00 um ol/L respectively) 
showed no significant differences (p =  0.62).
Remacemide and ARL12495XX pharmacokinetics
Mean pharmacokinetic parameters for remacemide and A R L 1 2 4 9 5 X X  following single and multiple 
dosing are shown in Table 4. M ean plasma concentrations following single and multiple dosing are 
illustrated for remacemide in Figure 3 and for A R L 1 2 4 9 5 X X  in Figure 4. As anticipated from a drug 
with a considerably shorter half-life than dosing interval, there was little carry-over o f  remacemide 
from dose to dose, and the steady-state profiles attained consisted o f  levels only slightly higher than 
those following the single dose (Figure 3 and Table 4). For A R L 1 2 4 9 5 X X , however, consistent w ith  
its longer terminal half life, there was a greater carry-over during multiple dosing. A t steady-state, 
peak (Cm ax) and trough (Cm in) oscillations were much smaller than for remacemide, and the 
maximum concentrations attained were approximately twice those following the single dose (Figure 4 
and Table 4). W ith  both remacemide and A R L 1 24 95 X X , there was good predictability o f  multiple 
dose profiles compared with single dose profiles based on linear superposition o f  the concentration 
data and comparisons o f A U C s following single and multiple dosing. This suggests that there was no 
autoinduction o f remacemide or A R L 1 2 4 9 5 X X  metabolism.
Adverse events
Mo major adverse events were reported, and no patients were withdrawn from the study due to 
adverse events, although one patient (016) had his dose o f remacemide hydrochloride halved 4 days
8
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in to  t h e  m u l t ip le - d o s e  p h a s e  b e c a u s e  o f  d iz z in e s s .  O v e r a l l ,  m o r e  e v e n ts  w e r e  r e p o r t e d  w h i l e  p a t ie n ts  
w e re  o n  p la c e b o  ( 3 6  a d v e r s e  e v e n ts )  th a n  f o l lo w in g  r e m a c e m id e  h y d r o c h lo r id e  t r e a t m e n t  ( 2 6  e v e n ts  
re p o r te d ) .  S im i l a r  n u m b e r s  o f  p a t ie n ts  r e p o r t e d  a d v e r s e  e v e n ts  f o l l o w i n g  m u l t ip le  d o s in g  w i t h  a c t iv e  
t r e a tm e n t  ( 1 0  p a t ie n t s )  a s  w e r e  r e p o r t e d  w i t h  p la c e b o  ( 9  p a t ie n t s ) .  T h e r e  w e r e  s im i la r  n u m b e r s  o f  
c e n tra l n e r v o u s  s y s te m  e v e n ts  ( 4  o n  r e m a c e m id e  h y d r o c h lo r id e  v e r s u s  3  o n  p la c e b o ) ,  a n d  
g a s t r o in te s t in a l  s y m p t o m s  r e p o r t e d  w e r e  e q u a l w i t h  b o t h  t r e a t m e n t s  ( 2  e a c h ) .
DISCUSSION
C B Z  is  a  w e l l - k n o w n  in d u c e r  o f  h e p a t ic  c y t o c h r o m e  P 4 5 0  m o n o - o x y g e n a s e  e n z y m e s  ( 1 1 ) .  T h is  
re s u lts  in  m a r k e d  in t r a -  a n d  in t e r - in d iv id u a l  v a r ia t io n s  in  s e r u m  c o n c e n t r a t io n s  o f  o t h e r  a n t ie p i le p t ic  
dru g s d u r in g  p o ly p h a r m a c y ,  a n  u n p r e d ic t a b i l i t y  w h ic h  is  e x a c e r b a t e d  b y  v a r ia b le  a u t o in d u c t io n  o f  
m e ta b o lis m  ( 1 0 ) .  I n  a d d i t io n ,  m a n y  o t h e r  d r u g s  h a v e  b e e n  s h o w n  t o  in t e r a c t  p h a r m a c o k in e t ic a l ly  
w ith  C B Z  ( 1 4 ) ,  I t s  c le a r a n c e  in  m a n  is  a lm o s t  e x c lu s iv e ly  b y  h e p a t ic  m e t a b o l ic  t r a n s f o r m a t io n .  A  
m a jo r p a t h w a y  in v o lv e s  o x id a t io n  o f  C B Z  t o  1 0 ,1 1  e p o x id e  ( C B Z - E ) ,  w h ic h  is  i t s e l f  b io t r a n s f o r m e d  
by t h e  e n z y m e  e p o x id e  h y d r o la s e  t o  t h e  in e r t  d ih y d r o d io l  ( 1 7 ) .  T h e s e  t w o  p r o c e s s e s  p r o v id e  a  t a r g e t  
for in t e r a c t io n s  b e t w e e n  C B Z  a n d  o t h e r  a n t ie p i le p t ic  d r u g s  ( 1 3 , 1 8 - 1 9 ) .  C h a n g e s  in  t h e  c o n c e n t r a t io n  
of C B Z - E  m a y  b e  im p o r t a n t  b e c a u s e  th is  c o m p o u n d  c o n t r ib u t e s  t o  t h e  e f f ic a c y  a n d  a d v e r s e  e v e n ts  
as s o c ia te d  w i t h  C B Z  t r e a t m e n t  ( 1 2 ) .  I n  o n e  s tu d y  t h e  m a jo r i t y  o f  p a t ie n t s  o n  c o - m e d ic a t io n  w i t h  
re m a c e m id e  h y d r o c h lo r id e  a n d  C B Z  h a d  d o s e  r e la te d  in c r e a s e s  in  t r o u g h  c o n c e n t r a t io n s  o f  C B Z ,  
n e c e s s ita tin g  a  r e d u c t io n  in  t h e  C B Z  d o s e  in  a  f e w  p a t ie n t s  ( 2 0 ) .
L ike C B Z ,  r e m a c e m id e  is  a ls o  e l im in a t e d  a lm o s t  e x c lu s iv e ly  b y  m e t a b o l ic  t r a n s f o r m a t io n .  A p a r t  f r o m  
the a c t iv e  m e t a b o l i t e ,  A R L 1 2 4 9 5 X X ,  w h ic h  is  f o r m e d  b y  u b iq u i t o u s  a m in o p e p t id a s e  e n z y m e s ,  t h e r e  
are a  n u m b e r  o f  o x id a t iv e  b io t r a n s f o r m a t io n  p r o d u c ts .  I n  a d d i t io n ,  r e m a c e m id e  h y d r o c h lo r id e  
u n d e rg o e s  d i r e c t  g lu c u r o n id a t io n  t o  f o r m  a  c a r b a m o y l  g lu c u r o n id e  m e t a b o l i t e ,  a n  i m p o r t a n t  p a t h w a y
9
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in man (20). This interaction study used a placebo-controlled design in order to investigate the 
potential interaction between remacemide hydrochloride and CBZ. Following multiple dosing with  
remacemide hydrochloride, there was an overall small inhibition o f C B Z  metabolism during active 
treatment compared with placebo. A  minority o f patients demonstrated a rise in C B Z  trough levels 
>30%. There were no significant changes overall in C B Z -E  concentrations during treatment with  
remacemide hydrochloride, although there were marked differences in individual response w ith one 
patient exhibiting an increase in C B Z -E  level o f  more than 100%. N o  patients had any clinical 
sequelae.
These findings are consistent with in-vitro experiments using 6-B-hydroxylation o f  testosterone as a 
marker o f  C Y P 3A 4 activity (Riley - manuscript in preparation), which showed that remacemide is an 
inhibitor o f  cytochromal activity associated with this isoform. Since the concentrations o f  
remacemide required in the in-vitro mixture to achieve inhibition o f C YP3 A4 are in excess o f those 
reached in vivo, it is fair to assume that any increase in C B Z concentrations will be modest.
Remacemide has not been shown to affect epoxide hydrolase in vitro, in keeping with the findings in 
the study.
This study also offered the opportunity to explore the pharmacokinetics o f remacemide and 
AR L12495XX in enzyme-induced patients. For both compounds, the multiple dose profile was 
consistent w ith that predicted from the single dose, indicative o f linear disposition and the absence o f  
autoinduction o f  metabolism. The terminal half life o f  remacemide was similar to that found in 
previous clinical studies in human volunteers (Figure 5), whereas that o f  A R L 1 2 4 9 5 X X  in enzyme- 
induced patients was shorter than in untreated healthy volunteers (20). Exposure to remacemide 
based on A U C  values was around 60%  o f that reported previously in non-induced subjects taking the 
same dose o f  the drug, while that o f  A R L 1 2 4 9 5 X X  was about 30%  (Figure 5).
1 0
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The most common adverse events reported with remacemide hydrochloride are dizziness and mild to 
moderate gastrointestinal upset (20). There were few adverse events reported in this study. In  
particular, there was none resulting in withdrawal from the study, although one patient developed 
dizziness, necessitating a decrease in remacemide hydrochloride dose. A  greater number o f adverse 
events were reported during the placebo phase. In healthy volunteers, the A U C  following similar 
dosing w ith remacemide hydrochloride (600mg/day) was between two and three times higher than that 
observed in patients in this study. Consequently, 600mg remacemide hydrochloride per day is unlikely 
to be the maximum tolerated dose in patients receiving treatment with CB Z.
Although vigilance should be exercised in adding remacemide hydrochloride to antiepileptic drug 
regimes containing C B Z, it is unlikely that a reduction in C B Z dosage will be required in most 
patients. Since the presence o f  C B Z will result in lower bioavailability o f  remacemide and 
A R L 12495X X , patients pre-treated with an enzyme-inducer such as C B Z  will require higher doses o f  
remacemide hydrochloride than non-induced patients. In  addition, the remacemide concentration can 
be expected to rise when carbamazepine is withdrawn. The mutual interaction between C B Z  and 
remacemide hydrochloride is predictable and modest, and should not present a barrier to their w ide­
spread clinical use in combination. As remacemide and A R L 1 2 4 9 5 X X  exhibit predictable and linear 
kinetics in C B Z patients, with no evidence o f autoinduction, there should be little need for routine 
therapeutic monitoring o f either drug in this clinical setting.
Acknowledgement
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Table 1
Demographic characteristics o f  study population
Patient Sex Age
(years)
Seizure
type
CBZ dose 
(mg/day)
Treatment
schedule
001 M 36 CPS/2GTCS 600 tid
002 M 47 SP/2GTCS 800 tid
003 M 48 CPS/2GTCS 800 bd
016 F 65 CPS/2GTCS 800 bd
017 F 43 CPS/2GTCS 800 bd
018 M 46 2GTCS 400 bd
019 M 56 SP/CPS 600 tid
020 M 39 CPS/2GTCS 600 od
021 F 57 2GTCS 400 bd
022 F 46 SP/CPS/2GTCS 1200 bd
023 M 57 SP/CPS/2GTCS 800 bd
024 F 51 1GTCS 800 bd
025 F 40 CPS/2GTCS 1200 od
027 F 40 1GTCS 1600 bd
SP =  simple partial seizures
1GTCS =  idiopathic tonic-clonic seizures
CPS =  complex partial seizures
2G TCS =  localisation-related tonic-clonic seizures
12
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Table 2
M e a n  c a r b a m a z e p in e  p h a r m a c o k in e t ic  p a r a m e t e r s  ( S D )  a f t e r  s in g le  a n d  m u l t ip le  d o s e s  o f  r e m a c e m id e  
h y d r o c h lo r id e  a n d  p la c e b o  in  1 0  e p i le p t ic  p a t ie n ts
A U C
( u m o l . h r . r * )
C m a x
( u m o l . l ' l )
T m a x
( h o u r s )
C m i n
( u m o U ‘ 1 )
P la c e b o 3 6 7 . 8 ( 1 3 5 . 2 ) 4 0 . 5  ( 8 . 7 ) 4 . 6  ( 4 . 8 ) 3 4 . 7  ( 8 . 2 )
S in g le  d o s e 3 9 2 . 3  ( 1 6 1 . 1 ) 4 3 . 3  ( 1 0 . 1 ) 7 .1  ( 4 . 2 ) 3 4 . 0  ( 7 . 2 )
M u l t ip le  d o s e s 4 2 5 . 4 ( 1 5 6 . 9 ) 5 0 . 6 ( 1 2 . 2 ) 5 .1  ( 3 . 5 ) 4 0 . 8 ( 1 1 . 6 )
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Table 3
Mean carbamazepine 10,11 epoxide pharmacokinetic parameters (SD) after single and multiple dose of 
remacemide hydrochloride and placebo in 10 epileptic patients
AUC
(umol.hr.r*)
Cmax
(um ol.rl)
Tmax\
(hours)
Cmin
(umol.l- )^
Placebo 53.8 (32.7) 5.6 (2.6) 6.2 (5.1) 5.0 (2.4)
Single dose 46.7 (26.9) 5.0 (2.2) 4.6 (4.6) 4.5 (2.2)
Multiple doses 48.4 (27.5) 5.9 (2.4) 5.2 (4.6) 4.9 (2.2)
i
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able 4
lean pharmacokinetic parameters (SD) of remacemide and ARL12495XX in 10 carbamazepine treated patients 
Mowing acute and chronic dosing.
' Cmax
(ng.ml'1)
Cmin
(ng-ml*1)
Tmax
(hours)
AUC* 
(ng.hr. ml**)
t*/2
(hours)
iingle dose
Remacemide 783 (229) NA 1.5 (1.0) 2266 (1344) 3.60 (1.31)
ARL 12495XX 30.2 (7.6) NA 2.0 (0.7) 395(125) 10.44 (0.65)
Multiple doses
Remacemide 1006(411) 60.9 (74.8) 1.1 (0.4) 2644 (1376) 3.54(1.47)-
ARL 12495XX 64.8 (23.2) 25.2 (7.9) 1.6 (0.9) 427 (108) 11.25 (4.11)
*AUCoo for single dose profiles, AUCo-i2h for multiple dose profiles NA = not applicable
15
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Legends to figures
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Mean plasma concentrations of carbamazepine in 10 patients with epilepsy following 
single (300mg) or multiple doses (300mg twice daily for 14 days) of remacemide
i
hydrochloride and multiple dose placebo
Mean plasma concentrations of carbamazepine 10,11-epoxide in 10 patients with 
epilepsy following single (300mg) and multiple doses (300mg twice daily for 14 days) 
of remacemide hydrochloride and multiple dose placebo
Mean (±SD) single dose and steady-state plasma concentrations of remacemide in 10 
patients taking carbamazepine who received a single dose (300mg) or multiple (300mg 
twice daily for 14 days) doses of remacemide hydrochloride
Mean (±SD) single dose and steady-state plasma concentrations of ARL12495XX in 10 
patients taking carbamazepine who received a single dose (300mg) or multiple (300mg 
twice daily for 14 days) doses of remacemide hydrochloride 
Mean pharmacokinetic parameters of remacemide and ARL12495XX in 
carbamazepine-treated patients versus healthy untreated volunteers (volunteer data 
taken from reference 20)
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